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Prenatal diagnosis using karyotyping is routinely offered to all pregnant women in developed 
countries who have an increased risk of carrying a child with a chromosomal abnormality. 
The aim of prenatal diagnosis is to determine the presence or absence of chromosomal 
abnormalities to allow parents an informed choice on the course of pregnancy1. Prenatal 
diagnosis is ultimately a patient’s choice. Prenatal diagnosis starts with counseling of the 
patient; explaining the intervention, the chromosomal abnormalities that can be detected 
and the consequences of these abnormalities. In case an abnormality is detected, prenatal 
diagnosis implies decision making on the continuation of pregnancy, timely medical treatment 
and emotional and psychological care. 
REFERRAL INDICATIONS
Prenatal diagnosis is offered to pregnant women with a higher than reference risk for fetal 
chromosomal abnormalities. The assessment of risk for fetal chromosomal abnormalities is 
based on several risk indicators; a family history of chromosomal abnormalities, the presence 
of ultrasound abnormalities, advanced maternal age, and an increased risk following 
prenatal screening tests. 
Presence of a parental chromosomal abnormality or a previous pregnancy with a chromosomal 
abnormality leads to an increased risk of chromosomal abnormalities in (the subsequent) 
pregnancy2. For example, if one of the parents is a carrier of balanced translocation between 
chromosome 13 and 14, the risk on having offspring with a trisomy 13 is 1%3.  
Single and especially multiple fetal abnormalities seen on ultrasound scan are associated 
with the presence of chromosomal abnormalities4, 5. These ultrasound abnormalities can be 
detected early in pregnancy. Since its introduction in 1990, first trimester nuchal translucency 
(NT) measurement has been implemented as a screening test for fetal chromosomal 
abnormalities. NT thickness is increased in fetus with trisomies 13, 18, and 21, and it 
is also associated with cardiac defects6 and genetic syndromes7. The 20-week anomaly 
scan was initially developed for the detection of neural tube defects but is now part of the 
national prenatal screening programme and carried out to detect or rule out the presence 
of structural abnormalities. Occasionally, soft markers are identified, e.g. echogenic bowel, 
mild ventriculomegaly, and echogenic focus in the heart. These soft markers may be related 
to fetal chromosomal abnormalities8. Subsequently, advanced ultrasound screening is done 







The most common indications for prenatal diagnosis are 1) advanced maternal age, 2) 
an increased risk of Down syndrome following prenatal screening, and 3) abnormalities 
detected at ultrasound scan. For these indications, Down syndrome is the most commonly 
detected abnormality.
Advanced maternal age is defined either as a maternal age of 35 years or 36 years during the 
18th gestational week. In the Netherlands, the most common indication is advanced maternal 
age (66%)10, 11. Women of at least 36 years of age in the 18th gestational week are eligible 
for prenatal diagnosis in the Netherlands. The risk of carrying a child with Down syndrome 
at term increases from 1: 940 at 30 years of age to 1:353 at 35 years of age and 1:85 at 
40 years of age. The combined risk for other common chromosomal abnormalities (Patau 
syndrome, Edward syndrome and sex chromosomal abnormalities) is also age-dependent, 
rising from 1:384 (30 years), to 1:178 (35 years), to 1:62 (40 years). On balance, when 
amniocentesis is performed, 43.5% of the chromosomal abnormalities detected are Down 
syndrome (trisomy 21), 10.3% are Edward syndrome (trisomy 18), 1.6% are Patau syndrome 
(trisomy 13) and 13% are sex chromosomal abnormalities, 15.4% are balanced structural 
rearrangements, 9.6% are mosaics, and the final 6.6% consist of unbalanced structural 
rearrangements, marker chromosomes or polyploidies2. 
Thirty years ago, prenatal screening using maternal serum markers became available to 
estimate the risk of carrying a child with Down syndrome. First trimester screening based on 
maternal age, serum markers, and nuchal translucency measurement is regarded upon as 
an effective screening test with a detection rate of 75.9-90.0% and a 3.3-5.0% false positive 
rate12-16. If an increased risk of carrying a baby with Down syndrome is present, prenatal 
diagnosis is offered. In the Netherlands, this is the second most common referral indication 
for prenatal diagnosis (10%). A cut-off risk level of 1 in 200 at the time of testing, comparable 
with a risk of 1 in 280 at term17, is used in the Netherlands18. The number of pregnant women 
participating in prenatal screening increased due to a change in government policy in 2003, 
making screening for Down’s syndrome available to all pregnant women, regardless their 
age. In 2006, 45,000 tests were performed18, leading to an uptake of approximately 27%. 
Psychological indicators are not formally part of the selection criteria for prenatal diagnosis. 
However, in clinical practice, parental distress or anxiety is considered an admissible 
criterium to undergo invasive prenatal diagnosis. It is used in 1% as a reason to undergo 
invasive prenatal diagnosis in our country. In the Netherlands, for all the above mentioned 
indications, except parental anxiety invasive prenatal diagnosis is fully covered by the 
insurance companies.
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CVS (figure 2) usually is done at 10 to 13 weeks of pregnancy either transabdominally or 
transcervically. CVS has a miscarriage risk of 1.3%-2%21, 22. Specimens yielded are cultured 
which takes 8-10days to give a result. Once a chromosomal abnormality has been detected 
a dilatation and evacuation can be performed to terminate pregnancy. 
Karyotyping
After withdrawal of fetal material either by amniocentesis or CVS, karyotyping (figure 3) is 
performed. It has been used for almost 50 years to determine if fetal chromosomal aberrations 
are present. It is a robust technique that is able to detect a range of numerical and structural 
chromosomal abnormalities with high accuracy (99.4-99.9%)23-25. Karyotyping requires 
culture of fetal cells in order to obtain cells at the metaphase stage. The cells may be grown 
PRENATAL DIAGNOSIS
If at least one of the above mentioned risk indicators is present, prenatal diagnostic care 
is offered and parents can decide to undergo an invasive diagnostic test; i.e. prenatal 
diagnosis. Prenatal diagnosis is performed on amniotic fluid cells obtained by amniocentesis 
or chorionic villi obtained by chorionic villus sampling (CVS). 
Amniocentesis is the most commonly used invasive prenatal diagnostic procedure worldwide19 
and is performed in one in 30 pregnancies in the Netherlands10. Amniocentesis usually is 
performed at 15 to 20 weeks’ gestational age. Amniocentesis (figure 1) has a miscarriage 
risk of 0.06-1.4%20-22. The amniotic fluid cells are cultured for karyotyping and the result 
is known in 2-3 weeks. Once a chromosomal abnormality has been detected and parents 
decide to terminate the pregnancy, delivery is induced. 
Figure 1: Amniocentesis: 
amniotic fluid cells are aspirated 










in tissue flask (the flask method), in which the cells have to be enzymatically removed prior to 
harvest or with an in situ method, in which cells are analysed without subculture. Failure to 
culture the fetal cells obtained occurs in a small number of cases; the average rate reported 
in the UK in 1999 was 0.3% of cases26. In the last five years, the failure rate for the culture 
of amniocytes was less than 0.01% in the Netherlands. On average 10 metaphases from 10 
different colonies are examined and analysed27. 
Cell culture takes on average 10 to 14 days before slides are stained for chromosomal 
banding. Parents have to wait two to three weeks for the test results, which generally leads 
to parental anxiety28. Karyotyping is considered time consuming and labour-intensive, both 
leading to high costs.
Karyotyping is able to detect any microscopic chromosomal abnormality of 3 to 5 Mega base 
(Figure 4)29, including chromosomal abnormalities with unclear or mild clinical relevance. 
The latter findings may cause difficult counselling issues, patient anxiety, and emotional 
dilemmas concerning the continuation of pregnancy in situations in which the outcome is 
uncertain or the phenotype predicted to be relatively mild30.  
Figure 2: Chorionic villus sampling: 
chorionoc villi are aspirated 
transabdominally or transcervically using 
ultrasound guidance.







Figure 4: Arrangement and size of submicroscopic and microscopic abnormalities. Mb= 
















































Due to technical progress in molecular biology, new molecular techniques have become 
available which have also been applied in prenatal diagnosis. These techniques, commonly 
referred to as rapid aneuploidy detection (RAD) techniques, do not need cultured cells 
and are therefore able to deliver quick results. Currently, there are three RAD techniques; 
fluorescent in situ hybridisation (FISH), quantitative fluorescent polymerase chain reaction 
(QF-PCR) and multiplex ligation-dependent probe amplification (MLPA). These techniques 
share several characteristics. They only use a small part of a chromosome and are able to 
detect only a few chromosomes within one test. Moreover, these tests are designed to detect 
only the most common fetal chromosomal abnormalities; i.e. aneuploidies of chromosomes 
13, 18, 21, X and Y. RAD is therefore a targeted test on chromosomes 13, 18, 21, X and Y 
which also implies that other chromosomal abnormalities will remain undetected. Compared 
to karyotyping, several advantages of RAD have been put forward; the shortening of the 
waiting time, the procedure is considerably less labour intensive since cultured cells are 
avoided, the test requires less amniotic fluid and it is suitable for high throughput testing. 
These factors all add to the assumed higher efficiency of RAD compared to karyotyping. 






Fluorescent in situ hybridisation (FISH)
FISH is a type of hybridization that uses a labelled complementary DNA or RNA strand 
(i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue in 
the interphase nucleus. The probe hybridizes to the target sequence at elevated temperature, 
and then the excess probe is washed away. Then, the probe that is labelled with fluorescent-
labelled bases is localized and quantified in the tissue using fluorescence microscopy. FISH 
is a powerful general technique and has also become an integral part of a comprehensive 
cytogenetic evaluation of structurally abnormal chromosomes, mosaicism and marker 
chromosomes in prenatal diagnosis31. A variety of probe types can be employed to detect 
chromosome rearrangements and aneuploidy. For RAD, probes are used for chromosomes 
13, 18, 21, X and Y only. Although FISH produces results in 1 to 2 days, the process still is 
still labour intensive requiring much expertise. 
Quantitative fluorescent polymerase chain reaction (QF-PCR)
In QF-PCR, highly polymorphic short tandem repeats (STRs) on chromosome 13, 18, 21, 
X and Y are amplified using fluorescence primers and PCR in a multiplex assay, followed 
by the automated analysis of fluorescence intensity of the alleles in a genetic analyser32. 
Generally, a minimum of 3-4 STRs for each chromosome tested is used to reduce the 
number of uninformative results. In normal cases at least two informative marker results for 
each investigated chromosome consistent with a normal diallelic (heterozygous) pattern with 
two peaks in a 1:1 ratio are required, a monoallelic (homozygous) pattern with one peak 
being uninformative. In trisomic cases three alleles are evident by three peaks in a 1:1:1 ratio 
(triallelic trisomy pattern) or two alleles in 2:1 or 1:2 ratios (diallelic trisomy pattern). Peak 
height, peak area or both can be used to calculate allele ratios. QF-PCR can be performed 
at highly automated protocols. At the start of our clinical study, no commercially available 
kits were available and non-informativeness of the polymorphic markers occurred regularly.
Multiplex Ligation-dependent Probe Amplification (MLPA)
The third RAD technique is Multiplex Ligation-dependent Probe Amplification (MLPA, MRC 
Holland). The commercially available kit SALSA P095 is designed to detect trisomies 13, 
18, 21, X and Y. More than 40 loci per multiplex can be tested in one reaction. For each 
genomic target, a set of 2 probes is designed to hybridize immediately adjacent to each 
other on the same target strand. Once hybridized, the two probes are joined by a ligase and 
the probe can then be amplified by PCR. All ligated probes have identical end sequences, 
permitting simultaneous PCR amplification by only one primer pair (a universal primer). The 
different length products are separated on an automated capillary sequencer. The relative 
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quantity of each of the PCR products is proportional to the number of copies of target 
sequence. Results are given as allele copy numbers as compared to normal controls: a ratio 
of about 1 is obtained if both alleles are present, a ratio of about 0.5 when one allele is 
absent and a ratio of about 1.5 if one allele is duplicated (figure 5).  MLPA is not expected 
to detect low grade chromosomal mosaicism33, 34.   
In 2003, a preclinical study of Slater et al. showed MLPA to be robust in detecting aneuploidies 
of chromosome 13, 18, 21 and non-mosaic sex chromosome abnormalities using amniotic 
fluid: highly automated protocols provided a test result within a few days33. This preclinical 
study, however, did not reveal if the favourable performance of MLPA could also be achieved 
in routine clinical care, nor the impact of MLPA on patient’s health related quality of life, 
patient’s and physician’s preferences and its costs-effectiveness.
THE CLINICAL PROBLEM
In prenatal diagnosis, there is neither agreement on the specific chromosomal abnormalities 
that should and should not be detected, nor on the degree of certainty required for a result 
to be negative or positive. Initially, only karyotyping was available and its ‘broad’ detection 
capacity and its high diagnostic accuracy made karyotyping to be accepted as gold standard. 
Figure 5: Detection of chromosome X (Chr X): the ratio for the male sample, containing one X 
chromosome, is 0.5; the ratio for the normal female sample, containing two X chromosomes, is 






Nowadays, due to technical progress, other prenatal diagnostic tests have become available 
next to karyotyping. The decision problem which test to use, and under what circumstances, 
indirectly raises the question what to test for in prenatal diagnosis. Which test strategy is 
considered optimal, depends on evaluative data from comparative clinical studies, with 
support from psychological, and decision analytic studies. 
In this thesis, MLPA is our RAD technique of choice, since a preclinical study showed MLPA 
to be a good test with high diagnostic accuracy at highly automated protocols33, 35. At study 
onset the commercially available SALSA P095 kit had been validated on amniotic fluid in 
the eight genetic centres in the Netherlands in contrast to other RAD tests. MLPA by design 
cannot detect chromosomal abnormalities other than aneuploidies of chromosome 13, 18, 
21, X and Y. Therefore, we evaluated if the diagnostic accuracy of MLPA was non-inferior 
to karyotyping when applied in a routine prenatal diagnosis setting and we assessed patient 
outcomes as well as the preferences of pregnant women and physicians for various tests 
and test strategies. We also estimated cost-effectiveness of MPLA compared to standard 
karyotyping.  
STUDY AIM
The aim of the study was to assess the diagnostic accuracy, impact on patient’s quality of 
life and preferences, and cost-effectiveness of MLPA in comparison to karyotyping as the 
reference diagnostic test, in clinical practice for women undergoing amniocentesis on behalf 
of their age, increased Down syndrome risk following first trimester prenatal screening, or 
parental anxiety. Should MLPA be implemented in prenatal diagnostic care and if yes, what 
is its optimal test strategy? 
The specific research questions were:
Is diagnostic accuracy of MLPA to detect trisomies 13, 18, 21 and sex chromosomal 
aneuploidies in routine clinical practice comparable (non-inferior) to karyotyping?
Do anxiety and quality of life differ between a combined strategy (MLPA followed by karyo-
typing) and karyotyping? And if MLPA has comparable diagnostic accuracy, is quality of life 
influenced by offering individual choice between standalone karyotyping and standalone 
RAD?
Is MLPA cost effective compared to karyotyping, taking into account short term and long-term 
effects?
Which test and which test characteristics do patients value most? Which type of test is 
preferred by physicians involved in prenatal diagnosis?
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Since karyotyping and MLPA have different detection capacities, which chromosomal 
abnormalities should be detected in prenatal diagnosis according to experts?
OUTLINE OF THE THESIS
Part 1: Clinical evaluation
Chapter 2 describes the diagnostic accuracy and failure rate of MLPA compared to 
karyotyping as reference test on 4585 amniotic fluid samples. Undetected chromosomal 
abnormalities are described (research question 1).
In Chapter 3 we analyse different aspects of health related quality of life, using validated 
questionnaires between women who receive both MLPA as well as a karyotype result and 
women who only receive karyotyping results (research question 2). 
In Chapter 4 we assess the motives and reasons to choose either karyotyping or RAD and 
evaluate different aspects of health related quality of life, using validated questionnaires 
of women who are offered individual choice between standalone RAD and karyotyping 
(research question 2). 
In Chapter 5 we present a detailed cost-effectiveness analysis. The analysis includes short 
term costs, i.e. time frame from amniocentesis until the decision to continue or terminate 
pregnancy, and long term costs, i.e. time from decision to continue or terminate pregnancy 
(research question 3).
Part 2: Patients ’and physicians’ preferences
Chapter 6 describes the differences in preferences for prenatal testing between physicians 
(obstetricians, clinical geneticists, clinical cytogeneticists, midwives, general practitioners) 
involved in prenatal diagnosis and pregnant women undergoing amniocentesis (research 
question 4). 
In Chapter 7 we investigate patient’s preferences for karyotyping or RAD and assess the 
value women place on test specific characteristics by using discrete choice experimentation. 
(research question 4)
In Chapter 8 we present the consensus and dissensus opinions of an expert panel 
of professionals on broad versus targeted testing by evaluating which chromosomal 
abnormalities should be detected and which should not be detected (research question 5).
Part 3: General discussion, conclusion and summary
In Chapter 9 we discuss the results and give clinical implications and implications for future 
research. Finally our conclusions are postulated. 
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ABSTRACT
Objective
To estimate whether Multiplex Ligation-dependent Probe Amplification (MLPA), a molecular 
technique used for detecting the most common chromosomal aneuploidies, is comparable 
to karyotyping for the detection of aneuploidies of chromosomes X, Y, 13, 18 and 21 in 
routine clinical practice and to estimate the costs differences of both techniques. 
Methods
In this prospective nationwide cohort study, we consecutively included 4585 women who 
had an amniocentesis on behalf of their age, increased risk following prenatal screening 
or maternal anxiety. Amniotic fluid samples were tested independently with both MLPA and 
karyotyping. The primary outcome was diagnostic accuracy of MLPA to detect aneuploidies 
of chromosomes X, Y, 13, 18 and 21. Secondary outcome measures were turnaround time 
and costs. A sample size was calculated using a critical noninferiority margin of 0.002, 
therefore at least 4497 paired test results were needed (one-sided alpha 0.05, power 0.90). 
Results
Diagnostic accuracy of MLPA was 1.0 (95 % confidence interval 0.99 to 1.0), sensitivity 
was 100% (95% confidence interval 0.96-1.0) and specificity was 100% (95% confidence 
interval 0.999-1.0). Diagnostic accuracy of MLPA was statistically similar (noninferior) to that 
of karyotyping (P<0.001). In 75 cases MLPA failed (1.6%); karyotyping failed once (0.02%). 
Compared with karyotyping, MLPA shortened the waiting time with 14.5 days (P<0.001, 
95% confidence interval 14.3-14.6), and cost less (-47%, P<0.001).   
Conclusions
In routine clinical practice, diagnostic accuracy of MLPA for detection of trisomies X, Y, 13, 
18, and 21 is comparable to that of karyotyping and it reduces waiting time at lower costs. 
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INTRODUCTION
Prenatal diagnosis is routinely offered to all pregnant women in developed countries who 
have an increased risk of carrying a child with a chromosomal abnormality. Amniocentesis is 
the most commonly used invasive prenatal diagnostic procedure worldwide and is performed 
in one in 30 pregnancies in developed countries1,2. 
Karyotyping detects fetal chromosomal abnormalities in amniotic fluid cells3,4. It is a robust 
technique and detects a range of numerical and structural chromosomal abnormalities with 
high accuracy (99.4-99.9%)3,5,6. However, due to the required fetal cell culture, karyotyping 
is time consuming and labor-intensive leading to high costs. The detection capacity of 
karyotyping may be perceived as a disadvantage as it detects chromosomal abnormalities 
with unclear or mild clinical relevance. The latter can cause patient anxiety, emotional 
dilemmas concerning the continuation of pregnancy in situations in which the outcome is 
uncertain or the phenotype predicted to be relatively mild7. 
In the last decade new molecular techniques have become available for rapid aneuploidy 
detection of the most common chromosome abnormalities (aneuploidies of chromosomes 
X, Y, 13, 18 and 21). Multiplex Ligation-dependent Probe Amplification (MLPA) is a rapid 
high-throughput technique shown to be robust in a preclinical setting8,9. MLPA avoids the 
detection of abnormalities with unclear clinical relevance. 
If under standard clinical conditions MLPA can accurately and rapidly detect aneuploidies 
of chromosomes X, Y, 13, 18 and 21, it would be a suitable test for routine diagnostic 
application in prenatal diagnosis. Therefore, we conducted a nationwide prospective study 
in which we compared MLPA with karyotyping in routine clinical practice and evaluated the 
cost differences of both techniques. We hypothesized that MLPA has equivalent diagnostic 
accuracy in detecting aneuploidies of chromosomes 21, 13, 18, X and Y at lower costs. 
MATERIALS AND METHODS
The M.A.K.E. (MLPA And Karyotyping, an Evaluation) study was a prospective multicentre 
diagnostic cohort study, comparing MLPA on amniotic fluid in a routine clinical setting with 
karyotyping (10). All eight Dutch prenatal diagnostic centers and their affiliated hospitals 
participated. The Institutional Review Boards approved the study and all participating women 
gave written informed consent.  
We consecutively included pregnant women from March 2007 to October 2008. Pregnant 










to undergo amniocentesis for advanced maternal age (36 years or older), increased risk 
of Down syndrome following prenatal screening or parental anxiety. We excluded women 
with other indications for amniocentesis since they have an increased risk of chromosomal 
abnormalities other than the most common aneuploidies which MLPA cannot detect and 
karyotyping is mandatory; ultrasound abnormalities including a nuchal translucency 
measurement of 3.5 mm, a parental chromosomal abnormality, or a previous child with a 
chromosomal abnormality. 
In all centers experienced maternal fetal medicine specialists performed amniocentesis 
following national guidelines11. Samples were included if the aspirated volume was at least 
14 ml, leaving sufficient amniotic fluid available for MLPA analysis. No extra amniotic fluid 
was withdrawn in favor of the study. 
For the MLPA procedure, DNA was isolated from 1 to 8 ml uncultured amniotic fluid samples, 
depending on the total amount of amniotic fluid received. We used a commercially available 
kit, the SALSA MLPA P095 (MRC Holland, the Netherlands). For each genomic target, a 
set of 2 probes is designed to hybridize immediately adjacent to each other on the same 
target strand. Both probes consist of a short target sequence and a universal polymerase 
chain reaction (PCR) primer-binding site. One of the probes contains a stuffer sequence 
with a unique length and sequence. Following hybridization, each pair of adjacent probes 
is joined by a ligation reaction. Next, PCR is performed using a fluorescent-labeled primer 
pair, which ensures that the relative yield of each of the PCR products is proportional to the 
amount of each of the target sequences. The different length products are separated on 
an automated capillary sequencer. The size and peak areas for each probe are quantified 
and analyzed by data analyzing software (GeneMarker, SoftGenetics, LLC, State College, 
PA, USA or Genescan and Genemapper version 3.7/4.0, Applied Biosystems, CA, USA) 
(8). Relative probe signals are calculated and compared with samples of normal male and 
female sex. In chromosomally normal samples, the relative probe signal is expected to be 1 
for all probes. A normal value is defined as a relative probe signal between 0.7 and 1.3. A 
relative probe value of <0.7 indicates a monosomy, whereas a relative probe value of >1.3 
indicates a trisomy. MLPA is not expected to detect low grade chromosomal mosaicism9,12.  
Technicians had a molecular genetics or a cytogenetics background; all were trained in 
the execution of MLPA prior to the study onset. MLPA was performed in duplicate, provided 
that at least 2 ml of amniotic fluid was available. MLPA results were conclusive if the results 
of both results matched. If one or either results were inconclusive and sufficient DNA was 
available, the MLPA reaction was repeated.  If the results still disagreed after the repetition, 
MLPA failed. Technicians carrying out MLPA were blinded to karyotyping results and vice 
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versa. However, if MLPA detected an aneuploidy the head of the laboratory could initiate the 
earliest possible harvesting of cell culture. 
We allowed a phase 1 (median time 6 months) in which test results were not reported 
to patients and centers could train extra personnel for sample identification, tracking and 
accurate reporting of test results. In phase 2 conclusive MLPA results were reported to 
pregnant women as a provisional result, awaiting the definite karyotype result. Patients were 
also informed if MLPA failed. For karyotyping, fetal cells were cultured and spread on slides, 
which were stained for chromosomal banding. Routinely, metaphases for 10 colonies were 
investigated. All centers followed national quality guidelines but minor differences in the 
amount of cell colonies cultured, staining and reporting of the results were allowed13. 
The primary outcome variable was diagnostic accuracy for detecting aneuploidies of 
chromosomes 21, 13, 18, X and Y. We quantified the other chromosomal abnormalities 
that were not detected by MLPA and recorded reasons for failed test results. Turnaround 
time for test results was measured on laboratory level (time span between carrying out the 
amniocentesis and authorization of test result) and, in phase 2, on patient level (time span 
between amniocentesis and the result given to the patient).
Mean cost differences between MLPA and karyotyping as standalone strategies were 
evaluated according to international guidelines14,15. Costs per strategy were calculated as 
the sum of resource use between amniocentesis and the decision to continue or terminate 
pregnancy, using individual data from the case record forms and direct observations in 
three centers, multiplied by resource unit prices, covering for personnel costs, equipment, 
consumables, additional costs in case of chromosomal abnormality, and overhead costs. 
Costs were calculated in Euros and then converted into U.S. dollars (€1.00 = U.S. $1.37). 
Sample size was estimated to demonstrate noninferiority of the index test (MLPA) to 
karyotyping. During a pre-trial meeting, experts in prenatal diagnosis, clinical epidemiology 
and statistics agreed on a critical noninferiority margin of 0.002. At least 4497 paired test 
results were needed (one-sided alpha 0.05, power 0.90), to reject the null hypothesis that 
MLPA is inferior to karyotyping. We calculated diagnostic accuracy by dividing the sum of 
the true positive and true negative results by the total number of participants. Sensitivity 
and specificity were calculated by standard formulas for binominal proportions; 95 percent 
confidence intervals were calculated by the Wilson interval method16,17. Failed results were 
expressed in absolute numbers and percentages. To identify patient, procedural and centre-
specific characteristics associated with failure rate, we performed backward-selection logistic 
regression analysis. Differences in costs were tested with Student’s t-tests (SPSS version 16.0). 
Differences in turnaround time for test results were compared with a Kruskal-Wallis followed 











In total 4648 women were eligible and 64 (1.4%) were excluded; 4585 amniotic fluid 
samples were tested with both MLPA and karyotyping (figure 1). The laboratory results of 
280 women were published before (18). Patient and procedural characteristics are listed 
in table 1 and 2. In 4484/4585 samples (97.8%) MLPA and karyotyping were concordant, 
showing normal results in 4386/4585 (95.7%) and aneuploidy in 98/4585 (2.1%) (table 
3). Discordant results were found in 26/4585 (0.6%) samples, representing an abnormal 
Figure 1: Enrolment of patients undergoing amniocentesis in the M.A.K.E.study according to 
STARD guidelines
Table 1. Demographic Characteristics of the Studied Cohort. n=4585
Demographic characteristic Number %
Median Age 38.1* 29.0†
Indication
Advanced maternal age 3463 75.6%
Increased risk following prenatal screening 1074 23.4%
Anxiety 47 1.0%
Median Gravidity 2* 13†
Median Parity 1* 8 †
Median Gestational age (weeks +days) 16 + 1* 14+6-17+4 †
† range
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karyotype not detected by MLPA (table 4 and table 5). Diagnostic accuracy of MLPA was 1.0 
(95% confidence interval (CI) 0.99 to 1.0) with a sensitivity of 100% (95% CI 0.96-1.0) and 
a specificity of 100% (95% CI 0.999 to 1.0). Therefore, we rejected the null hypothesis that 
MLPA is inferior to karyotyping (P< 0.001). 
In 75 cases (1.6%) the MLPA test result failed. Karyotyping failed in one of these 75 cases 
(0.02%). The failure rate of MLPA was 2.4% in the first four months of the study, thereafter 
decreasing to 1.5% in the last 11 months. Variables significantly associated with increasing 
failure rate were: contaminated amniotic fluid (odds ratio (OR) 5.29 95% CI 2.4 to 11.6) and 
Table 2. Procedural Characteristics of the 4585 studied amniocentesis. 
Procedural characteristic Description Number %
Amniotic fluid (ml) 20* 10†
Color of amniotic fluid Clear/yellow 4465 97.4%
Red/Brown/Turbid/Green 118 2.6%
Attempts of amniocentesis 1 attempt 4506 98.3%
>1 attempt 79 1.7%
Needle size 20 Gauche 2620 57.1%
22 Gauche 1942 42.4%
Other (18 Gauche,19 Gauche) 14 0.3%
Unknown 9 0.2%
Transplacental approach Yes 477 10.4%
No 4053 88.4%
Unknown  55 1.2%
Operator technique of amniocentesis Single operator no continuous 
US**
1131 24.7%
Single operator with continuous 
US***
1152 25.1%




Cell pellet color White 3923 85.6%
Trace of blood 381 8.3%
Red/Brown/ Turbid/Green 256 5.6%
Unknown 25 0.5%
Amniotic fluid for MLPA (ml)  4* 9†
*median, † ranges
**Single operator technique without continuous US: obstetrician makes the ultrasound (US), selects 
the needle insertion site, inserts the needle under direct ultrasound guidance, and aspirates the 
amniotic fluid thereby keeping the needle in a fixed position. During the aspiration of 20 ml 
amniotic fluid the needle will not be visualized in utero. Directly following the removal of the 
needle, the obstetrician makes an ultrasound.
***Single operator technique with continuous US: obstetrician makes the ultrasound, selects needle 
insertion site, inserts the needle with ultrasound monitoring and aspirates the amniotic fluid with 
continuous ultrasound guidance.
****Dual operator technique with continuous US: a (physician-)sonographer performs and 










contaminated cell pellet (OR 3.39 95% CI 1.98 to 5.81). Variables significantly associated 
with a lower risk on failure were: time from start of study participation (per month OR 0.95 
95% CI 0.90 to 0.99) and milliliters amniotic fluid available for MLPA (per ml OR 0.78 95% 
CI 0.69 to 0.88). Compared with dual operator technique, the single operator technique 
with (OR 0.22 95% CI 0.1 to 0.48) and without (OR 0.28 95% CI 0.14 to 0.55) continuous 
ultrasound control was significantly associated with a lower risk of failure. 
We performed 1223 MLPA reactions in phase 1 (median time for phase 1 was 6 months) 
and 3362 in phase 2. Median laboratory turnaround time for MLPA was 6 days (interquartile 
range (IQR) 4 to 8) in phase 1, 3 days (IQR 2 to 7) in phase 2 and 17 days (IQR 15 to 20) 
for karyotyping (figure 2) (medians phase 1 vs phase 2 vs karyotyping: P<0.001; medians 
phase 1 vs phase 2: P<0.001; medians phase 1 vs karyotyping: P <0.001; and medians 
phase 2 vs karyotyping: P<0.001; all Kruskal-Wallis test followed by Dunn’s test). 
Table 3. Concordant test (n= 4484) results of MLPA and Karyotyping in the study.
MLPA results n Karyotype results n
Normal female/male 4386 46,XX or 46,XY 4386
Abnormal (total) 98 Abnormal (total) 98
trisomy 21 69 47,XX,+21 / 47,XY,+21 68
mos 47,XY,+21[8]/46,XY[3] 1
trisomy 18 15 47,XX,+18 / 47,XY,+18 15
trisomy 13 1 47,XX,+13 1
XXY 5 47,XXY 5
XYY 1 47,XYY 1
XXX 2 47,XXX 2
mosaic Trisomy 21 and mosaic Turner 1 45,X[13]/47,XX,+21[11] 1
mosaic Turner 1 mos 45,X[9]/46,XX [17]     1
mosaic Klinefelter 1 47,XXY[4]/46,XY[8] 1
structural chromosome X aberration suspected 2 45,X[6]/46,X,psu idic(X)(p21)[7] 1
46,X,i(X)(q10) 1
Total MLPA results 4484 Total karyotype results 4484
Table 4. Discordant and failed results of MLPA and Karyotyping in the study. 
MLPA n Karyotyping n
Normal male/female 26 Abnormal (total) 26
mosaicism 3
supernumerary marker chromosome 4
structural inherited balanced chromosome aberration 14
structural de novo apparently balanced chromosome aberration 4
structural de novo unbalanced chromosome aberration 2
Failed 75 46,XX or 46,XY 74
Failed 1
32
Figure 2: Laboratory turnaround time for multiplex ligationdependent probe amplification (MLPA) 


























Table 5. Total of chromosomal abnormalities detected with karyotyping and not detected with 
MLPA out of 4585 amniocentesis; arranged in order of clinical consequences























mos 45,X[6]/46,XX[11] confirmed postpartum 45,X[3]/46,XX[32]
Mos 47,XX,der (17)(p11.1q11.1)[10]/46,XX[12]













Median time between amniocentesis and informing pregnant women was 3 days (IQR 3 
to 7) for MLPA and 18 days (IQR 16 to 21) for karyotyping. Mean time reduction of MLPA 
compared with karyotyping was 13.8 days (P<0.001, 95% CI 13.7 to 14.0) and 14.5 days 
(P<0.001, 95%CI 14.3 to 14.6), on laboratory and patient level respectively. 
Costs for MLPA were $472. Costs for karyotyping were $915. Mean cost reduction per 
sample was $433 (95% CI $416 to $449; - 47%) in favor of MLPA (P<0.001).  
DISCUSSION
In this nationwide prospective cohort study including more than 4500 women, we 
demonstrated that diagnostic accuracy of MLPA to detect aneuploidies of chromosomes 
21, 13, 18, X and Y is comparable to karyotyping and MLPA is less costly than karyotyping. 
Our large study under standard practice conditions confirms and extends the findings of 
recent preclinical studies on MLPA19,20. Compared with other techniques for rapid aneuploidy 
detection, diagnostic accuracy of MLPA is similar to quantitative fluorescent polymerase 
chain reaction (QF-PCR) (0.99-1.0) and fluorescence in situ hybridization (FISH) (0.99-1.0) 
with comparable failure rates of 0.1%-3.7% for QF-PCR and 0.0%-4.9% for FISH (21-
26). However, few of these results were obtained under practice conditions. Compared 
with QF-PCR, MLPA is relatively sensitive to DNA quality and does not detect maternal 
cell contamination in female samples or female triploidies. MLPA can detect 40 genomic 
targets in one reaction and avoids the problem of noninformativeness of the polymorphic 
markers that may occur with QF-PCR. Compared with FISH, MLPA and QF-PCR are both 
more suitable for high-throughput testing at lower costs22. Therefore, QF-PCR and MLPA 
represent the preferred techniques for routine prenatal diagnosis. FISH, however, is preferred 
if chromosomal mosaicism is suspected, as detection levels of 5% can be achieved23.
Our study showed lower costs of MLPA compared to karyotyping; however, similar to studies 
on QF-PCR and FISH, considerable variation among laboratories exists, mainly caused by 
differences in sample throughput and logistics22. Further research is warranted to determine 
the additional costs accrued by life time costs of chromosomal abnormalities.
The failure rate of 1.6%, similar to previous studies12,19,20, is a concern. In a standalone 
policy, failure implies repeating the amniocentesis with its inherent risks. It is likely that the true 
failure rate in a standalone policy is lower. Firstly, there was a 38% reduction of the failure 
rate (from 2.4 % to 1.5%) between early and later experience with the test. Secondly, the 
study protocol prioritized karyotyping, which requires 12 ml of amniotic fluid. In a standalone 
policy, more amniotic fluid is available for MLPA and the failure rate will fall. Thirdly, a further 
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decrease of failure may occur when a lower number of bloody samples can be achieved. 
The American College of Obstetricians and Gynecologists recommends continuously 
visualizing the needle for this purpose27. From our study results and the available evidence, 
we recommend using the single operator technique with continuous ultrasound control. 
Furthermore, there are two options to manage macroscopically blood-stained samples; one 
is to detect the proportion of fetal hemoglobin (HbF) versus adult hemoglobin and perform 
MLPA if the HbF level is ≥ 85% of the total hemoglobin20, or to omit MLPA and perform 
karyotyping on these samples. Finally, in a standalone policy, we recommend short-term 
storage of AF cells to allow karyotyping should MLPA fail and subsequent storage of DNA 
to allow follow-up molecular diagnostics without repeated amniocentesis should ultrasound 
examination show an abnormality.
The main argument against replacing karyotyping by rapid aneuploidy detection is that 
some clinically severe chromosomal abnormalities will remain undetected. Of the 26 
chromosomal abnormalities (out of 4585; 0.6%) which MLPA could not detect, 17 were 
without clinical consequences for the current pregnancy (see table 5). Of these, 14 were 
inherited balanced rearrangements, which may lead to future unbalanced rearrangements. 
Six of the remaining nine abnormalities were chromosomal abnormalities with uncertain 
clinical consequences. If detected, this type of abnormality leads to difficult counseling issues 
and emotional dilemmas7. It is questionable whether their detection is in the best interest of 
the parents as it may lead to an unwarranted termination of pregnancy1,28. The last three 
chromosomal abnormalities were of serious clinical significance (see table 5); this overall 
residual risk of 0.07% confirms findings by others1,21. In our study, with knowledge of the 
karyotype, standard follow-up ultrasound examination showed abnormalities in one out of 
three. Hence, when using standalone MLPA combined with ultrasound examination, two 
chromosomal abnormality of serious clinical significance remain undetected. In total, three 
of the 26 pregnancies were terminated (one of uncertain clinical consequence, two of serious 
clinical significance) and 23 were continued. Therefore, in our sample of 4585 pregnancies, 
the added knowledge from karyotyping leads to three extra terminations of pregnancy. 
The provision of rapid, unambiguous and low cost results is an incentive to implement 
MLPA. Successful implementation also requires the support of pregnant women29. So far two 
studies show that pregnant women prefer rapid aneuploidy detection over karyotyping22,30. 
A Swedish study showed that 70% of women offered an actual choice preferred rapid testing 
over karyotyping31. At the public health level these studies suggest that rapid testing is the 
preferred strategy. If one adheres to individual choice, one could argue that the decision to 
either obtain as much cytogenetic information as possible versus a rapid specific result is 










In this era of rapid developments in prenatal diagnosis, the debate on what to test for remains 
essential. At present, the use of micro arrays, which can detect even more chromosomal 
abnormalities than karyotyping, is being studied32. Within a few years, non-invasive diagnosis 
of fetal chromosomal abnormalities in maternal blood may be available33, excluding the 
procedure-related miscarriage risk. Even with these new developments, the debate on 
targeted or whole genome testing remains in force. The widespread introduction of molecular 
tests changes the scope of prenatal diagnosis and should encourage the development of 
strategies that tailor the type of diagnostic test offered to the risk identified. Future studies 
should focus on the application of tailor-made strategies, including the views of pregnant 
women and possible barriers that hamper successful implementation of new prenatal test 
strategies. For now, the use of MLPA in prenatal diagnosis appears a prudent strategy. 
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ABSTRACT
Objective
To assess the impact of rapid aneuploidy detection (RAD) combined with fetal karyotyping 
versus karyotyping only on maternal anxiety and health related quality of life.
Methods
Women choosing to undergo amniocentesis were selected into group 1 i.e., receiving 
a karyotype result only (n=132) or to group 2 i.e., receiving both the result of RAD and 
karyotyping (n=181). 
Results
There were no systematic differences in time of RAD combined with karyotyping versus 
karyotyping only in terms of anxiety (P=0.91), generic physical health (P=0.76, P=0.46), 
generic mental health (P=0.52, P=0.72), personal perceived control (P=0.91), and stress 
(P=0.13). RAD combined with karyotyping reduced anxiety and stress two weeks earlier 
compared to karyotyping only. 
Conclusion
RAD as add-on to karyotyping reduces anxiety and stress in the short term, but it does not 
influence overall anxiety, stress, personal perceived control, and generic mental and physical 
health when compared to a karyotype only strategy. 
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INTRODUCTION
Amniocentesis is the most frequently used invasive prenatal diagnostic procedure in Western 
countries and is performed in about one in 30 pregnancies1,2. Advanced maternal age and/
or increased risk following first trimester prenatal screening for Down syndrome are the most 
common indications for invasive testing.
Karyotyping is considered the gold standard for the detection of fetal chromosomal 
abnormalities in amniotic fluid cells3,4. The reporting time may take up to three weeks, due 
to the required cell culture to obtain dividing cells. This waiting period is considered stressful 
and emotionally burdening to the parents5-7.
In the last decade new molecular techniques have become available for rapid aneuploidy 
detection (RAD) of the most common aneuploidies; aneuploidies of chromosomes X, Y, 13, 
18 and 21. A major advantage of RAD is a highly accurate result available within a few days. 
Potentially this should reduce parental stress and anxiety. Multiplex Ligation-dependent Probe 
Amplification (MLPA) is one of these techniques and was shown to be robust8,9.
As part of the nationwide MLPA And Karyotyping, an Evaluation (M.A.K.E.) study in which we 
compared MLPA head to head with karyotyping, we assessed the impact of MLPA as add-on 
to karyotyping on anxiety, mental and physical health, personal perceived control and stress 
during prenatal diagnosis. The aim of this comparative study was to assess the impact of MLPA 
as add-on to karyotyping on the experienced anxiety, stress and Health Related Quality of Life 
(HRQoL) of the prospective parents during the testing process. Our research question was: Do 
women who undergo amniocentesis experience less anxiety and better HRQoL when MLPA as 
add-on test is carried out prior to karyotyping when compared to a karyotyping only strategy? 
METHODS
Study design
This study was designed as a prospective cohort study. The aim was to compare the level of 
anxiety and HRQoL of women receiving a karyotype result (group 1) with women receiving 
both an MLPA and karyotype result (group 2). The study was carried out alongside the clinical 
M.A.K.E. study. The M.A.K.E. study has been described before in detail10. For the HRQoL 
study, we aimed at an inclusion of 175 women per group. Assuming an incomplete response 
rate of 30%, this would leave 123 women per group for analysis. Group 1 was recruited from 
December 2006 to August 2007 in three prenatal clinics (Leiden University Medical Center, 




pact of a rapid result in prenatal diagnosis
43
before the introduction of MLPA. Group 2 was recruited following the laboratory validation of 
MLPA and took place from April 2007 to December in 2007 in five hospitals (Leiden University 
Medical Center, Leiden; Erasmus University Medical Center, Rotterdam; Radboud University 
Medical Center, Nijmegen; Rijnstate hospital, Arnhem; St. Elisabeth hospital, Tilburg). 
In group 1, fetal karyotype was disclosed as soon as the result was available, usually within 
16-21 days. In group 2, participants received the MLPA results within 3-4 days and karyotyping 
results as soon as they were available. 
Women attending the department of prenatal care, who chose to have amniocentesis and 
considered eligible for study participation, were invited to participate. After a woman consented 
to participation, she received the set of surveys with prepaid envelopes. The surveys were 
to be filled in at home, according to the following scheme: one before amniocentesis was 
done (Q1), the other surveys at respectively 2 (Q2), 14 (Q4), 23 (Q5) and 63 days (Q6) 
after amniocentesis (table 2). For group 2 an additional survey was given at 5 days (Q3) 
after amniocentesis to measure anxiety after the MLPA result had been disclosed. Patient 
characteristics were collected in survey Q1 (table 2). 
Procedures
Amniocentesis was carried out by trained obstetricians following national guidelines11. Four 
genetic laboratories performed all diagnostic tests (Leiden University Medical Center, Academic 
University Medical Center, Erasmus University Medical Center, and Radboud University 
Medical Center). We used the MLPA P095 kit (MRC Holland, Amsterdam) for the detection of 
aneuploidies of chromosome X, Y, 13, 18 and 21. The principle of MLPA has been described 
before8. Karyotyping was carried out according to national guidelines12. 
Study population
The target population consisted of all pregnant women who chose to have amniocentesis for 
advanced maternal age (36 years or older), increased risk following first trimester screening for 
Down syndrome (risk > 1: 200)13 or parental anxiety for having a child with a chromosomal 
abnormality. Other inclusion criteria were a singleton pregnancy, sufficient command of the 
Dutch language, and age at least 18 years. Women were excluded from the analysis if they 
had received an abnormal test result or in case of a miscarriage. The Institutional Review 
Board approved of the study and written informed consent was judged not to be necessary. 
Outcome measures
Spielberger State-Trait Axiety Inventory (STAI) 
The aim of the STAI is to quantify the level of anxiety experienced at any point in time (State, 
s-anxiety), while allowing for the inherent anxiety (Trait, t-anxiety) normally felt by the subject14. 
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The State and Trait subscales, with 20 items each in a 4-point response format, range from 
20-80, with higher scores indicating greater anxiety. We used the validated Dutch version 
of the STAI15. The Trait scale was only asked at Q1, as this generally reflects the woman’s 
inherent anxious personality which should not change significantly in different situations. The 
State subscale was included in all surveys, as we expected fluctuations in State anxiety in 
response to various situations. 
Medical Outcome Study Short Form (SF-36) 
The SF-36 questionnaire is a self-administered health survey used to assess physical and 
mental health concerning the past 4 weeks. It comprises of 36 questions summarized in the 
following eight domain scores: physical functioning, role functioning due to physical and 
emotional problems, social functioning, bodily pain, mental health, vitality, and general health 
perceptions. The eight domain scores are summarized in two summary scales: the physical 
component summary scale (PCS) and the mental component summary scale (MCS), which are 
derived using weighted averages of the individual domain scores. The PCS and MCS scores 
range from 0-100 (100 indicating optimal score). We used the validated Dutch version of the 
SF-36 (mean Cronbach’s alpha 0.84)16. We included the SF-36 in surveys Q1 and Q6, since 
the questionnaire focuses on the physical and mental health during the preceding 4 weeks.
Personal Perceived Control (PPC)
The PPC was introduced in 1997 to evaluate the process of genetic counseling17. The aim of 
the PPC is to measure an individual’s belief that they have the resources necessary to respond 
to an event in a way that will decrease its negative effect18. The quality of counseling can 
influence the feeling of control and thereby influence the patient’s experienced control and 
stress. We used the Dutch PPC as a one-dimensional instrument with a possible score ranging 
from 0 to 2, with higher scores indicating more perceived control19. The PPC was included 
in all surveys to assess the woman’s control during the complete prenatal diagnostic process.
Impact of Event Scale (IES) 
The aim of the 15-item IES is to measure the impact of a named stressor20. The scale 
distinguishes the components intrusion and avoidance in a 4-point response format with a 
possible total score ranging from 0 to 75. Higher scores indicate higher stress levels. We 
used the validated Dutch version of the IES21. The stressor varied according to the process 
of care: in Q2 and Q4 it was amniocentesis, in Q3 the MLPA result, in Q5 the karyotyping 
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Missing data
Participants with two or more missing surveys (Q1-Q6) were regarded as incomplete responders 
and excluded from analysis. Missing data were imputed if one survey was missing using REML 
procedures of linear mixed models (LMM, SPSS 16.0). In case less than 50% of the responses 
to a questionnaire were missing, data were imputed using mean imputation; otherwise the 
questionnaire was regarded missing.
Statistical analyses 
Descriptive summaries of patient characteristics and quality of life measurements included 
means and standard deviations (SD) for normally distributed variables and medians with 
ranges for other variables. Demographic characteristics of group 1 and 2 were compared 
by independent t test and Χ2 test, or Mann Whitney U, if appropriate. We compared 
demographic characteristics as well as mean baseline quality of life scores between women 
completing all questionnaires and those who did not in order to test for selection bias. 
We used repeated measurement analysis (SPSS 16.0, linear mixed models, unstructured 
covariance) on transformed State, PPC (log transformed), and IES (√IES+0.5 transformed) 
scores to evaluate longitudinal differences between the groups with adjustment for differences 
in baseline characteristics. Differences in State, PPC and IES between the groups at the 
separate time points were assessed with Mann Whitney U. Linear regression analysis was used 
to analyze difference in the eight domains of the SF-36, and PCS and MCS scores, adjusted 
for differences in baseline characteristics. A P-value of <0.05 (two sided) was considered 
statistically significant in all analyses. 
RESULTS
Eligible for study participation in group 1 and 2 were 175 and 225 consecutive women 
respectively, of whom 165 (94.3%) and 209 (92.3%) agreed to participate. The most commonly 
cited reasons to decline participation were disinterest and lack of time (figure 1). Seven women 
in group 1 and six women in group 2 were excluded after MLPA or karyotyping disclosed a 
chromosomal abnormality (figure 1). One woman in group 2 was excluded due to ruptured 
membranes after the amniocentesis and subsequent termination of pregnancy. 
Table 1 shows demographic characteristics of both groups and for complete and incomplete 
responders. A total of 313 (83.7%) women completed all or all but one questionnaires. 132 
out of 158 (83.5%) women in group 1 and 181 out of 203 (89.2%) women in group 2. In 
group 1, the incomplete responders had a significant lower Trait anxiety (P= 0.002) (table 
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0.03) (table 1). Complete responders in group 2 had a significantly lower educational level 
than women in group 1 (P= 0.02), but otherwise the groups did not differ (table 1). 
Quality of life outcome
State-anxiety 
There were no systematic longitudinal differences in anxiety between the groups (P=0.91, 
table 3). Pattern of anxiety differed significantly over time, with a decrease of anxiety in both 
groups after obtaining a test result (figure 2). Cross-sectionally, anxiety scores between the 
groups differed significantly at 2, 14, and 23 days (P=0.001, P= 0.02, P= 0.009, respectively 
Supplementary Table S1) following amniocentesis, with alternating dominance of test technique 
(figure 2). Women with high State and Trait scores prior to amniocentesis reported high anxiety 
scores in the subsequent questionnaires (P<0.001, table 3); demographic factors did not 
Table 1: Patient characteristics and baseline scores of complete and incomplete responders of 
group 1 (karyotyping) and group 2 (MLPA and karyotyping).
Group 1 (Karyotyping) Within
group 1
Group 2 (MLPA + Karyotyping) Within
group 2
Complete group 
1 vs 2complete incomplete complete incomplete
Number 139 26* 187 22
Chromosomal abnormality 7 (5.0%) 1 (3.8%) 6 (3.2%) 1 (4.5%)
Analysed 132 181
Mean age (SD) 38.3 (2.69) 38.5 (3.09) p 0.77 37.9 (2.69) 37.3 (3.20) p 0.45 p 0.16
Mean parity (SD) 0.9 (1.00) 1.0 (0.70) p 0.47 1.1 (1.08) 1.0 (0.98) p 0.68 p 0.15
Mean gravidity (SD) 1.6 (1.40) 1.8 (1.10) p 0.49 1.8 (1.57) 2.0 (1.43) p 0.51 p 0.26
Indication p 0.38 p 0.41 p 0.63
maternal age 112 (84.8%) 21 (80.0%) 157 (86.7%) 20 (90.9%)
prenatal screening 16 (12.1%) 3 (11.5%) 21 (11.6%) 2 (9.1%)
anxiety 4 (3.0%) 1 (3.8%) 3 (1.7%) 0 (0%)
Highest educational level p 0.65 p 0.13 p 0.02
Lower vocational, lower secondary school 17 (12.9%) 4 (15.4%) 29 (16.0%) 4 (18.2%)
Intermediate and higher vocational, higher secondary 33 (25.0%) 5 (19.2%) 69 (38.1%) 6 (27.3%)
College/University 82 (62.1%) 16 (61.5%) 83 (45.9%) 12 (54.5%)
Western? 118 (89.4%) 19 (73.1%) p 0.17 168 (92.8%) 17 (77.3%) p 0.03 p 0.29
Religion p 0.41 p 0.27 p 0.16
atheist 76 (57.6%) 16 (61.5%) 90 (49.7%) 8 (36.4%)
catholic 37 (28.0%) 6 (23.1%) 58 (32.0%) 9 (40.9%)
protestant 9 (6.8%) 0 (0%) 24 (13.3%) 2 (9.1%)
other 10 (7.6%) 3 (11.5%) 9 (5.0%) 3 (13.6%)
Previous PND? 25 (18.9%) 8 (30.8%) p 0.11 44 (24.3%) 3 (13.6%) p 0.26 p 0.26
Median state at S1 (IQR) 35.0 (30-42) 36.5 (31-47) P 0.35 36.0 (30-47) 41 (31-48) p 0.55 p 0.33
Median trait at S1 (IQR) 32.0 (26-38) 37.0 (32-42) p 0.002 32.0 (27-39) 31.0 (25-42) p 0.71 p 0.45
Median PCS at S1 (IQR) 52.7 (48-57) 54.6 (49-56) p 0.39 53.0 (45-57) 53.0 (45-57) p 0.33 p 0.76
Median MCS at S1 (IQR) 48.9 (41-53) 48.1(33-52) p 0.22 49.3 (42-53) 51.0 (42-55) p 0.79 p 0.52
Median PPC at S1 (IQR) 1.3 (0.9-1.6) 1.3 (1.0-1.7) p 0.39 1.4 (0.8-1.7) 1.3 (1.1-1.6) p 0.99 p 0.90
*one participant returned questionnaire B and D, therefore baseline characteristics are unknown 
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affect anxiety scores. Interaction effects between anxiety levels and group over time differed 
significantly on day 2, 14 and 23 between group 1 and 2 (P= 0.007; P<0.001; P=0.01 
respectively, table 3).
SF-36
There were no significant differences in mean PCS and MCS scores, nor in the eight domain 
scores between the groups before and at 63 days after amniocentesis (PCS: P= 0.76; P= 
0.46; MCS: P= 0.52; P=0.72; table 4). The changes in PCS and MCS, adjusted for education 
and western origin, did not differ significantly between the groups (PCS: beta -0.17 95% CI 
-2.11 to 1.77 p 0.86; MCS: beta -0.34 95% CI -2.33 to 1.65 p 0.74). 
PPC
There were no systematic longitudinal differences between the groups (P=0.91, Supplemental 
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Mean gravidity (SD) 1.6 (1.40) 1.8 (1.10) p 0.49 1.8 (1.57) 2.0 (1.43) p 0.51 p 0.26
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prenatal screening 16 (12.1%) 3 (11.5%) 21 (11.6%) 2 (9.1%)
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Intermediate and higher vocational, higher secondary 33 (25.0%) 5 (19.2%) 69 (38.1%) 6 (27.3%)
College/University 82 (62.1%) 16 (61.5%) 83 (45.9%) 12 (54.5%)
Western? 118 (89.4%) 19 (73.1%) p 0.17 168 (92.8%) 17 (77.3%) p 0.03 p 0.29
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Median trait at S1 (IQR) 32.0 (26-38) 37.0 (32-42) p 0.002 32.0 (27-39) 31.0 (25-42) p 0.71 p 0.45
Median PCS at S1 (IQR) 52.7 (48-57) 54.6 (49-56) p 0.39 53.0 (45-57) 53.0 (45-57) p 0.33 p 0.76
Median MCS at S1 (IQR) 48.9 (41-53) 48.1(33-52) p 0.22 49.3 (42-53) 51.0 (42-55) p 0.79 p 0.52
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Table 2: Description of questionnaires and its contents in time
Questionnaire Point in time Content Group
Questionnaire 1 Before amniocentesis Demographic characteristics, STAI, PPC, MOS SF-36 1 and 2
Questionnaire 2 Amniocentesis + 2 days STAI, PPC, IES 1 and 2
Questionnaire 3 Amniocentesis + 5 days STAI, PPC, IES 2
Questionnaire 4 Amniocentesis + 14 days STAI, PPC, IES 1 and 2
Questionnaire 5 Amniocentesis + 23 days STAI, PPC, IES 1 and 2






































































Figure 2: Median scores with interquartile ranges (IQR) of 132 women receiving karyotyping and 
181 women receiving MLPA and karyotyping.
Significant differences in cross-sectional analysis are marked with the P-value
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file S2). Time had a significant effect on PPC levels before and 2 days after amniocentesis 
(P<0.001) with higher perceived control in both groups before obtaining a test result. 
Compared to a university education, lower and middle education was associated with a 
lower PPC score. Cross-sectionally, there were no significant differences between the groups 
(figure 2).
IES
There was no systematic difference in stress level between the groups (P=0.13; supplementary 
Supplemental file S3). Pattern of stress, however, differed significantly over time, with a decrease 
of stress in both groups after obtaining a test result (figure 2). Cross-sectionally, group 1 had 
significantly higher stress scores at 14 and 23 days after amniocentesis compared to group 2 
(P= 0.01, P<0.001 respectively; figure 2). Interaction effects between IES scores and group 
over time differed significantly on day 14 and 23 following amniocentesis (P<0.001; P<0.001).
DISCUSSION
Overall, our study showed no systematic gain in quality of life, personal perceived control 
and stress by RAD combined with karyotyping compared to karyotyping only. 
Table 3: Repeated measurement analysis. Linear mixed models on log transformed State scores. 
Parameter Estimate 95% CI P value
Intercept 1.82 1.59 to 2.05 <0.001
AC + 2 days 0.29 0.25 to 0.33 <0.001
AC + 5 days 0.06 0.02 to 0.09 0.001
AC + 14 days 0.10 0.06 to 0.13 <0.001
AC +23 days 0.01 -0.02 to 0.03 0.66
AC +63 days ref . .
Group 1 -0.002 -0.05 to 0.05 0.91
Group 2 ref . .
Interaction AC + 2 days *group 1* -0.09 -0.15 to -0.02 0.007
Interaction AC + 14 days* group 1* 0.11 0.06 to 0.17 <0.001
Interaction AC +23 days* group 1* -0.05 -0.09 to -0.01 0.01
Interaction AC +63 days*group1* ref . .
Baseline log State 0.33 0.26 to 0.40 <0.001
Baseline Trait 0.01 0.01to 0.01 <0.001
Lower vocational, lower secondary school -0.04 -0.10 to 0.01 0.11
Intermediate and higher vocational, higher secondary 0.004 -0.04 to 0.04 0.85
College/University ref . .
Non western origin 0.009 -0.05to 0.07 0.79
Western origin ref . .
-2 loglikelyhood= -658,02, * reference: interaction time*group2, AC= amniocentesis; group 1= karyotyping; 
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The impact of providing a RAD result, followed by later reporting of the full karyotype consisted 
of three components. Firstly, providing a rapid test result induced significantly higher levels 
of anxiety at 2 days following amniocentesis. Secondly, after disclosure of the MLPA result, 
anxiety decreased significantly. Thirdly, the karyotype only group had significant lower anxiety 
scores after disclosure of the karyotype result. We also found that the reduction of anxiety 
after disclosure of MLPA in the combined strategy approximately equals the reduction of 
anxiety after disclosure of the karyotype result in the karyotyping only strategy. On balance, a 
combined strategy accelerates the reduction of anxiety and stress with two weeks compared 
to a karyotyping only strategy. 
The strength of our study is the prospective study design with high response rate of the 
consecutively included women and the broad perspective evaluating various aspects of 
psychological health. The limitation of this study design is its non-randomized design. The 
various outcome measures had to be adjusted for differences between patient characteristics 
at baseline and between complete and incomplete responders. We cannot rule out over- or 
under adjustment. Furthermore, it is unclear if the patterns of anxiety, stress, PPC and HRQoL 
for normal results also apply to women with fetal chromosomal abnormalities. 
The temporary reduction of anxiety after receiving the MLPA result is consistent with previous 
studies22-25 on QF-PCR and FISH. We found a rise in anxiety just before the disclosure of 
the RAD test result. This increase in anxiety may be related to the novelty of introducing 
RAD. It is more likely represent anxiety related with a prospective but uncertain outcome26. 
A similar pattern of increasing anxiety was seen in the ARIA trial before disclosure of the 
karyotype22. In our study we did not measure anxiety at that point. If the anxiety peak truly 
exists, a strategy can be developed to decrease this peak. During the counseling process the 
pattern of anxiety can be discussed and this knowledge might be helpful to cope better with 
the anxiety. We found lower anxiety scores in the karyotype only group after disclosure of 
the karyotype compared to the combined group. A similar pattern was observed in the ARIA 
trial22, but other studies do not show this difference23,25. We speculate that the lower anxiety 
scores in the karyotype only group can be explained by the ‘relief’ effect in learning that the 
test result was normal27,28, while the RAD group already expected a normal result, since the 
RAD result was normal. Alternatively, it is also possible that the combined strategy induces 
anxiety temporarily. Issuing a result twice may induce anxiety by fixing the parent’s attention 
twice on a possible genetic problem, hereby reducing the feeling of a carefree pregnancy. In 
the long term, however, no differences in anxiety were present. This finding is in agreement 
with other studies23,25. Compared to the similar studies previously mentioned22,23,25, the 
average anxiety levels in our groups were remarkably lower. We speculate that this difference 
is mainly caused by differences in referral indication, which was mostly advanced maternal 
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age in our study rather than increased risk following first trimester prenatal screening in the 
other studies22,25. However, in our analysis indication had no significant effect on anxiety, 
stress, personal perceived control and HRQoL (data not shown). Another explanation could 
be that Dutch women experience less anxiety during prenatal diagnosis, because of cross-
cultural differences or the organization of Dutch obstetrical care. The decentralized obstetrical 
care with independent midwives, the Dutch physiological approach of pregnancy by maternal 
health care providers, and the national prenatal screening program may all lead to increased 
personal perceived control, possibly leading to decreased anxiety levels. Previous similar 
studies did not measure PPC and thus this cannot be compared. Our groups reported equal 
personal perceived control; thereby supporting the notion that differences in anxiety and stress 
were not the result of differences in personal control. 
The major differences in anxiety and stress on the short term apparently did not translate into 
long term effects on overall mental and physical health. Previous studies on mental health 
in pregnancies showed stable MCS scores during first and second trimester29,30. Our results 
suggest that the RAD plus karyotype strategy has no adverse long term effects on HRQoL 
and, in addition, that normal results reassure and improve mental HRQoL. The reduction 
in physical health during the test process is in agreement with two studies that reported on 
the relationship between RAD and HRQoL23,25 and is associated with increasing gestational 
age28,29. Assuming that a 5 point difference on a scale from 0-100 is clinically relevant25,31, 
the size of effect of rapid testing on anxiety and stress reduction by issuing a rapid result is 
clinically relevant. However, the clinically relevant difference between the groups was not 
observed in the days following RAD disclosure. Therefore, we conclude that the reduction in 
anxiety and stress by providing an MLPA result next to karyotyping is clinically relevant on the 
short term, but on the long term there is no psychological benefit from the add-on strategy. 
Recently, a debate emerged in European countries whether RAD should replace karyotyping in 
prenatal diagnosis for advanced maternal age, increased risk following first trimester prenatal 
screening and maternal anxiety; i.e. substitution rather than a combined strategy as in our 
study. The substitution would lead to substantial cost savings, with a risk of 0.06 % of failure 
to detect a chromosomal abnormality likely to have serious clinical significance which can be 
detected with karyotyping1,23. We feel that the decision to either obtain as much cytogenetic 
information as possible versus a rapid but specific result of the most common chromosomal 
abnormalities is most appropriately made by individuals who will bear the responsibility of 
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CONCLUSION
Although many women and caregivers regard stress and anxiety as important side effects 
of prenatal diagnosis, the low STAI and IES scores indicate that most women can cope with 
the situation. RAD as add-on to karyotyping reduces anxiety and stress in the short term by 
providing a rapid result. Overall, there were minor psychological benefits of the combined 
strategy compared to karyotyping only. Therefore, from the psychological point of view RAD 
as add-on is of limited value to women having amniocentesis for relatively low risk indications. 
Supplementary Table S1: Cross-sectional analysis of median differences in State, PPC, IES, 
SF-36 in time.   
Questionnaire Time Median group 1 Median group 2 P value
State Before AC 35.0 36.0 0.33 
AC + 2 days 34.0 38.0 0.001 
AC + 14 days 34.0 32.0 0.02  
AC +23 days 26.0 30.0 0.009 
AC +63 days 28.0 30.0 0.42
PPC Before AC 1.33 1.33 0.98
AC + 2 days 1.44 1.33 0.41
AC + 14 days 1.33 1.33 0.16
AC +23 days 1.33 1.33 0.27
AC +63 days 1.33 1.33 0.46
IES AC + 2 days 10.0 10.0 0.69
AC + 14 days 7.0 4.0 0.01 
AC +23 days 7.0 3.0 <0.001
AC +63 days 2.0 1.0 0.22
SF-36 PCS Before AC 52.7 53.0 0.76
AC +63 days 47.7 47.3 0.46
SF 36 MCS Before AC 48.9 49.3 0.52
AC +63 days 54.4 54.4 0.72
AC= amniocentesis; group 1= karyotyping, group 2= MLPA + karyotyping
PPC= personal perceived control; IES= Impact of Event Scale; SF-36 PCS= physical component score, SF-36 
MCS= mental component score
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Supplemental file S2: Repeated measurement analysis. Linear mixed models on log transformed 
personal perceived control scores. 
Parameter Estimate 95% CI P value
Intercept 0.76 0.71 to 0.82 <0.001
Before AC 0.11 0.07 to 0.17 <0.001
AC + 2 days 0.11 0.07 to 0.15 <0.001
AC + 5 days 0.03 -0.01 to 0.07 0.11
AC + 14 days 0.03 -0.01 to 0.07 0.15
AC +23 days -0.01 -0.04 to 0.02 0.49
AC +63 days ref . .
Group 1 0.00 -0.07 to 0.08 0.91
Group 2 ref . .
Interaction before AC *group 1* -0.04 -0.11 to 0.03 0.24
Interaction AC + 2 days *group 1* -0.01 -0.07 to 0.06 0.84
Interaction AC + 14 days* group 1* 0.04 -0.02 to 0.10 0.17
Interaction AC +23 days* group 1* 0.01 -0.04 to 0.06 0.81
Interaction AC +63 days*group1* ref
Lower vocational, lower secondary school -0.12 -0.18 to 0.06 <0.001
Intermediate and higher vocational, higher secondary -0.07 -0.11 to -0.02 <0.001
College/University ref . .
Non western origin -0.03 -0.11 to 0.04 0.38
Western origin ref . .
-2 loglikelyhood= -819.38
* reference: interaction time*group2
AC= amniocentesis, group 1= karyotyping, group 2= MLPA+karyotyping. 
Supplemental file S3: Repeated measurement analysis. Linear Mixed Models on root+0.5 
transformed Impact of Event scale scores. 
Parameter Estimate 95% CI P value
Intercept 1,79 1.58 – 1.99 <0.001
AC + 2 days 1.70 1.44 – 1.96 <0.001
AC + 5 days 1.65 1.42 – 1.89 <0.001
AC + 14 days 0.57 0.35 – 0.78 <0.001
AC +23 days 0.36 0.16 – 0.57 <0.001
AC +63 days ref . .
Group 1 0.25 -0.07 – 0.57 0.13
Group 2 ref . .
Interaction AC + 2 days *group 1* -0.23 -0.60 – 0.14 0.22
Interaction AC + 14 days* group 1* 0.57 0.24 – 0.91 0.001
Interaction AC +23 days* group 1* 0.57 0.25 – 0.88 <0.001
Interaction AC +63 days*group1* ref . .
Lower vocational, lower secondary school 0.39 -0.03 – 0.82 0.07
Intermediate and higher vocational, higher secondary 0.07 -0.25 – 0.40 0.67
College/University ref . .
Non western origin -0.03 -0.57 – 0,51 0.91
Western origin ref . .
-2 loglikelyhood= 4297.65
* reference: interaction time*group2
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To assess the reasons and perceptions of women who are offered a choice between 
karyotyping and standalone rapid aneuploidy detection (RAD) and to compare the impact of 
both tests on anxiety and health related quality of life.
Methods
In this prospective comparative study, women undergoing amniocentesis on behalf of their 
age or for an increased Down syndrome risk were offered a choice between karyotyping 
(group1, n=68) and standalone RAD (group 2, n=61). Follow-up was 9 weeks post 
amniocentesis. 
Results
The most commonly cited reason for choosing karyotyping was obtaining as much information 
as possible, while for choosing standalone RAD it was the short waiting time. Prenatal 
screening (OR 7.09), no knowledge of karyotyping (OR 4.2) and an intermediate perceived 
risk for chromosomal abnormalities (OR 3.6) were associated with choosing standalone 
RAD. There were no systematic differences in time of karyotyping and standalone RAD in 
terms of anxiety (P= 0.11), generic physical and mental health (P=0.94, 0.52; P=0.66, 
P=0.07), personal perceived control (P=0.69), and stress (P=0.66). 
Conclusion
Offering a choice between karyotyping and standalone RAD does not influence anxiety, 
stress, personal perceived control, or generic health. Individual choice in prenatal diagnosis 
meets individual needs and thereby could reduce anxiety and stress.
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INTRODUCTION
In the last five years, a debate emerged in European countries whether rapid aneuploidy 
detection (RAD) should replace karyotyping in prenatal diagnosis for advanced maternal 
age and increased Down syndrome risk following first trimester prenatal screening (PNS). 
Opponents’ main argument is that substitution of karyotyping by RAD would lead to an 
increase of live births of children with undetected chromosomal abnormalities with severe 
clinical consequences in women undergoing an invasive diagnostic test. Proponents’ main 
argument is that the substitution of karyotyping would lead to a shortening of the stressful 
waiting time for parents, more straightforward prenatal and genetic counseling, and 
substantial cost savings, while the risk of missing a chromosomal abnormality with serious 
consequences is small1,2. At this point in time, prenatal centers decide individually whether 
or not to implement RAD as standalone test. 
Thus far, clinical studies have mainly focused on diagnostic accuracy of RAD tests compared 
to karyotyping3-5 but little is known about testing behavior and women’s perceptions 
associated with targeted versus broad testing.
To strengthen the debate, we aimed to evaluate quality of life and testing behavior of women 
when they are offered a real choice between standalone RAD and karyotyping. The aim of 
this comparative study was 1) to find out which test is preferred by women who are offered 
a real choice between karyotyping and RAD, and to elicit the reasons for their choice and 2) 
to assess the impact of the chosen test on the experienced anxiety, stress and Health Related 
Quality of Life (HRQoL). 
METHODS
Study design
This study was designed as a prospective cohort study. We compared the level of anxiety and 
HRQoL of women undergoing amniocentesis. Group 1 received a karyotype result; group 2 
received a RAD result (i.e. Multiplex Ligation-dependent Probe Amplification, MRC Holland), 
detecting aneuploidies of chromosomes X, Y, 13, 18 and 21. In group 1, fetal karyotype 
was disclosed as soon as the result was available, usually within 16-21 days. In group 2, 
participants received the RAD results as soon as the result was available, usually within 3 
to 4 days. The study was carried out as final part of the clinical MLPA And Karyotyping, an 










Women were recruited consecutively in six prenatal clinics (Leiden University Medical Centre, 
Leiden; Bronovo Hospital, The Hague; Radboud University Medical Centre, Nijmegen; Rijnstate 
hospital, Arnhem; St. Elisabeth Hospital, Tilburg; Jeroen Bosch Hospital, ‘s Hertogenbosch) 
after the results of the M.A.K.E. study showed comparable diagnostic accuracy of MLPA 
and karyotyping6. The population consisted of all pregnant women who chose to have 
amniocentesis for advanced maternal age (36 years or older) or increased Down syndrome 
risk following first trimester screening (risk > 1: 200 at the time of testing)7. Other inclusion 
criteria were a singleton pregnancy, sufficient command of the Dutch language, and age at 
least 18 years. Women were excluded from the analysis if they had received an abnormal 
test result or in case of a miscarriage. The Institutional Review Board approved of the study 
and all participants gave informed consent. Women attending the department of prenatal 
care, who chose to have amniocentesis and considered eligible for study participation, were 
invited to participate. It was routine policy to offer a choice between standalone RAD and 
karyotyping to women who opted for amniocentesis, even if they did not want to participate 
in this HrQoL study. The prenatal counselor explained the tests using both oral and written 
information. Women received the set of surveys with prepaid envelopes and completed the 
surveys at home, according to the following scheme: one before amniocentesis was done 
(Q1), the other surveys at respectively 2 (Q2), 5 (Q3), 14 (Q4), 23 (Q5) and 63 days (Q6) 
after amniocentesis (table 2). Patient characteristics and reasons and perceptions to choose 
karyotyping or RAD were collected once in survey Q1 (table 1). 
Outcome measures
Reasons and perceptions
In Q1, we asked if women had some knowledge of both tests, whether the counselor gave 
them information on both tests and whether women had tried to obtain extra information. 
Patients indicated the most important reason for selecting the specific test, stated if they still 
supported their test of choice, and their risk perceptions (high, neither low nor high, and low 
risk) for carrying a fetus with a chromosomal abnormality.  
Spielberger State-Trait Axiety Inventory (STAI) 
The aim of the STAI is to quantify anxiety levels experienced at any point in time (State, 
s-anxiety), while allowing for the inherent anxiety (Trait, t-anxiety) normally felt by the 
subject8. The State and Trait subscales, with 20 items in a 4-point response format, range 
from 20-80, with higher scores indicating greater anxiety. A State score of 42 and more 
represents pathological anxiety9. We used the validated Dutch version of the STAI10. The 
Trait scale was asked at Q1, as this reflects the woman’s inherent anxiety which should not 
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change in different situations. The State subscale was included in all surveys, as we expected 
fluctuations in State anxiety in response to various situations. 
Medical Outcome Study Short Form (SF-36) 
The SF-36 questionnaire is a self-administered health survey assessing physical and mental 
health concerning the past 4 weeks. It comprises of 36 questions summarized in eight domain 
scores: physical functioning, role functioning due to physical and emotional problems, social 
functioning, bodily pain, mental health, vitality, and general health perceptions. The eight 
domain scores are summarized in two summary scales: the physical component summary 
scale (PCS) and the mental component summary scale (MCS), which are derived using 
weighted averages of the individual domain scores. The PCS and MCS scores range from 
0-100 (100 indicating optimal health score). We used the validated Dutch version of the 
SF-36 in Q1 and Q6, see table 111.
Personal Perceived Control (PPC)
The PPC measures an individual’s belief that they have the resources necessary to respond 
to an event in a way that will decrease its negative effect12,13. The quality of counseling 
can influence the feeling of control and thereby influence the patient’s experienced control 
and stress. We used the Dutch PPC ranging from 0 to 2, with higher scores indicating more 
perceived control and included it in all surveys (table 1)14.
Impact of Event Scale (IES) 
The aim of the 15-item IES is to measure the impact of a named stressor15. The scale 
distinguishes the components intrusion and avoidance in a 4-point response format with a 
total score ranging from 0 to 75. Higher scores indicate higher stress levels. We used the 
validated Dutch version of the IES16. The stressor varied according to the process of care.
Statistical analyses 
We aimed to include 45 women per group in the analysis (difference log transformed State 
0.15 on Q3; SD 0.25). Adjusted for refusal and drop-out, we aimed to include 60 women 
per group. Descriptive summaries of patient characteristics and quality of life measurements 
included means and standard deviations (SD) for normally distributed variables and 
medians with ranges for other variables. Demographic characteristics of group 1 and 2 
were compared by independent t test and Χ2 test, or Mann Whitney U, if appropriate. 
We compared demographic characteristics as well as mean baseline quality of life scores 
between women completing all questionnaires and those who did not in order to test for 
selection bias. The reasons and perceptions to choose either karyotyping or MLPA are 









we performed backward-selection logistic regression analysis (forward-selection logistic 
regression produced similar results). We used repeated measurement analysis (SPSS 16.0, 
linear mixed models, unstructured covariance) on log transformed State, PPC, and IES scores 
to evaluate longitudinal differences between the groups with adjustment for differences in 
baseline characteristics. Differences in State, PPC and IES between the groups at the separate 
time points were assessed with Mann Whitney U. Linear regression analysis was used to 
analyze differences in the eight domains of the SF-36, and PCS and MCS scores, adjusted 
for differences in baseline characteristics. A P-value of <0.05 (two sided) was considered 
statistically significant in all analyses. Participants with two or more missing surveys (Q1-Q6) 
were regarded as incomplete responders and excluded from analysis. Missing data were 
imputed if one survey was missing using REML procedure of linear mixed models (LMM, SPSS 
16.0). In case less than 50% of the responses to a questionnaire were missing, data were 
imputed using mean imputation; otherwise the questionnaire was regarded missing.
RESULTS
In group 1 and 2, 87 and 74 women agreed to participate. One woman in group 1 and 
two women in group 2 were excluded after MLPA or karyotyping disclosed a chromosomal 
abnormality (figure 1). 
Table 2 shows demographic characteristics of both groups. In group 1 and 2, 68 (85%) and 
61 (85%) women completed all or all but one questionnaire, respectively. The indication 
of complete responders in group 1 vs. group 2 was significantly more often maternal age 
(P<0.01) with significantly lower State scores (P<0.01) and lower perceived control than 
women in group 1 (P= 0.05), otherwise the groups did not differ (table 2). In group 1, the 
incomplete responders had a significantly higher State anxiety (P= 0.05) (table 1).  In group 
2, the complete responders were significantly more often of western origin (P= 0.04) with 
significantly lower perceived control scores (P<0.01) (table 2). 
Table 1: Description of questionnaires and its contents in time. 
Questionnaire Point in time Content Group
Questionnaire 1 Before amniocentesis Demographic characteristics, motivation to choose 
RAD or karyotyping, STAI, PPC, MOS SF-36
1 and 2
Questionnaire 2 Amniocentesis + 2 days STAI, PPC, IES 1 and 2
Questionnaire 3 Amniocentesis + 5 days STAI, PPC, IES 1 and 2
Questionnaire 4 Amniocentesis + 14 days STAI, PPC, IES 1 and 2
Questionnaire 5 Amniocentesis + 23 days STAI, PPC, IES 1 and 2
Questionnaire 6 Amniocentesis + 63 days STAI, IES, PPC, MOS SF-36 1 and 2
STAI= State Trait and Anxiety Inventory, PPC= Personal Perceived Control, MOS SF-36= Medical Outcome 
Study Short Form, IES= Impact of Event Scale
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Figure 1: Flowchart of the study.
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Reasons and perceptions to choose RAD or karyotyping
In group 1 and 2, 88% versus 72% had knowledge of karyotyping and 35% versus 26% of 
RAD; 88% versus 87% of women were informed on both tests and 31% versus 32% had tried to 
find complementary information. The dominant reason to choose karyotyping was: to obtain 
as much information as possible (54.4%), less uncertainty (32.4%), previous experience with 
the test (7.4%), the historical use of the test (4.4%), and advised by my obstetrician (1.5%). 
For group 2 the dominant reason to choose RAD was: the short waiting time (47.5%), less 
anxiety (18%), the clear consequences of the test (14.8%), the detection of the most common 
chromosomal abnormalities (13.1%), and recommended by my obstetrician or midwife 
(6.6%). For group 1 and 2, 86.8% vs. 80.0% were confident of their choice.
Patient characteristics significantly associated with choosing RAD were: referral indication 
PNS (vs. advanced maternal age) (OR 7.09 95% CI 1.82 to 27.65), no knowledge of 
karyotyping (vs. knowledge) (OR 4.2 95% CI 1.3 to 14.3) and a neither low nor high 
perceived risk for fetal chromosomal abnormalities (vs. a low perceived risk) (OR 3.6 95% CI 
1.12 to 11.55). Age, knowledge of RAD (vs. no knowledge), baseline State and Trait scores 
Table 2: Patient characteristics and baseline scores of complete and incomplete responders of 
group 1 (karyotyping) and group 2 (RAD).
Group 1 (Karyotyping) Within
group 1
Group 2 (RAD) Within
group 2
Complete group 
1 vs 2complete incomplete complete incomplete
Number 69 18 63 9
Chromosomal abnormality 1 0 2 0
Analysed 68 61
Median age (IQR) 38.3 (35-43) 37.9 (37-40) p 0.48 37.9 (32-41) 38.6 (37-39) p 0.36 p 0.06
Median parity (IQR) 1.0 (0-2) 1.0 (0-2) p 0.86 1.0 (0-2) 1.0 (0-2) p 0.93 p 0.63
Median gravidity (IQR) 1.0 (1-2) 1.0 (1-2) p 0.36 1.0 (1-2) 2 (0-3) p 0.53 p 0.80
Indication p 0.79 p 0.38 p <0.01
maternal age 63 17 46 8
Prenatal screening 5 1 15 1
Highest educational level p 0.17 p 0.27 p 0.20
Lower vocational, lower secondary school 10 6 11 3
Intermediate and higher vocational, higher secondary 14 2 20 4
College/University 44 10 30 2
Western 66 18 p 0.46 58 6 p < 0.01 p 0.56
Religion 0.69 0.34 p 0.46
Atheist 30 7 22 2
Religious  38 11 38 7
Previous PND 13 2 p 0.42 7 3 p 0.08 p 0.23
Median state at S1 (IQR) 34.0 (26-46) 44.5 (31-53) p 0.05 42.0 (32-54) 33 (25-48) p 0.13 p < 0.01
Median trait at S1 (IQR) 30.0 (27-36) 36.0 (29-38) p 0.07 32.0 (27-38) 29 (27-34) p 0.18 p 0.20
Median PCS at S1 (IQR) 55.2 (48-58) 53.2 (47-57) p 0.30 54.6 (48- 59) 54.3 (48-57) p 0.71 p 0.94
Median MCS at S1 (IQR) 50.3 (47-54) 48.6 (46-54) p 0.65 49.5 (44-54) 54.4 (50-57) p 0.08 p 0.66
Median PPC at S1 (IQR) 1.3 (1.1-1.8) 1.2 (0.9-1.5) p 0.15 1.3 (1-1.6) 1.7 (1.4-1.9) p < 0.01 p 0.05
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Table 2: Patient characteristics and baseline scores of complete and incomplete responders of 
group 1 (karyotyping) and group 2 (RAD).
Group 1 (Karyotyping) Within
group 1
Group 2 (RAD) Within
group 2
Complete group 
1 vs 2complete incomplete complete incomplete
Number 69 18 63 9
Chromosomal abnormality 1 0 2 0
Analysed 68 61
Median age (IQR) 38.3 (35-43) 37.9 (37-40) p 0.48 37.9 (32-41) 38.6 (37-39) p 0.36 p 0.06
Median parity (IQR) 1.0 (0-2) 1.0 (0-2) p 0.86 1.0 (0-2) 1.0 (0-2) p 0.93 p 0.63
Median gravidity (IQR) 1.0 (1-2) 1.0 (1-2) p 0.36 1.0 (1-2) 2 (0-3) p 0.53 p 0.80
Indication p 0.79 p 0.38 p <0.01
maternal age 63 17 46 8
Prenatal screening 5 1 15 1
Highest educational level p 0.17 p 0.27 p 0.20
Lower vocational, lower secondary school 10 6 11 3
Intermediate and higher vocational, higher secondary 14 2 20 4
College/University 44 10 30 2
Western 66 18 p 0.46 58 6 p < 0.01 p 0.56
Religion 0.69 0.34 p 0.46
Atheist 30 7 22 2
Religious  38 11 38 7
Previous PND 13 2 p 0.42 7 3 p 0.08 p 0.23
Median state at S1 (IQR) 34.0 (26-46) 44.5 (31-53) p 0.05 42.0 (32-54) 33 (25-48) p 0.13 p < 0.01
Median trait at S1 (IQR) 30.0 (27-36) 36.0 (29-38) p 0.07 32.0 (27-38) 29 (27-34) p 0.18 p 0.20
Median PCS at S1 (IQR) 55.2 (48-58) 53.2 (47-57) p 0.30 54.6 (48- 59) 54.3 (48-57) p 0.71 p 0.94
Median MCS at S1 (IQR) 50.3 (47-54) 48.6 (46-54) p 0.65 49.5 (44-54) 54.4 (50-57) p 0.08 p 0.66
Median PPC at S1 (IQR) 1.3 (1.1-1.8) 1.2 (0.9-1.5) p 0.15 1.3 (1-1.6) 1.7 (1.4-1.9) p < 0.01 p 0.05
and a high perceived risk for a chromosomal abnormality (vs. a low risk) did not influence 
the test choice. 
Quality of life outcome
State-anxiety 
There were no systematic longitudinal differences in anxiety between the groups (P=0.11, 
table 3). Pattern of anxiety differed significantly over time, with a decrease of anxiety in both 
groups after obtaining a test result with alternating dominance of test technique (figure 2). 
Women with high State and Trait scores at Q1 reported high anxiety scores in the subsequent 
questionnaires (P<0.01, table 3); women with the indication advanced maternal age had 
significantly higher State scores (P=0.02), other demographic factors did not affect anxiety 
scores. Interaction effects between anxiety levels and group over time differed significantly 
on day 2, 5, and 23 (P< 0.01; P<0.01; P=0.05 respectively, table 3). From Q1 to Q6 the 
following percentages of group 1 vs. 2 suffered pathological anxiety; 31% vs. 46%, 18% vs. 









Table 3: Repeated measurement analysis: Linear mixed models on log transformed (a) State, (b) 
PPC, (c) IES scores. AC= amniocentesis, group 1= karyotyping; group 2= RAD, AMA=advanced 
maternal age. Bold values indicate p-values of P < 0.05.
Parameter Estimate 95% CI P value
State scorea 1.82 1.47 – 2.16 0.00
Intercept
Group 1 0.07 -0.02 – 0.15 0.11
Group 2 ref .
AC + 2 days 0.42 0.33 – 0.51 0.00
AC + 5 days 0.00 -0.07 – 0.06 0.95
AC + 14 days 0.07 0.00 – 0.14 0.06
AC +23 days 0.06 0.00 – 0.12 0.04
AC +63 days ref .
Interaction AC + 2 days *group 1* -0.23 -0.35 - -0.11 0.00
Interaction AC + 5 days* group 1* 0.14 0.05 – 0.23 0.00
Interaction AC + 14 days* group 1* 0.08 -0.02 – 0.17 0.12
Interaction AC +23 days* group 1* -0.08 -0.16 – 0.00 0.05
Interaction AC +63 days*group 1* ref .
Baseline log State 0.28 0.17 – 0.38 0.00
Baseline Trait 0.01 0.01 – 0.01 0.00
Indication AMA 0.09 0.02 – 0.17 0.02
Indication other ref .
Western -0.03 -0.17-0.10 0.63
Non western ref .
PPC scoreb
Intercept 0.70 0.58- 0.81 0.00
Before AC 0.10 0.01-0.2 0.04
AC + 2 days 0.10 0.01-0.19 0.03
AC + 5 days -0.06 -0.16-0.04 0.22
AC + 14 days 0.01 -0.07-0.09 0.85
AC +23 days -0.02 -0.09-0.04 0.47
AC +63 days ref .
Group 1 0.03 -0.11 – 0.16 0.69
Group 2 ref .
Interaction before AC *group 1* 0.06 -0.07-0.19 0.38
Interaction AC + 2 days* group 1* 0.03 -0.09-0.15 0.58
Interaction AC + 5 days* group 1* 0.19 0.05-0.32 0.01
Interaction AC +14 days* group 1* 0.08 -0.03-0.19 0.17
Interaction AC +23 days*group 1* 0.03 -0.06-0.12 0.51
Interaction AC +63 days*group 1* ref .
Indication AMA -0.04 -0.12-0.05 0.39
Indication other ref .
Western 0.05 -0.11-0.25 0.53
Non western ref .
IES scorec
Intercept 1.21 0.79-1.64 0.00
AC + 2 days 1.54 1.25-1.83 0.00
AC + 5 days 1.80 1.51-2.08 0.00
AC + 14 days 0.40 0.10-0.71 0.01
AC +23 days -0.04 -0.28-0.20 0.74
AC +63 days ref .
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SF-36
There were no significant differences in mean PCS and MCS scores between the groups 
before and at 63 days after amniocentesis (PCS: P= 0.94; P= 0.52; MCS: P= 0.66; 
P=0.07). Both groups showed a lower PCS score at Q6 compared to Q1, while for the 
MCS both groups showed a higher score at Q6. The changes in PCS and MCS, adjusted for 
indication and western origin did not differ significantly between the groups (PCS: beta 0.05 
95% CI -1.33 to 2.15 p 0.64; MCS: beta -0.20 95% CI -3.57 to 0.02 p 0.06). 
PPC
There were no systematic longitudinal differences between the groups (P=0.69, Table 3). 
Time had a significant effect on PPC levels before and 2 days after amniocentesis (P=0.04 
and P= 0.03) with higher perceived control in both groups before obtaining a test result. 
Demographic characteristics did not influence the PPC score. Interaction effects between 
PPC scores and group over time differed significantly on day 5 (P< 0.01; table 3).
IES
There was no systematic difference in stress level between the groups (P=0.66; Table 3). 
Interaction effects between IES scores and group over time differed significantly on day 5 and 
23 following amniocentesis (P<0.01; P<0.01; Table 3).
Table 3: (Cont)
Parameter Estimate 95% CI P value
Group 1 -0.09 -0.47-0.30 0.66
Group 2 ref .
Interaction AC + 2 days* group 1* -0.18 -0.58-0.21 0.36
Interaction AC + 5 days* group 1* -0.93 -1.31- -0.54 0.00
Interaction AC +14 days* group 1* 0.27 -0.14-0.68 0.19
Interaction AC +23 days*group 1* 0.48 0.16-0.81 0.00
Interaction AC +63 days*group 1* ref .
Indication AMA -0.43 -0.85- -0.02 0.04
Indication other ref .
Western -0.39 -1.13-0.36 0.31
Non western ref .
-2 log likelihood State = -170.99; -2 log likelihood PPC= -208.01; -2 log likelihood IES= 










This study assessed both the reasons to choose standalone RAD or karyotyping and the 
difference in health-related quality of life. Overall, women had a clear individual preference 
for targeted or broad testing. Despite individual differences, our study showed no systematic 
differences in time of standalone RAD versus karyotyping in terms of anxiety, general physical 
Figure 2: Median scores with interquartile ranges (IQR) of women receiving karyotyping and 














































































and mental health, personal perceived control and stress. Offering a choice does not lead 
to increased anxiety levels or reduced health-related quality of life. 
The strength of our study is the prospective design with sufficient power. Most studies are 
limited to psychological health; we also evaluated the reasons and perceptions for the test 
choice. In contrast to previous literature17-19, we offered women a real choice between RAD 
and karyotyping.  Therefore, we cannot compare our results to other studies. One study 
mimicked a standalone policy by treating the RAD result as final diagnosis20. However, 
karyotyping was still performed but the result was only given in case of an additional 
chromosomal abnormalities. The course of anxiety in this study was similar to our results, 
although the average anxiety levels in our groups were remarkably lower. We observed 
this difference in a previous study, most likely caused by cross-cultural differences or the 
organization of Dutch obstetrical care17.   
Offering a choice makes a randomized controlled trial impossible. We had to adjust various 
outcome measures for differences between patient characteristics at baseline and between 
complete and incomplete responders. We cannot rule out over- or under-adjustment. A 
confounder may be the quality of prenatal counseling. Although this should be nondirective, 
five women stated that the dominant reason to choose RAD (4) or karyotyping (1) was the 
caregiver’s advice. Some counselors may implicitly hint at their views, or explicitly impose their 
own views upon counselees21,22. This study shows patterns of anxiety, stress, PPC and HRQoL 
for normal results. For women with fetal chromosomal abnormalities patterns may differ.
We found an association with prenatal screening, no knowledge of karyotyping and an 
intermediate perceived risk and the choice for standalone RAD.  An unfavorable outcome of 
prenatal screening and an intermediate perceived risk leads to an urgent need for a definite 
diagnosis23. It may be logical that prenatal screening for Down syndrome is followed by the 
choice for diagnostic test focused on Down syndrome and therefore RAD. Knowledge of 
karyotyping was associated with not choosing RAD. We assume that this is the expose effect, 
i.e. people tend to choose karyotyping because they are familiar with it. 
Women in the prenatal screening group had higher State scores. The unfavorable outcome 
of PNS likely leads to increased anxiety9. State scores in group 2 are remarkably higher 
before amniocentesis and just before the RAD result. This result cannot be explained by 
a difference in personal anxiety (Trait). Expecting a result within a few days may lead to 
increased anxiety and stress scores. In both groups anxiety scores decreased significantly 
after disclosure of the test result. This was also seen in pathological anxiety; women in group 
1 and 2 had pathological anxiety of respectively 33% and 50% before disclosure of the 
result, decreasing to 6% and 2% after disclosure. The reduction of anxiety after test disclosure 









in the karyotyping strategy. We speculate that (pathologically) anxious women are quickly 
reassured by RAD and therefore may benefit most of RAD tests. 
The stress scores (IES) on day 5 for group 2 were higher, which can be explained by the 
limited amount of time leading to a bigger impact of the named stressor, i.e. the RAD result. 
With respect to the low IES scores during the testing process, both groups can handle the 
stress. The PPC scores were stable in both groups, thus the quality of the counseling process 
did not influence anxiety.  
The differences in anxiety on the short term did not translate into long term effects on overall 
mental and physical health (SF-36). Our results suggest that the RAD vs. karyotyping strategy 
has no adverse long term effects on quality of life and, in addition, that normal results 
reassure and improve mental quality of life. The reduction in physical health during the test 
process is in agreement with two studies that reported on the relationship between RAD and 
HRQoL19,20 and is associated with increasing gestational age24,25. 
Assuming that a 5 point difference on a scale from 0-100 is clinically relevant20,26 the 
effect size of a rapid test on anxiety is clinically relevant and leads to higher scores before 
RAD disclosure and lower scores after RAD disclosure compared to women who chose 
karyotyping. 
We conclude that anxiety and HRQoL following standalone RAD or karyotyping do not differ 
systematically. Therefore, from the psychological point of view, offering an individualized 
choice in prenatal diagnosis seems an appropriate strategy and encourages the development 
of strategies that tailor the type of diagnostic test. 
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ABSTRACT
Objective
To assess the cost-effectiveness of Multiplex Ligation dependent Probe Amplification (MLPA) 
compared to karyotyping.
Methods
A cost-minimization analysis alongside a nationwide prospective clinical study of 4585 
women undergoing amniocentesis on behalf of their age (≥36 years), an increased risk 
following first trimester prenatal screening or parental anxiety. 
Results
Diagnostic accuracy of MLPA was comparable to karyotyping (1.0 95% CI: 0.999 to 
1.0). Health-related quality of life did not differ between the strategies (summary physical 
health: mean difference 0.31, p=0.82; summary mental health: mean difference 1.91, 
p=0.22). Short term costs were lower for MLPA: mean difference € 315.68 (bootstrap 
95% CI: € 315.63 to € 315.74; - 44.4%). The long term costs were slightly higher for 
MLPA: mean difference € 76.42 (bootstrap 95% CI: 71.32 to 81.52; +8.6%). Total costs 
were on average € 240.13 (bootstrap 95% CI: 235.02 to 245.23;-14.9%) lower in favor 
of MLPA. Cost differences were sensitive to proportion of terminated pregnancies, sample 
throughput, individual choice and performance of tests in one laboratory, but not to failure 
rate or the exclusion of polluted samples.
Conclusion
From an economic perspective, MLPA is the preferred prenatal diagnostic strategy in women 
who undergo amniocentesis on behalf of their age, following prenatal screening or parental 
anxiety.   
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INTRODUCTION
In many countries, prenatal diagnosis by chorionic villus sampling or amniocentesis is 
routinely offered to pregnant women who have an increased risk of carrying a child with 
a chromosomal abnormality. Amniocentesis is the most commonly used invasive prenatal 
diagnostic procedure in Western countries and is performed in about one in 30 pregnancies1,2. 
Karyotyping is considered the reference test to detect fetal genetic abnormalities in amniotic 
fluid cells with considerable accuracy3,4. However, it is labour intensive and the costs are 
high. Furthermore, obtaining results takes 2-3 weeks and the extensive detection capacity 
of karyotyping can be perceived as a disadvantage due to the detection of abnormalities 
with unclear or mild clinical relevance, causing difficult counselling issues, patient anxiety, 
emotional dilemmas concerning the continuation of pregnancy and, albeit rare, unwarranted 
pregnancy terminations1,5,6. 
Due to these disadvantages, karyotyping as routine test has been challenged for relatively 
low risk indications. In 2003, a molecular PCR-based technique, MLPA (multiplex ligation-
dependent probe amplification) became available to detect fetal aneuploidies in amniotic 
fluid cells7. Following the results of preclinical laboratory studies, MLPA has been proposed 
as a promising alternative for the detection of the most common chromosomal aneuploidies, 
i.e. trisomy 13, 18, 21 and sex chromosome aneuploidies. Compared to karyotyping, MLPA 
has several potential advantages; the waiting time for test results is reduced with simultaneous 
reduction of anxiety, the preceding prenatal counselling process can focus on the most 
common chromosomal aneuploidies, and the technique is considerably less labour-intensive 
and more suitable for high-throughput testing, thereby exploiting economies of scale. 
Nowadays, much effort has been put into priority setting based on a trade-off of costs and 
health gains. From an economic perspective, the preferred prenatal diagnostic strategy is 
the one that overall yields favourable health gains relative to associated cost differences8.
In order to compare the MLPA and karyotyping strategies in terms of diagnostic accuracy, 
health-related quality of life and cost-effectiveness, we initiated a prospective diagnostic study 
comparing MLPA with karyotyping in routine clinical practice; the MLPA And Karyotyping, 
an Evaluation (M.A.K.E.) study (ISRCTN47252164)9. If MLPA has comparable diagnostic 
accuracy and is able to reduce maternal anxiety and costs in routine clinical practice, MLPA 
could present a suitable substitute for karyotyping. Our research question was: what are 
the costs and effects of MLPA compared to karyotyping when applied to the indications 










The clinical M.A.K.E. study was set up as a prospective nationwide cohort study enrolling 
4,585 consecutive women undergoing amniocentesis for advanced maternal age (≥36 
years), increased risk following prenatal screening or anxiety. Other referral indications 
were excluded (e.g. ultrasound abnormalities) since these are associated with an increased 
risk of a chromosomal abnormality other than trisomies 13, 18, 21 and sex chromosome 
abnormalities. Details of the study design have been published elsewhere9,10. In summary, 
after obtaining informed consent, amniocentesis was carried out by specifically trained 
obstetricians. All amniotic fluid samples were tested with both MLPA and karyotyping, 
allowing a pair wise comparison of MLPA and the reference test; karyotyping. Sample size was 
estimated to demonstrate non-inferiority (i.e. comparable diagnostic accuracy) of MLPA to 
karyotyping. During a pre-trial meeting, experts in prenatal diagnosis, clinical epidemiology 
and statistics agreed on a critical non-inferiority margin of 0.002. At least 4,497 paired 
test results were needed (one-sided alpha 0.05, power 0.90) to be able to reject the null 
hypothesis that MLPA is inferior to karyotyping.
MLPA
DNA was isolated from 1 to 8 ml uncultured amniotic fluid samples, depending on the 
total amount of amniotic fluid received. MLPA samples were analysed with the commercially 
available SALSA MLPA P095 kit (MRC Holland, the Netherlands). For each genomic target, 
a set of 2 probes is designed to hybridize immediately adjacent to each other on the same 
target strand. Both probes consist of a short target sequence and a universal polymerase 
chain reaction (PCR) primer-binding site. One of the probes contains a stuffer sequence 
with a unique length and sequence. Following hybridization, each pair of adjacent probes 
is joined by a ligation reaction. Next, PCR is performed using a fluorescent-labelled primer 
pair, which ensures that the relative yield of each of the PCR products is proportional to the 
amount of each of the target sequences. The different length products are separated on 
an automated capillary sequencer. The size and peak areas for each probe are quantified 
and analyzed by data analyzing software (GeneMarker, SoftGenetics, LLC, State College, 
PA, USA or Genescan and Genemapper version 3.7/4.0, Applied Biosystems, CA, USA)7. 
Relative probe signals are calculated and compared with samples of normal male and 
female sex. In chromosomally normal samples, the relative probe signal is expected to be 1 
for all probes. A normal value is defined as a relative probe signal between 0.7 and 1.3. A 
relative probe value of <0.7 indicates a monosomy, whereas a relative probe value of >1.3 
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indicates a trisomy. Technicians had a molecular genetics or a cytogenetics background; 
all were trained in the execution of MLPA prior to the study onset. MLPA was performed in 
duplicate, provided that at least 2 ml of amniotic fluid was available. All eight genetic centres 
have different sample throughput, depending on the amount of patients in their referring 
prenatal diagnostic centres.  
Karyotyping
Fetal cells were cultured and karyotyped after banding. Routinely, metaphases of at least 
10 colonies were investigated. All centres followed national quality guidelines but minor 
differences in the number of cell colonies cultured, chromosome banding and reporting of 
the results were allowed11.
Economic analysis framework
The economic analysis was performed from the societal perspective which means that all 
significant costs and health effects both in the short and long term should be considered, 
regardless of who experiences the costs or the health gains8. The economic evaluation was 
initially designed as a cost-effectiveness analysis (CEA)8, with incremental costs per case 
of Down’s syndrome missed by MLPA. In case of comparable diagnostic accuracy for the 
detection of Down syndrome, a cost-utility analysis (CUA) was considered the appropriate 
economic framework, calculating the difference in costs in relation to differences in health-
related quality of life8. If differences in quality of life between the strategies were also absent, 
a cost-minimisation analysis (CMA) was carried out. CMA implies that the preferred strategy 
from the societal perspective is the one with lowest costs, since health effects are equal8. We 
did not include a do-nothing strategy, since the target population is eligible for karyotyping. 
Health-related quality of life
Alongside the clinical M.A.K.E. study we assessed health-related quality of life (HRQoL) in 
two groups: group 1 having karyotyping and group 2 having MLPA. Included were women 
with the indications maternal age, increased risk following the findings of prenatal screening 
for Down syndrome and parental anxiety. We used the MOS SF-36 health survey, measuring 
overall mental and overall physical health. Mental and physical health were measured before 
amniocentesis and at day 63 following amniocentesis, since the SF-36 focuses on health 
status during the preceding 4 weeks. Overall mental and physical health were calculated 
according to accepted scoring algorithms12.  
Costs
We distinguished the costs of the MLPA and karyotyping strategies in two components; short 
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that occur between amniocentesis and parents’ decision to terminate or continue pregnancy. 
These costs consist of the costs of the diagnostic tests and other costs. The second component 
consists of the long term costs, i.e. all societal costs that occur between parents’ decision 
to terminate or continue pregnancy and lifetime costs. Although it is controversial whether 
the costs associated with chromosomal abnormalities should be included in this type of 
analysis13-15, we decided to display the impact of missed chromosomal abnormalities on 
long term costs. 
Short term and long term costs were further distinguished in direct medical costs (i.e. 
laboratory costs, additional in-hospital medical costs during follow-up), direct non-medical 
costs (patient expenses e.g. patient time and travel costs) and indirect costs (societal costs 
due to absence from work)8.
 The main outcome parameters were the difference in short term costs between the MLPA and 
TKT strategies, the long term cost difference, and the overall cost difference.
Short term costs 
The short term costs consisted of the costs associated with performing MLPA and/or 
karyotyping and other costs related to the testing process. Direct medical costs of performed 
tests were calculated as actual volumes of resource use multiplied by the costs per unit of 
resource. Number and type of tests performed were recorded in the clinical record form or 
obtained by observation or questionnaire. We used direct observations and measurements 
of working time, materials, and depreciation costs of equipment to quantify resource use 
associated with MLPA. Costs per units were obtained from a university hospital’s budgetary 
and accounting system and were subsequently applied to the resource use observed in a 
small and large centre. The costs per units reflected the costs of staff, materials, equipment, 
housing and departmental and hospital overheads. 
The other short term costs consisted of additional diagnostic tests, costs of genetic counselling 
in case a chromosomal abnormality was detected, and travel costs. Use of additional 
diagnostic tests was recorded in the case record form. In case of a chromosomal abnormality, 
we assumed parents visited the hospital twice for genetic counselling (50% of cases by 
performed by gynaecologists (trisomies 13, 18 and 21) and 50% seen by clinical geneticists 
and social workers (all other chromosomal abnormalities)). Travel costs per client were based 
on the average travel distance to hospitals16. The unit costs of direct non-medical costs were 
based on Dutch guidelines16,17. Short-term indirect costs did not occur.
Study specific costs as well as costs not associated with diagnostic test performance (prenatal 
test counselling, amniocentesis, ultrasound, sample transport, procedure related miscarriages) 
were expected to be independent of the type of diagnostic test, and were therefore excluded 
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from analysis. Given the time horizon no discount rate is used. When necessary, costs were 
updated to the 2007 price level by using the Dutch Consumer Price Index18. 
Long term costs
The long term costs were defined as the costs associated chromosomal abnormalities 
and consisted of 1) incremental costs for a child having a chromosomal abnormality and 
2) costs for parents of the affected child. We first categorised chromosomal abnormalities 
according to clinical relevance: severe consequences and other chromosomal abnormalities 
leading to severe fetal morbidity or mortality (category I; includes trisomies 13, 18, and 21); 
uncertain consequences (including sex chromosomal abnormalities) and de novo balanced 
chromosomal abnormalities which can lead to 6% mental retardation and/or congenital 
abnormalities19 (category II); and no consequences including inherited chromosomal 
abnormalities and chromosomal abnormalities of known clinical irrelevance (category III). For 
category I chromosomal abnormalities, we used an incremental lifetime cost of € 200.000 
per child20-22, a weighted average of the costs of trisomies 13, 18 and 21 adjusted for the 
average costs per child.  The costs of a category II abnormality were estimated to be 6% of 
the costs of a child with category I abnormality. Category III abnormalities were considered 
not to induce extra costs. 
Productivity loss due to absence from work in case of a chromosomal abnormality was 
estimated according to the friction cost method16. In case the pregnancy was terminated, 
both parents were considered to have a sick leave; on average 6 weeks for mothers and 
2 weeks’ leave for partners. If the parents decided to continue the pregnancy in case of 
a severe chromosomal abnormality, the productivity loss exceeded the friction period (22 
weeks) and no extra costs beyond the friction period were included. Assuming pregnant 
women to have on average one child, working 26 hours/week and aged of 25 to 44 years, 
the productivity loss is € 33.60 per hour lost18. Assuming the partner to be male, aged 25 to 
44 years old and working fulltime, his productivity loss is on average € 40.86 per hour lost18. 
Sensitivity analysis
We used a sensitivity analysis to test the robustness of the cost differences. We varied the 
major assumptions underlying the cost-effectiveness model for the following parameters: 1) 
proportion of failed MLPA results, according to the 5th and 95th percentiles of the observed 
failure rate; 2) only samples with clear amniotic fluid are analysed with MLPA, all other 
samples with karyotyping; 3) the proportion of terminated pregnancy in case of category 
I chromosomal abnormalities varies from 70% to 80%); 4) women are allowed individual 
choice; 50% of women opts for MLPA and 50% for karyotyping23; 5) Sample throughput 
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laboratory; 7) All samples are analysed with both MLPA and karyotyping. Parameters 1 and 
5 are subject to different laboratory practices. Parameter 3 might relate to societal trends, 
counselling style or the counsellor’s medical specialty24. Parameters 2, 4, 6, and 7 might 
change following changes in prenatal diagnostic protocols or guidelines. 
Statistical analysis
Data were recorded and analysed by using statistical software (SPSS version 16.0; SPSS, 
Chicago, Illinois). Observed data described with descriptive statistical measures; medians 
with range, or mean differences with 95% confidence intervals (CIs). Due to skewness of cost 
data, the 95% CI of the mean short term, long term and overall cost differences between 
the strategies were obtained with the nonparametric bootstrap method, based on10,000 
bootstrap samples25. P value less than .05 (two-tailed) was considered statistically significant.
RESULTS
Patients and test results 
Between March 2007 and October 2008 we included 4585 consecutively pregnant women. 
Patient and procedural characteristics are displayed in Table 1. 
Outcomes: diagnostic accuracy and quality of life
In 4484/4585 samples (97.8%) MLPA and karyotyping were concordant, showing normal 
results in 4387/4585 (95.7%) and aneuploidy in 98/4585 (2.1%). Discordant results were 
Table 1. Baseline and Procedural characteristics
Median age (years) (5th to 95th %) 38.1 (31.8 to 42.4)
Indication (%)
Advanced maternal age 3464 (75.6)
 Increased risk following prenatal screening 1074 (23.4)
 Anxiety 47 (1.0)
Median gravidity (5th to 95th %) 2 (1 to 5)
Median parity (5th to 95th %) 1 (0 to 3)
Median gestational age (weeks +days) (5th to 95th %) 16 +1 (14+6 to 17+4)
Withdrawn amniotic fluid (median) (5th to 95th %) 20 ml (16.0 to 20.0)
Colour of amniotic fluid
Clear/yellow 4467 (97.4%)
Red/Brown/ Turbid/Green 118 (2.6%)
Cell pellet colour
White 3923 (85.6%)
Trace of blood 381 (8.3%)
Red/Brown/Green, Yellow, Turbid 281 (6.1%)
Amniotic fluid for MLPA (median) (5th to 95th%) 4 ml (2.0 to 8.0)
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found in 26/4585 (0.6%) samples, representing an abnormal karyotype undetected by MLPA. 
All aneuploidies of chromosomes 13, 18, 21 and non-mosaic X and Y were also detected 
by MLPA. MLPA, by design, could not detect three severe chromosomal abnormalities other 
than trisomies 13, 18, 21. Diagnostic accuracy of MLPA was comparable (non-inferior) 
to karyotyping (1.0 95% CI: 0.999 to 1.0). Sensitivity and specificity for the detection of 
trisomies 13, 18, 21, X and Y were 100% (95%CI: 96% to 100%) and 100% (95%CI: 99.9% 
to 100%), respectively.10 There were neither statistical nor clinically relevant differences in 
HRQoL. Summary physical and mental health scores between people receiving a karyotype 
or MLPA did not differ (mean difference 0.31; 95% CI -3.06 to 2.44 p 0.82 and mean 
difference 1.91 95% CI -1.15 to 4.99 p 0.22, respectively) (see supplemental file Table 1). 
Therefore we considered cost minimisation analysis the appropriate framework. 
Supplemental file Table 1: 9 weeks change score in generic health using the SF-36
Mean change score compared with baseline p 95% CI
TKT MLPA 
PCS -5.14 -5.8 0.63 -2.14 to 3.51
MCS 5.16 3.11 0.23 -1.31 to 5.41
PCS* 0.04 0.35 0.82 -3.06 to 2.44
MCS* 3.12 1.21 0.22 -1.15 to 4.99
*Corrected for education, indication, religion, and offering a choice between the tests. 
PCS= Physical Component Score; MCS= Mental Component Score
Short term costs
The costs of the MLPA test performed in duplicate were € 344.60 per sample (65% direct and 
35% overhead costs) while the costs of karyotyping was € 668.00 per sample (74% direct 
and 26% overhead costs). 
Table 2 details the volumes of resource use, unit costs per resource and the total short 
term costs. In the MLPA strategy, 173 subsequent karyotyping were performed because 
MLPA failed (n=75) or because MLPA showed a chromosomal abnormality and inheritance 
patterns needed to be examined (n=98). Repeat amniocentesis did not occur. MLPA was 
repeated in 1.6% (5th to 95th percentile: 1.3% to 2.1%) due to an inconclusive result. Five 
subsequent FISH analyses were done; three because MLPA showed a deletion on a single 
probe and the laboratory wished to exclude a sub-microscopic deletion, and two for a mosaic 
chromosome pattern (combined mosaic pattern of Turner and Down syndrome and a mosaic 
pattern for Turner syndrome and a normal female cell line). In 22 cases in the MLPA strategy 
and 34 cases in the karyotyping strategy, advanced ultrasound examination was required to 
exclude other severe congenital abnormalities (e.g. cardiac abnormalities) in the presence of 
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In the karyotyping strategy, 11 subsequent FISH analysis were performed for various reasons; 
additional information on the grade of mosaicism (mosaic pattern Turner and Down 
syndrome, mosaic pattern of Turner syndrome)(n=2), for marker chromosomes (n=4), de 
novo unbalanced chromosomal abnormalities (n=2), a chromosomal abnormality which 
appeared to be a normal variant (n=2), and for a mosaic pattern of male and female 
karyotype which was determined to be a culture artefact (n=1). In the latter case biochemical 
investigation on amniotic fluid was also carried out to determine the testosterone/FSH ratio 
and karyotyping was repeated in a postnatal sample. In 24 cases parental karyotyping was 
performed to address the origin of the chromosomal abnormality (inherited or de novo). To 
assess the consequences of the de novo interstitial deletion, MLPA on subtelomeres and a 
genomic micro array was carried out. One karyotype failed due to contaminated amniotic 
fluid (blood and clots). Repeat amniocentesis was offered but the prospective parents declined. 
The median short term costs per sample, i.e. from amniocentesis until the decision to continue 
or terminate pregnancy, were € 344.60 (range 344.60 to 3,216.08) for the MLPA strategy 
and € 668.00 (range 668.00 to 4,669.48) for the karyotyping strategy. The short term costs 
of the MLPA strategy were on average € 315.68 (bootstrap 95% CI: € 315.63 to € 315.74) 
lower than the karyotyping strategy (- 44.4%). 
Table 2. Short term costs: Resource use and costs between amniocentesis and the decision to 
continue or terminate pregnancy.
















*Direct costs in the hospital
Primary procedure
MLPA 4585 87.3% 0 0.0% € 344.60
Karyotyping 0 0.0% 4585 93.98% € 668.00
Additional diagnostic tests
 Karyotyping 173 6.4% 0 0.0% € 668.00
 FISH 5 0.22% 11 0.27% € 809.00
Additional diagnostic tests in case of CA
Parental karyotyping 0 0.0% 44 0.90% € 668.00
DNA and/or biochemical investigation 0 0.0% 3 0.09% € 934.00
Ultrasound examination (type II) 22 0.79% 34 0.68% € 653.00
Outpatients visit in case of CA
Consult gynaecologist (2 visits) 35 0.48% 35 0.26% € 246.00
Consult clinical geneticist and social worker 
(2 visits)
63 4.82% 89 3.78% € 1385.00
*Direct medical costs outside the hospital
Travel costs in case of CA (2 visits to hospital) 98 0.05% 124 0.04% € 9.48
Total short term costs € 394.93 € 710.65
CA= chromosomal abnormality
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Long term and total costs
Table 3 displays the main volumes of resource use, the unit costs per resource use and 
the long term costs following the decision to continue or terminate pregnancy. Seventy-six 
pregnancies in the MLPA strategy (72 clinically severe; 4 clinically uncertain; 0 clinically 
not relevant) and 79 pregnancies in the karyotyping strategy (74 clinically severe; 5 
clinically uncertain; 0 clinically not relevant) were terminated. In two pregnancies, postnatal 
karyotyping was carried out to confirm the prenatal diagnosis (mosaic marker chromosome 
and mosaic Turner).   
The median long term costs per sample, i.e. from the decision to continue or terminate 
pregnancy onwards, were € 0.00 (range 0 to 233,940.00) for the MLPA strategy and € 
0.00 (range 0 to 237,000.08) for the karyotyping strategy (table 2). The long term costs of 
Table 3: Long term costs: Resource use and costs after the decision to terminate or continue 
pregnancy
Long term consequences MLPA 
strategy
(n=4585)









Terminated pregnancies for detected CA
Total termination of pregnancy 76 2.2% 79 2.5% € 1,314.00
Clinically severe CA (T21/13/18 and other) 72 74 -
Clinically uncertain CA (X/Y and other) 4 5 -
Travel costs 76 0.01% 79 0.01% € 4.74
Productivity loss for terminated pregnancies 
with CA 
76 11.2% 79 12.9% € 6,730.38
Continued pregnancies for detected CA  
Clinically severe CA (T21/13/18 and other) 13 56.8% 14 68.1% € 200,000.00-
Clinically uncertain CA (X/Y and other) 9 2.4% 14 4.1% € 12,000,-
Clinically not relevant CA (other) 0 0.0% 17 0.0% –
Confirmation of prenatal cytogenetic result 
after birth 
0 0.0% 2 0.04% € 739.72
Productivity loss for continued pregnancies with 
severe CA
13 9.6% 14 11.6% € 33,940.00
Productivity loss for continued pregnancies with 
uncertain CA
9 0.4% 14 0.7% € 2,036.40
Productivity loss for continued pregnancies with 
not relevant CA
0 0.0% 17 0.0% –
Costs for undetected chromosomal 
abnormalities
Other clinically severe CA 3 13.1% 0 0.0% € 200,000,00
Other clinically uncertain CA 6 1.6% 0 0.0% € 12,000.00
Other clinically not relevant CA 17 0.0% 0 0.0% –
Productivity loss for undetected severe CA 3 2.4% 0 0.0% € 36,861.00
Productivity loss for undetected uncertain CA 6 0.3% 0 0.0% € 2,211.66
Productivity loss for undetected not relevant CA 17 0.0% 0 0.0% € 0,00 
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the MLPA strategy were on average € 76.42 higher compared to the karyotyping strategy 
(bootstrap 95% CI: 71.32 to 81.52; +8.6%).
The total costs, including both short and long term costs, were median € 344.60 (range 
344.60 to 237.000,08) for the MLPA strategy and € 668.00 (range 668.00 to € 238,956.48) 
for the karyotyping strategy. The total cost difference was € 240.13 (bootstrap 95% CI: 
235.02 to 245.23) in favour of MLPA (cost reduction: -14.9%).
Sensitivity analysis
Table 4 displays the results of the sensitivity analyses. Total MLPA costs were sensitive to the 
following parameters: the proportion of women deciding to terminate pregnancy, women 
allowed individual choice, the level of sample throughput, and performing both MLPA 
and karyotyping. Except for the combined MLPA and karyotyping strategy, the total costs 
difference remained in favour of MLPA. 
DISCUSSION
In this study we evaluated the cost-effectiveness of two prenatal diagnostic test strategies; MLPA 
and karyotyping. Diagnostic accuracy of MLPA was comparable (non-inferior) to karyotyping 
Table 4. Sensitivity analysis. Impact of parameters varied on short term, long term and total MLPA 
costs per sample (Euros, %) compared to baseline; and impact on the total (short term and long 
term) cost difference of MLPA – karyotyping
Parameter varied Short term costs of 
MLPA strategy per 
sample (€ (% change))*
Long term costs of 
MLPA strategy per 
sample 
(€ (% change))*




MLPA vs. karyotyping 
per sample 
((€ (% change))**
Baseline strategy 394.93 (n.a.) 997.85 (n.a.) n.a. -214.06 (-13.3%)
Failure rate
1.31% 392.75 (-0.6%) 997.85 ( – ) -2.19 (-0.2%) -216.20 (-0.5%)
2.05% 397.70 (+0.7%) 997.85 ( – ) +2.77 (+0.2%) -211.29 (+1.3%)
Only samples with clear amniotic fluid analysed with MLPA 401.44 (+1.7%) 997.85 ( – ) +6.50 (+0.5%) -207.55 (-3.0%)
% TOP if severe CA
80% 394.93 ( – ) 1195.18 (+20.8%) +197.33 (+14.2%) -213.59 (-0.5%)
70% 394.93 ( – ) 1638.32 (+64.2%) +640.48 (+48.7%) -214.06 ( – )
Women are allowed individual choice 552.18 (+39.8%) 971.65 (-2.8%) +131.05 (+9.4%)  -  83.00 (+61.2%)
Sample throughput
286 samples/year 500.55 (+26.7%) 997.85 ( – ) +105.62 (+7.6%) -108.60 (+ 49.3%)
1153 samples/ year 374.94 (  -5.1%) 997.85 ( – ) -  19.99 (-1.4%) -234.05 (- 0.5%)
One nationwide MLPA laboratory 294.68 (-29.6%) 997.85 ( – ) -100.25 (-7.20%) -314.31 (-46.83%)
All samples analysed with MLPA and karyotyping 660.85 (+167.3%) 896.19 (-10.1%) +599.19 (+43.02) +345.10 (+61.2%)
CA=chromosomal abnormality; TOP = termination of pregnancy. * change compared to baseline
** change compared to karyotyping strategy. A positive change implies a reduction of the cost 
difference.
86
and health-related quality of life was equal between strategies. For the complete testing process, 
the MLPA strategy leads to a 14.9% cost reduction per amniotic fluid sample for women with 
relatively low risk indications (-44.4% on the short term, and +8.6% on the long term).
Our study has several limitations. Firstly, we used the outcome data of the nationwide, 
prospective M.A.K.E.study which prioritised karyotyping, since at least 12 ml of amniotic 
fluid was required. The failure rate of MLPA (1.6%) may be lower when MLPA is applied as 
standalone technique since MLPA requires at least 1-2ml. Sensitivity analysis however showed 
that variations in failure rate had little impact on the overall cost difference. Secondly, we were 
unable to measure quality of life for women who decided to continue or terminate pregnancy 
in case of a chromosomal abnormality and in parents with rare prenatally undetected fetal 
chromosomal abnormalities. However, since diagnostic accuracy was high and comparable, 
we can speculate that the decision to continue or terminate pregnancy in case of a chromosomal 
abnormality is the same, regardless of the diagnostic test used. The three severe chromosomal 
abnormalities undetected by MLPA may result in a decrease in quality of life at the individual 
level but not in differences at the group level. Thirdly, we did not adjust the costs associated 
with pre-test counselling. We expect that targeted testing reduces complex counselling issues 
and is therefore less costly. Taking this into account, the cost reduction of MLPA compared to 
karyotyping may be even larger than we estimated. 
Table 4. Sensitivity analysis. Impact of parameters varied on short term, long term and total MLPA 
costs per sample (Euros, %) compared to baseline; and impact on the total (short term and long 
term) cost difference of MLPA – karyotyping
Parameter varied Short term costs of 
MLPA strategy per 
sample (€ (% change))*
Long term costs of 
MLPA strategy per 
sample 
(€ (% change))*




MLPA vs. karyotyping 
per sample 
((€ (% change))**
Baseline strategy 394.93 (n.a.) 997.85 (n.a.) n.a. -214.06 (-13.3%)
Failure rate
1.31% 392.75 (-0.6%) 997.85 ( – ) -2.19 (-0.2%) -216.20 (-0.5%)
2.05% 397.70 (+0.7%) 997.85 ( – ) +2.77 (+0.2%) -211.29 (+1.3%)
Only samples with clear amniotic fluid analysed with MLPA 401.44 (+1.7%) 997.85 ( – ) +6.50 (+0.5%) -207.55 (-3.0%)
% TOP if severe CA
80% 394.93 ( – ) 1195.18 (+20.8%) +197.33 (+14.2%) -213.59 (-0.5%)
70% 394.93 ( – ) 1638.32 (+64.2%) +640.48 (+48.7%) -214.06 ( – )
Women are allowed individual choice 552.18 (+39.8%) 971.65 (-2.8%) +131.05 (+9.4%)  -  83.00 (+61.2%)
Sample throughput
286 samples/year 500.55 (+26.7%) 997.85 ( – ) +105.62 (+7.6%) -108.60 (+ 49.3%)
1153 samples/ year 374.94 (  -5.1%) 997.85 ( – ) -  19.99 (-1.4%) -234.05 (- 0.5%)
One nationwide MLPA laboratory 294.68 (-29.6%) 997.85 ( – ) -100.25 (-7.20%) -314.31 (-46.83%)
All samples analysed with MLPA and karyotyping 660.85 (+167.3%) 896.19 (-10.1%) +599.19 (+43.02) +345.10 (+61.2%)
CA=chromosomal abnormality; TOP = termination of pregnancy. * change compared to baseline
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Compared to other RAD techniques, MLPA and quantitative fluorescent polymerase chain 
reaction (QF-PCR) are both suitable techniques for high-throughput testing at lower costs 
compared to fluorescent in situ hybridization (FISH)26. A cost analysis of QF-PCR and FISH 
(2003) revealed that both tests are sensitive to sample throughput and staff skill-mix26. Grimshaw 
reported for a laboratory with a throughput of 1000 samples per annum, that karyotyping is 
the most expensive test to perform, with FISH and Q-PCR calculated to incur approximately 
half the direct test costs of karyotyping26. However, these studies did not include long term 
costs. Due to differences in methodology, a full comparison with our study is impossible. 
Costs differences were insensitive to variations in failure rate, or the use of MLPA on 
contaminated amniotic fluid samples. However, the costs of MLPA proved sensitive to the 
proportion of terminated pregnancies and therefore to societal trends, but this is unlikely to 
affect the overall cost difference. Furthermore, the costs of the MLPA strategy were sensitive to 
sample throughput as well as the concentration of MLPA analyses in one nationwide centre. 
This shows that the costs and cost differences depend on the way care is organised. Since 
the impact of concentration on costs was larger than the impact of higher throughput, we 
recommend the use of one (or several) nationwide MLPA laboratories. Our study also shows 
that a combined strategy of MLPA followed by karyotyping is rather inefficient. Costs are 
considerably increased without any gain in diagnostic accuracy or health-related quality of life 
compared to the karyotyping only strategy. 
The provision of a rapid, unambiguous and a low cost result is an incentive to implement 
MLPA. Successful implementation, however, also requires the support of pregnant women. 
If one supports individualised choice for principle or other reasons27, one could argue that 
the decision to either obtain as much cytogenetic information as possible versus a rapid but 
specific result on the most common chromosomal abnormalities is most appropriately made by 
individuals who will bear the responsibility for raising the child. Our study shows that allowing 
individualized choice –assuming that 50% chooses karyotyping and 50% chooses MLPA23– 
also has large impact on costs, reducing the cost difference of € 240 per sample to € 83 per 
sample). While individual choice as strategy is less efficient than a uniform strategy in which 
every patient would receive MLPA, the overall cost reduction is still in favour of MLPA over 
the current karyotyping strategy. One could argue that offering a choice between the tests 
meets most individual needs and wishes, and thereby might outweigh the cost difference. 
In a discrete choice experimentation28, women valued the comprehensive information of 
karyotyping at ₤ 791 and the simple and quick information of a Down only test at ₤ 690. This 
supports our idea that the option to choose may outweigh the previously mentioned efficiency 
loss of € 240 per sample to € 83 per sample.  
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In summary, MLPA is able to detect trisomies 13, 18, 21, X and Y with comparable diagnostic 
accuracy and without adverse effect on quality of life at considerably lower costs for the 
complete testing process. We conclude that MLPA is the preferred strategy and recommend 
substitution of karyotyping for MLPA for relatively low risk indications. Future research should 
be done to evaluate which RAD technique delivers best ‘value for money’, to estimate the 
cost-effectiveness of this RAD technique on chorionic villus biopsy, and to evaluate the most 
advantageous organisation for the optimal RAD technique. 
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ABSTRACT
Developments in prenatal diagnosis raise the question which test strategy should be 
implemented. However, preferences of women and caregivers are underexposed. This 
study investigates what kind of prenatal test pregnant women and caregivers prefer and 
if differences between the groups exist, using self-report questionnaires. Women preferred 
either karyotyping (50%) or rapid aneuploidy detection (43%). Caregivers opted for the 
latter (78%). A test targeted on Down syndrome was the least preferred in both groups. 
We recommend the use of individualised choice for genetic test in prenatal diagnosis, 
overcoming the existing differences in preferences between women and caregivers.
96
INTRODUCTION
In developed countries, prenatal diagnosis is routinely offered to all women who are 
considered to be at increased risk for chromosomal abnormalities. In invasive prenatal 
diagnosis, karyotyping on amniocytes is considered the gold standard. Karyotyping can 
detect a range of numerical and structural chromosomal abnormalities with considerable 
accuracy and reliability1. Karyotyping is labour intensive, the costs are high and parents 
have to wait two to three weeks for the test result. Furthermore, karyotyping can detect 
chromosomal abnormalities with unclear or mild clinical relevance which can cause patient 
anxiety and emotional dilemmas concerning the continuation of pregnancy.
In the last decade, new techniques (e.g. fluorescent in situ hybridisation, quantitative 
polymerase chain reaction, multiplex ligation-dependent probe amplification) have become 
available in prenatal diagnosis. These techniques, often referred to as rapid aneuploidy 
detection (RAD) can detect aneuploidies of chromosome 21, 13, 18, X and Y within 1-4 
days2. Various studies showed high diagnostic accuracy of RAD for the detection of these 
aneuploidies2, which account for more than 80% of the clinically relevant chromosomal 
abnormalities. Besides, the costs are low and rare abnormalities with unclear or mild 
consequences are not detected.
In recent years, a debate emerged in European countries whether RAD should replace 
karyotyping in prenatal diagnosis for the following indications; advanced maternal age, 
increased risk following prenatal screening and maternal anxiety. In the Netherlands, a 
decision on the use of RAD as sole diagnostic tool has not been reached yet. Although the 
views of stakeholders should be incorporated in medical decision-making, little effort has 
been put into exploring the preferences of pregnant women and caregivers. So far, two 
studies have been published on this topic3,4. One study, with small sample size, showed that 
pregnant women preferred rapid aneuploidy detection as long as the test result was known 
six days prior to the karyotype result4. The other study, with fairly simple design, showed that 
pregnant women and caregivers in the UK opted for rapid aneuploidy detection3. These two 
studies give us insufficient evidence of clear consensus in favour of one of the strategies. 
Considering the low evidence on this topic and important health care dilemmas, we aimed to 
determine the preferences of pregnant women and caregivers on this topic in the Dutch health 
care system. Our research questions were: Which basic type of prenatal test do pregnant 
women and caregivers prefer and, second, do the preferences of these two stakeholders 
differ? To answer these questions, we collected preferences on three hypothetical tests 
through a self-report questionnaire, which focused on the key factors in the current debate 
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METHODS
As part of the ongoing Dutch nationwide M.A.K.E. (MLPA And Karyotyping, an Evaluation) 
study (ISRCTN 47252164) in which the technical and clinical performance of multiplex 
ligation-dependent probe amplification (MLPA) versus karyotyping in prenatal diagnosis is 
compared, we developed a self-report questionnaire to determine pregnant women’s and 
caregivers’ preferences for three hypothetical, yet close-to-reality, test strategies in prenatal 
diagnosis (see appendix). We described three different tests (A, B and C), each characterized 
by three test characteristics; 1) detection capacity, 2) the comprehensibility of the result in 
case of a detected abnormality, and 3) the waiting time for the test result. We focused on 
these three characteristics because these are the key factors in the debate among caregivers 
and essential to women scheduled for prenatal diagnosis. Test A is described as a test where 
Down’s syndrome is the single aneuploidy tested for, with clear consequences in case of a 
detected aneuploidy and a waiting time of 4 days. Test B is described as a test detecting the 
most common aneuploidies (trisomy 21, 13, 18 and sex chromosomal abnormalities); with 
almost always clear consequences in case of a detected chromosomal aneuploidy and a 
waiting time of 4 days. Test C, resembling traditional karyotyping, is described as a test where 
any chromosomal abnormality can be detected, with often-clear consequences in case of 
a detected chromosomal abnormality and a waiting time of 21 days. We aimed at neutral 
wording of the probability to have an unequivocal result, rather than the probability to have 
an uncertain or difficult to interpret result.
The target patient population consisted of 150 pregnant women undergoing amniocentesis 
in one of four Dutch hospitals: Onze Lieve Vrouwe Gasthuis and Academic Medical Centre 
in Amsterdam, St. Elisabeth Hospital in Tilburg and Leiden University Medical Centre in 
Leiden. Eligible for participation were women with sufficient command of the Dutch language. 
Women received a questionnaire with a prepaid return envelope when they attended the 
hospital for consultation prior to amniocentesis. Participating women were asked to complete 
the questionnaire at home two days after amniocentesis, when the karyotype result was still 
unknown. At this stage procedure related anxiety had been eliminated, while the choice 
between the tests as presented in the survey still mimicked a realistic choice.  
The target professional population consisted of 140 caregivers involved in prenatal diagnosis, 
i.e. obstetricians, midwives, clinical geneticists, cytogeneticists and general practitioners. 
These caregivers were randomly selected from the eight Dutch centres performing Prenatal 
Diagnosis. 
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Both pregnant women and caregivers were invited to rank the three tests in order of 
preference. The Institutional Review Board approved the study and decided that informed 
consent was redundant.  
We used the χ2 test to calculate differences in preferences between referral indications as 
well as the various groups of caregivers.
RESULTS
From January 2007 until July 2007 150 consecutive pregnant women received a 
questionnaire. Seventy-five percent (113/150) responded to the survey. Median age of the 
responders was 38 years (29 to 44 years); median parity was 1.0 (0 to 7). The non-responders 
had comparable characteristics; median age was 38 years (33 to 41) and median parity was 
1.0 (0 to 2). In 84.1% (95/113) of the responders the indication for amniocentesis was 
advanced maternal age (AMA), in 11.5% (13/113) it was increased risk following prenatal 
screening and in 2.7% (3/113) maternal anxiety was the indication. Almost all responding 
pregnant women expressed a preference either for test C resembling karyotyping (50.4%) or 
test B, the rapid technique detecting the most common aneuploidies (43.4%). A minority of 
women chose the test detecting Down’s syndrome only (table 1). The dominant preference 
did not differ between the various indication groups (χ2 5.21 p=0.771).
In June 2007, 140 caregivers received an identical questionnaire and prepaid return 
envelope. Of the caregivers (70% female; median age 44 years, 26 to 63 years), 55% 
(77/140) returned the questionnaire. Non-responders had a similar gender distribution 
Table 1. Ranking order of three prenatal diagnostic tests. 
Test A represents a rapid test, detecting aneuploidy of chromosome 21 (Down syndrome)
Test B represents a rapid test, detecting aneuploidies of chromosome 21, 13, 18, X and Y 
Test C represents traditional karyotyping, detecting a range of numerical and structural chromosome 
abnormalities of all chromosomes
Ranking order test A, B and C
A-B-C A-C-B B-A-C B-C-A C-A-B C-B-A Total
Pregnant women 5 2 13 35 0 56 111*
- Advanced maternal age 4 2 9 32 0 48 95
- Risk following prenatal screening 1 0 4 2 0 6 13
- Parental anxiety 0 0 0 1 0 2 3
Caregivers 7 1 48 12 3 5 76**
- Obstetricians and gynaecologists 3 1 15 2 3 1 25
- Midwives and general practitioners 4 0 26 6 0 1 37
- Clinical (cyto)geneticists 0 0 7 4 0 3 15**
*2 pregnant women only stated their 1st preference
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(64% female). The majority of the caregivers preferred test B (77.9%) while the remaining 
preferences for test A and C were equally divided (10.4%) (table 1). The answer of one 
clinical geneticist (1.3%) who proposed a non-existing combination of test B and C was 
excluded. The dominant preference did not differ between the various groups of caregivers 
(χ2 7.28 p=0.122).
DISCUSSION
The aim of this study was to address which type of prenatal diagnostic test is preferred 
by pregnant women and caregivers and to investigate whether the preferences of these 
two stakeholders differ. The study showed a considerable difference in preferences amongst 
pregnant women. Half of our respondents opted for a test providing extensive information 
with considerable waiting time, while the other half preferred RAD, a rapid test providing 
specific information on the most common aneuploidies. In contrast to pregnant women, the 
majority of caregivers favour the rapid aneuploidy test, which can detect the most common 
aneuploidies. The caregivers studied represent all professional stakeholders in the field of 
prenatal diagnosis in our country. Hence, the fact that they largely agree seems promising 
and offers ample opportunity to reach consensus and equity in the provision of prenatal 
diagnostic care. On balance, there is a remarkable difference in what women want and 
caregivers prefer. 
A number of limitations of this study are recognized. Firstly, in absence of extensive debriefing, 
we can only speculate why women and caregivers choose Test A, B or C. A discrete choice 
experiment of sufficient sample size may reveal the background of women’s preference for 
either an extensive yet slow test or a selective and rapid test in more detail. Secondly, the 
generalizability of our results to other European countries can be a concern, because the 
majority of women chose to undergo amniocentesis on behalf of their age. In the Netherlands 
advanced maternal age still is the major indication for invasive prenatal diagnosis, while 
the National UK Screening Committee recommends not offering prenatal diagnosis for an 
age-related risk alone5. We did not include costs as test characteristic, since in the Dutch 
health care systems costs are usually fully covered by the insurance companies. However, in 
countries where co-payment is required or all costs are born by the pregnant woman; cost 
considerations may influence the preferred test. Another concern relates to the response rate 
of caregivers: with a response rate of 55%, selection bias cannot be ruled out.
Compared to the previous preference studies, the strength of our study is that we included 
women actually undergoing amniocentesis and we provided information on the tests 
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using the three main test characteristics3,4. Furthermore, this was a prospective study of a 
consecutive cohort, with a high (75%) response rate. In addition, we invited pregnant women 
and caregivers who live and work in different areas of the Netherlands, excluding possible 
regional differences.  
In 2004, the UK National Screening Committee5 recommended the use of RAD as a sole 
diagnostic tool (i.e. QF-PCR) to all women of increased risk of Down’s syndrome (with a 
nuchal translucency scan <3.0 mm). Although the preceding HTA report showed consensus 
for women and caregivers in favour of RAD3, the subsequent use of RAD as standalone test 
was not adopted in all centres. At this moment, we do not have insight in the reasons why 
the nationwide implementation was not successful. In the Netherlands, the perspective seems 
even less favourable: there is no clear consensus between caregivers and pregnant women. 
Although it is generally acknowledged that patient’s preferences should play a role in the 
process of medical decision-making, caregivers and policymakers may enforce a uniform 
policy leading to the implementation of RAD, which is preferred by caregivers and seems 
less expensive. Assuming the differences to be truly representative for women’s preferences, 
a uniform policy should be avoided, because it will not meet the choice of 50% of the 
consumers. 
To bridge the gap between caregivers and pregnant women, several solutions come to hand. 
One is that centres supply either karyotyping or RAD and women can choose which centre 
they attend. Another option is that centres offer both tests and women are allowed to choose, 
with or without additional payment. In line of our study results, an individualised choice in 
prenatal diagnosis should be offered, with or without economic incentives. 
When offering individualised choice, one should realise that the prenatal counselling process 
is of the highest importance. It is well known that counsellors should provide adequate 
nondirective counselling service, taking into account both a patient individualised risk 
assessment and her preferences. However, several studies suggest that counsellors frequently 
deviate from nondirectiveness: their attitudes and preferences can influence women’s 
decision-making6. Especially in case of individualised choice, the difference in preferences 
between women and caregivers could jeopardise the non-directive counselling process. 
Alerting counsellors to the discrepancy between client’s and their own preference will help to 
improve the process of informed and autonomous decision-making. 
In this new era with rapid developments in genetic testing and growing societal individualisation, 
a uniform policy seems out of date. The provision of prenatal genetic testing should be based 
upon individualized choice since the choice may have far reaching consequences. Future 
research and policymaking should focus on the implementation of available diagnostic tests 
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CONCLUSION
This study shows that the preferences for prenatal tests differ greatly among pregnant women. 
Caregivers mostly opt for RAD detecting the most common chromosomal aneuploidies. The 
divergent preferences amongst women and the difference between women and caregivers 
make us plea for individualised choice, provided that nondirective counselling is available.  
Questionnaire
We describe three hypothetical prenatal tests, named Test A, Test B and Test C. The three tests 
have different test characteristics, which are described in the text boxes below. For all three 
tests, amniocentesis has to be carried out. There is a risk of one in 250 for a miscarriage 
with amniocentesis. 
Firstly, read the description of the three hypothetical tests. Secondly, rank the tests in order 
of your preference. 
Test A
Characteristic 1: The test will determine whether or not your baby has Down syndrome 
(trisomy 21). 
Characteristic 2: In case of a detected Down’s syndrome, the doctor can provide clear 
information on the consequences of the abnormality. 
Characteristic 3: You have to wait 4 days for the test result.
Test B
Characteristic 1: The test will determine whether or not your baby has one of the most 
common chromosomal abnormalities, including Down syndrome (trisomy 21). These 
chromosomal abnormalities account for 80% of all chromosome aberrations identified 
prenatally.  
Characteristic 2: In case of a detected chromosomal abnormality, the doctor can provide 
in most cases clear information on the consequences of the abnormality. 
Characteristic 3: You have to wait 4 days for the test result.
Test C
Characteristic 1: The test will determine whether or not your baby has a chromosomal 
abnormality by testing all chromosomes, including Down syndrome (trisomy 21). 
Characteristic 2: In case of a detected chromosomal abnormality, the doctor can often 
provide you clear information on the consequences of the abnormality. Sometimes however, 
the exact consequences for the development of your child can’t be provided. 
Characteristic 3: You have to wait 21 days for the test result.
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Question 1: Which of the described tests do you prefer most?  
 Test A  Test B  Test C
Question 2: Which of the described tests do you prefer second best?  
 Test A  Test B  Test C
Question 3: Which of the described tests do you prefer least?  
 Test A  Test B  Test C
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To determine the pregnant women’s preference for rapid aneuploidy detection (RAD) or 
karyotyping and which test attributes influence their preference most.
Methods
We designed a discrete choice experiment, in which pregnant women had to choose between 
prenatal test profiles that differed in five treatment attributes: detection capacity, anxiety, 
waiting time, failure rate and consequences of detected chromosomal abnormalities. We 
assessed preference for i) a RAD test for the detection of aneuploidies of chromosome 21, 
18, and 13, ii) a RAD test for aneuploidies of chromosome 13, 18, 21, X, and Y, and iii) 
karyotyping. Test specific attributes that influence women’s preference were estimated. 
Results
In total 103/118 (87%) women participated. Women placed most value on the detection of 
chromosomal abnormalities with severe consequences for their child (P<0.01). The failure 
rate of the test, the waiting time for test results, and the experienced anxiety influenced 
women’s preferences significantly (P <0.05). For the currently available tests, women prefer 
karyotyping to RAD (P <0.01) in a setting where the detected chromosomal abnormalities 
have severe consequences for their child. However, in a setting where karyotyping detects 
chromosomal abnormalities with uncertain or no clinical consequences for their child, RAD 
tests are preferred (P <0.01). 
Conclusion
While anxiety and waiting time have some effect on women’s preferences, the potential 
clinical consequences of the detected chromosomal abnormality and failure rate influenced 
test choice most. Since RAD and karyotyping both detect the most common chromosomal 
abnormalities with severe consequences, both tests are appropriate for prenatal diagnosis.
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INTRODUCTION
In the last decade, a debate emerged in Europe whether rapid aneuploidy detection (RAD) 
should replace traditional karyotyping in prenatal diagnosis for relatively low risk indications 
such as advanced maternal age, increased risk following first trimester prenatal screening 
and maternal anxiety1,2. Opponents argue that substitution of karyotyping by RAD leads 
to undetected chromosomal abnormalities with severe clinical consequences while having 
a procedure related miscarriage risk. Proponents’ main argument is that substitution of 
karyotyping leads to a shortening of the stressful waiting time for parents, efficient prenatal 
counselling, substantial cost savings, and a negligible risk of missing a chromosomal 
abnormality with clinical significance3,4. 
While it is generally acknowledged that patient preferences should be incorporated into 
medical decision making5, and that many decisions need to be individualized, especially 
when they involve choices between possible outcomes that may be viewed differently by 
different patients6, only few studies have assessed pregnant women’s preferences for RAD or 
karyotyping7,8. In order to support policy-making for prenatal testing, it is important to know 
what pregnant women want and which test features are important to them. 
We assessed women’s preferences for RAD, both with or without detection of sex chromosome 
aneuploidies, and karyotyping. We used a so-called discrete choice experimentation (DCE) 
to determine the preferred diagnostic test strategy of women who considered having 
amniocentesis, and to evaluate which test characteristics they valued most.  We also analyzed 
if differences in preferences existed based on the prenatal test women chose in real life.  
METHODS
This study was conducted alongside the clinical MLPA And Karyotyping, an Evaluation 
(M.A.K.E.) study, a cohort study comparing MLPA and karyotyping on 4586 amniotic fluid 
samples9,10. The M.A.K.E. study has been described in detail elsewhere9,10. The diagnostic 
accuracy of MLPA was comparable to karyotyping as reference test.
From October 2008 to October 2009, women were invited attending a tertiary hospital 
(Erasmus Medical Centre, Rotterdam) to obtain information on prenatal testing. We selected 
this group because they represent the users of prenatal diagnostic tests and at that point 
they had not decided which test to choose. Women without sufficient command of the Dutch 
language were excluded. There were no other exclusion criteria. The prenatal counsellor 
provided nondirective oral and written information on prenatal screening and diagnosis. 
C
hapter 7 
Patients’ preferences for rapid aneuploidy detection or karyotyping
107
Referral indication, gravidity, parity, ethnicity, previous prenatal testing and education were 
recorded. This study was approved by the medical review ethics committee of the Onze Lieve 
Vrouwe Gasthuis, Amsterdam (reference number 06032). 
DCEs are increasingly being used as a means to elicit patient preferences11-13. DCEs 
assume that a given healthcare intervention or treatment (e.g. screening programme) can 
be fully described by its characteristics (‘attributes’; e.g. test duration) and that any woman’s 
preference for an intervention or treatment are determined by the variants of the attributes 
(‘levels’; e.g. 2, 4 and 6 days)14. The attributes and levels should be identified beforehand 
as potentially important determinants for the choice of an intervention or treatment15,16. In 
a DCE, each individual is presented a series of two hypothetical interventions in which the 
levels are varied. Next, individuals are invited to tick the preferred option. In the analysis, 
the series of choices made are linked to the differences in levels between options in order to 
obtain the relative weight assigned to that level or attribute. 
We distinguished three test strategies; RAD with and without the possibility to detect sex 
chromosome abnormalities (RAD+XY and RAD-XY respectively) and karyotyping (TKT). Both 
RAD tests are able to detect aneuploidies of chromosomes 13, 18 and 21. Although RAD 
can also detect sex chromosome aneuploidies using appropriate probes or primer sets, 
some centres do not test for sex chromosome anomalies. Karyotyping detects both numerical 
and structural chromosomal abnormalities of at least 5 Megabases. The study was designed 
as one set of choices comparing RAD+XY and TKT, and one set comparing RAD-XY and TKT.
Each choice set consisted of two juxtaposed vignettes; one vignette depicted a RAD+XY or 
RAD-XY strategy, the other displayed a TKT strategy. Each vignette consisted of an equal and 
fixed number of attributes. The levels within each attribute varied between the test strategies. 
To identify the relevant attributes, we conducted a literature review and a pilot survey among 
150 women who underwent amniocentesis. The survey contained 12 questions on detection 
capacity, consequences, waiting time, failure rate, anxiety, false positive and false negative 
test results, including a ranking exercise. The five most important attributes were detection 
capacity, consequences, anxiety, failure rate and waiting time. We did not include costs or 
co-payment as attribute, since these costs are fully covered in the Dutch healthcare system 
and therefore do not affect choices. The specific levels for each test attribute covered the 
range of possible test outcomes for each of the three strategies (RAD-XY, RAD+XY and TKT) 
based on literature review. The attribute levels are shown in Table 1, where detection capacity 
is incorporated in the test strategy. 
We adopted a so-called labelled design (i.e. each strategy was labelled RAD-XY, RAD+XY or 
TKT) because the levels of several attributes differed according to the test strategy. Such an 
approach is considered to increase realism and validity of our results17,18. The full factorial 
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design, combining all possible attributes with all possible levels, resulted in 1024 possible 
RAD-XY versus TKT comparisons and 2048 possible RAD+XY versus TKT comparisons. Since 
it is not feasible to present a single individual with all these combinations, we applied a 
so-called fractional factorial design consisting of 16 RAD-XY versus TKT and 16 RAD+XY 
versus TKT comparisons. This design, which was 92% efficient18, is the most efficient design 
possible under the restrictions imposed on the design. Further details about the DCE design 
are available on request.   
Each of the 32 comparisons was presented as two juxtaposed vignettes, one being a 
RAD+XY or RAD-XY strategy, the other being a TKT strategy. Each comparison was displayed 
graphically and with text to present the numbers in a balanced manner19. Vignettes, study 
materials and procedures were pilot-tested in 15 pregnant women and optimized before 
study onset. Figure 1 displays one of the vignettes (see page 118). 
The DCE survey containing the 32 comparisons was devised as a booklet. First, we provided 
general information on prenatal testing, prenatal diagnosis and chromosomal abnormalities. 
Secondly, we outlined the study aim and explained the vignettes. A legend chart of all used 
symbols and colours was provided to facilitate the choices. Thirdly, women were invited 
to evaluate the 32 comparisons and tick the preferred option. Finally, women’s socio-
demographic characteristics were collected.  Women who agreed to participate received the 
survey after the prenatal counselling visit, filled in the survey at home and returned the survey 
by prepaid envelope. No remuneration was done. 
Table 1: Alternatives, attributes and the alternative specific levels.
Characteristics Alternatives and levels
RAD-XY RAD+XY TKT
Waiting time (days) 4 4 14
7 7 21
Anxiety No No No
Little Little Little
Quite a lot Quite a lot Quite a lot
A great deal A great deal A great deal








RAD-XY= test detecting trisomies 21, 18, 13
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The choices between the three strategies were analyzed by multinomial logit regression 
models with test specific parameters using SAS version 9.1, (SAS Institute Inc., Cary, NC, 
USA). We assumed that there was no linear relationship between the different levels of the 
characteristics. We estimated the following models:
V RAD-XY= β0+ βref wait4 + β1wait7+ βref anxietygreatdeal+ β2anxietyquite+ 
β3anxietylittle+ β4anxietyno + βref failure3+ β5failure10+ β6failure20+ β7failure30
V RAD+XY= β8+ βref wait4+ β9wait7+ βref anxietygreatdeal+ β10anxietyquite+ 
β11anxietylittle+ β12anxietyno+ βref failure3+ β13failure10+ β14failure20+ 
β15failure30+ βrefsevereconsequence+ β16mildconsequence 
V TKT= βref det cap+ βref wait14+ β17wait21+ βref anxietygreatdeal+ β18anxietyquite+ 
β19anxietylittle+ β20anxietyno + βrefsevereconsequence+ β21mildconsequence + 
β22uncertainconsequence+ β23noconsequence 
V base case TKT = 0 (i.e. base case is karyotyping with a waiting time of 14 days, experiencing no 
anxiety, and detecting chromosomal abnormalities with severe consequences) 
V represents the preference score for each strategy on an interval scale, relative to VTKT  as 
base case. I.e., the higher the V score, the stronger the preference for that strategy, but the 
absolute value of V has no direct interpretation14. The constants β0 and β8 are alternative 
specific constants that indicate the general attitude of women towards RAD-XY and RAD+XY 
compared to karyotyping. The β-coefficients represent the preference weights associated 
with the levels of the respective attributes (β1,9,17 are the preference weights associated with 
the attribute waiting time, β2-4, 10-12, 18-20 with anxiety, β5-7,13-15 with failure rate, and β16,21-23 
with respect to consequences of the chromosomal abnormality for the unborn child). As in 
any regression, the sign of the β-coefficients indicates whether the alternative specific level 
has a positive or negative effect on V compared to the reference level. The magnitude of 
the β-coefficients indicates the relative importance of the specific level compared with the 
reference level for that attribute (see Table 3). A two-sided p-value ≤ 0.05 was considered 
statistically significant. 
We calculated the relative preference (V) for currently available tests by choosing the most 
realistic level of each attribute by using the results of the clinical M.A.K.E. study9; i.e., the 
relative preference (V) of a currently available test was equal to the sum of the coefficient 
weights of its attribute levels. For RAD-XY, we included the constant coefficient (β0), waiting 
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time of 7 days ( β1), quite a lot of anxiety (β2), and a failure rate of 10/1000 (β5). For 
RAD+XY, we included the constant coefficient (β8), waiting time of 7 days (β9), a lot anxiety 
(β10), and a failure rate of 10/1000 (β13), detecting chromosomal abnormalities with severe 
consequences (βref). For TKT, we included a waiting time of 21 days (β17), a great deal of 
anxiety (βref), and detecting chromosomal abnormalities with severe consequences (βref). 
Wald chi-squared test assessed the differences in preferences per currently available test.   
A priori we expected all attributes to be important and we expected positive effects of a short 
waiting time, a low failure rate, and no anxiety. Subgroup analysis was done for women 
who chose to have amniocentesis versus the women who opted for prenatal screening, no 
prenatal testing, chorionic villus sampling, or did not decide yet).  
RESULTS
A total of 103/118 (87.3%) women returned the survey. Often cited reasons to decline 
participation were no interest, survey is difficult to fill in, and lack of time. Table 2 shows 
respondent’s characteristics. Two women who only filled in part of the survey were excluded 
from analysis.
Table 2: Respondents’ characteristics
median IQR





 maternal age 95 94.1%
 anxiety 5 5%
 prenatal screening 1 1%
Western-European ethnicity 94 93.1%
Education
 lower vocational 2 2
 lower secondary 18 17.8 %
 intermediate and higher vocational, higher secondary 41 40.6 %
 college/university 40 39.6 %
PND in previous pregnancy 14 17.3%
PNS in previous pregnancy 30 37.0%
Definitive choice
 no testing 2 2%
 prenatal screening 30 29.7%
 chorionic villus sampling 12 11.9%
 Amniocentesis 52 51.5%
 I have not decided yet 5 5%
n=103, 2 missing, IQR= interquartile range, PND= prenatal diagnosis, PNS= prenatal screening
C
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Table 3 shows the β-coefficients associated with the levels of each strategy. All β-coefficients 
had p-values <0.05, i.e. consequences for the unborn child, failure rate, detection capacity, 
waiting time and anxiety all significantly attributed to women’s preferences. The signs of 
all significant coefficients of the attributes were as we expected except for waiting time for 
RAD-XY. The negative signs of failure rate (β5-7, β13-15) and consequences for the unborn 
child (β16, β21-23) indicate that women prefer a test with the lowest failure rate and a test 
that is able to detect chromosomal abnormalities with severe consequences for the unborn 
child. For TKT, a short waiting time was preferred over a longer waiting time. In contrast, 
Table 3: Coefficients of the different tests and attributes
Attributes and levels β Coeff CI P-value
Detection capacity RAD-XY with severe 
consequences
β0 -1.78 -2.21 to -1.36 <.01
RAD+XY β8 -1.43 -1.85 to -1.02 <.01
TKT with fail 3/1000 ref
Waiting time 4 days, RAD-XY ref
7 days, RAD-XY β1 0.23 0 to 0.47 0.05
4 days, RAD+XY ref
7 days, RAD+XY β9 0.07 -0.18 to 0.31 0.60
14 days, TKT ref
21 days, TKT β17 -0.17 -0.35 to 0 0.05
Anxiety great deal, RAD-XY ref
quite a lot, RAD-XY β2 -0.05 -0.38 to 0.27 0.75
little, RAD-XY β3 -0.16 -0.47 to 0.16 0.33
no, RAD-XY β4 -0.12 -0.44 to 0.2 0.46
great deal, RAD+XY ref
quite a lot, RAD+XY β10 0.14 -0.18 to 0.47 0.40
little, RAD+XY β11 0.40 0.03 to 0.76 0.03
no, RAD+XY β12 0.36 0.01 to 0.70 0.04
great deal, TKT ref
quite a lot, TKT β18 0.46 0.21 to 0.70 0.00
little, TKT β19 0.33 0.06 to 0.59 0.01
no, TKT β20 0.34 0.10 to 0.59 0.01
Failure rate 3/1000, RAD-XY ref
10/1000, RAD-XY β5 -0.13 -0.45 to 0.20 0.45
20/1000, RAD-XY β6 -0.21 -0.53 to 0.11 0.20
30/1000, RAD-XY β7 -0.33 -0.66 to -0.01 0.05
3/1000, RAD+XY ref
10/1000, RAD+XY β13 -0.14 -0.45 to 0.16 0.36
20/1000, RAD+XY β14 -0.84 -1.21 to -0.47 <0.01
30/1000, RAD+XY β15 -1.03 -1.38 to -0.68 <0.01
Consequences severe, RAD+XY ref
mild, RAD+XY β16 -0.73 -0.98 to -0.47 <0.01
severe, TKT ref
mild, TKT β21 -1.72 -2.01 to -1.44 <0.01
uncertain, TKT β22 -2.50 -2.78 to -2.22 <0.01
no, TKT β23 -2.52 -2.80 to -2.24 <0.01
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for RAD-XY and RAD+XY women expressed a positive attitude toward a waiting time of 
7 days compared to 4 days (β=0.23, p=0.05; β=0.07, p=0.60). Furthermore, women 
valued less anxiety positively for RAD+XY and TKT. In contrast, for RAD-XY, women valued 
less anxiety negatively (β2-4 <0), but coefficients were small and not significant.  Detection 
capacity, failure rate and consequences had β’s of high magnitude, with highest for TKT, 
Table 4: Subgroup analysis of women choosing amniocentesis versus women who opt for prenatal 
screening, no testing, chorionic villus sampling
Attributes and levels β AC 95% CI β no AC 95% CI P-value
Detection capacity RAD-XY with severe 
consequences
-2.51 -3.22 to -1.8 -1.39 -1.96 to -0.81 0.02
RAD+XY -1.86 -2.51 to -1.21 -1.15 -1.71 to -0.59 0.10
TKT with failure 
3/1000
ref ref
Waiting time 4 days, RAD-XY ref ref
7 days, RAD-XY 0.21 -0.16 to 0.58 0.25 -0.06 to 0.57 0.86
4 days, RAD+XY ref ref
7 days, RAD+XY 0.00 -0.4 to 0.4 0.12 -0.22 to 0.45 0.67
14 days, TKT ref ref
21 days, TKT -0.12 -0.43 to 0.18 -0.26 -0.49 to -0.02 0.50
Anxiety no, RAD-XY -0.09 -0.57 to 0.39 -0.02 -0.47 to 0.44 0.82
little, RAD-XY -0.32 -0.81 to 0.17 -0.07 -0.5 to 0.36 0.45
quite a lot, RAD-XY -0.25 -0.74 to 0.25 -0.05 -0.49 to 0.39 0.56
great deal, RAD-XY ref ref
no, RAD+XY -0.11 -0.59 to 0.36 0.37 -0.09 to 0.82 0.15
little, RAD+XY -0.02 -0.58 to 0.54 0.67 0.17 to 1.18 0.07
quite a lot, RAD+XY 0.02 -0.54 to 0.58 0.54 0.08 to 1.01 0.16
great deal, RAD+XY ref ref
no, TKT 0.15 -0.26 to 0.55 0.66 0.33 to 0.99 0.06
little, TKT 0.23 -0.27 to 0.73 0.41 0.07 to 0.74 0.57
quite a lot, TKT 0.06 -0.35 to 0.47 0.51 0.18 to 0.84 0.09
great deal, TKT ref ref
Failure rate 3/1000, RAD-XY ref ref
10/1000, RAD-XY -0.11 -0.59 to 0.37 -0.14 -0.59 to 0.31 0.93
20/1000, RAD-XY -0.35 -0.85 to 0.15 -0.15 -0.59 to 0.30 0.54
30/1000, RAD-XY -0.38 -0.88 to 0.13 -0.34 -0.79 to 0.11 0.91
3/1000, RAD+XY ref ref
10/1000, RAD+XY -0.09 -0.53 to 0.35 -0.19 -0.63 to 0.25 0.77
20/1000, RAD+XY -1.07 -1.67 to -0.48 -0.80 -1.29 to -0.30 0.48
30/1000, RAD+XY -1.28 -1.86 to -0.7 -0.95 -1.41 to -0.48 0.38
Consequences severe, RAD+XY ref ref
mild, RAD+XY -1.13 -1.54 to -0.73 -0.49 -0.83 to -0.15 0.02
severe, TKT ref ref
mild, TKT -2.49 -3.01 to -1.96 -1.27 -1.64 to -0.91 <0.01
uncertain, TKT -3.22 -3.74 to -2.7 -2.12 -2.47 to -1.76 <0.01
no, TKT -3.26 -3.78 to -2.75 -2.12 -2.47 to -1.76 <0.01
AC= amniocentesis group, No AC= rest (prenatal screening, no testing, chorionic villus sampling 
or not decided yet)
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where women valued the consequences of the detected chromosomal abnormality other 
than severe significantly more negatively (β= -2.52; β= -2.50; β= -1.72).   
When the results of the M.A.K.E. study (9) are entered into the models, the relative preference 
(V) score for each test strategy can be estimated: V RAD-XY = -1.73, V RAD+XY= -1.37 and V TKT= 
-0.17. These results show that compared to the base case TKT (i.e. detection capacity 23, 
waiting time 14 days, no anxiety, failure 3/1000, severe consequences), women value the 
three strategies negatively. Calculating the difference in preference for the currently available, 
women have no significant preference for either RAD-XY or RAD+XY (p= 0.14). Karyotyping 
is preferred over RAD-XY and RAD+XY as long as it detects chromosomal abnormalities 
with severe consequences for the unborn child (p <0.01 and p <0.01 respectively). When 
karyotyping detects chromosomal abnormalities with mild consequences for the unborn 
child, no test is preferred (RAD-XY vs. TKT p =0.98; RAD+XY vs. TKT p= 0.11). When TKT 
detects chromosomal abnormalities with uncertain or no clinically relevant consequences, 
both RAD tests are preferred (p <0.01). 
Table 4 shows the preferences weights when women who chose to undergo amniocentesis 
(n=52) are distinguished from women who did not (n=49). The only characteristic that was 
valued significantly different at all levels was the consequence of the detected chromosomal 
abnormality (table 4). Women undergoing amniocentesis valued the consequences of the 
detected chromosomal abnormality significantly more. 
DISCUSSION
Our study demonstrates that women place more value on the consequences of a chromosomal 
abnormality, detection capacity, and the test’s failure rate while anxiety and waiting time are 
valued less. Especially consequences of the detected chromosomal abnormalities for the 
unborn child have considerable impact on preferences. 
Women prefer karyotyping over RAD as long as the karyotype detects chromosomal 
abnormalities with severe consequences for the unborn child. If karyotyping detects 
chromosomal abnormalities with uncertain or no clinically relevant consequences, RAD is 
preferred. Women have no preference if chromosomal abnormalities are detected with mild 
consequences. The fact that women base their preference mainly on the outcome of a test 
may be interpreted as of little to help to current practice in which pregnant women have to 
choose a test in advance. However, these results do indicate the importance of risk selection 
before undergoing prenatal testing and prenatal counselling. Pregnant women should be 
informed clearly on the detection capacity of prenatal tests and the consequences of detected 
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chromosomal abnormalities taking into account the personalized risk. In that way physicians 
can assist pregnant women and their partners with choosing between the available tests.
Women who actually chose to have an amniocentesis placed more value on the characteristic 
consequences compared to women who chose not to undergo amniocentesis. Likely, the 
former are women who prefer clear results in everyday life, while the group choosing no test 
or prenatal screening can cope with uncertainties.    
Only few studies on preferences for RAD and karyotyping in prenatal diagnosis have been 
published. Two studies have been published on this topic and show no clear preference 
for RAD or karyotyping7,8. Compared to our study, both studies used a simplified design 
not representative for the complexity of real life decision-making in prenatal diagnosis. 
The simplified DCE, only including 49 women of which 10 were actually undergoing 
amniocentesis7, showed that women preferred a broad detection capacity and a short 
waiting time corresponding to our results. Grimshaw et al8 showed that of the 141 women 
who had been nonrandomly allocated to receive RAD and karyotyping, 67% chose RAD 
before amniocentesis, while 52% chose RAD after all test results were known. These results 
show that preferences can differ between individuals6,20 and preferences can change with 
circumstances21. In Stockholm, women are offered a real choice between QF-PCR and 
karyotyping and it has been reported that the majority (70%) opts for RAD22. Although, this 
study does give insight in the motivations of choices, it is the only study reporting on women’s 
actual decisions.
The labelled design with realistic scenarios adds to the validity of the results. Women 
placed value on all included attributes and except for waiting time for RAD, the signs of 
the coefficients were as we expected except for waiting time. Apparently, a waiting time of 
four days is too short for most women and the optimum time lies between 4 and 7 days. 
Furthermore, our prospective DCE included many women consecutively. Despite the complex 
design, the questionnaire was feasible given the high response rate of 87%. The design 
included many parameters, which might have led to loss of power with inability to detect all 
significant betas. However, an interim analysis of the survey results of 60 respondents showed 
that the coefficients of the betas were similar to the results reported here. 
None of the currently available tests meets the preference of women. Since RAD-XY, RAD+XY 
and TKT are all capable of detecting the most common severe chromosomal abnormalities 
(i.e. trisomies 13, 18 and 21), all tests are appropriate to offer in prenatal diagnosis and 
women should be allowed to make decisions in the context of their own priorities and life 
circumstances. 
At this point, microarray comparative hybridization, detecting more and smaller chromosomal 
abnormalities than karyotyping, is presented as having the potential to become the primary 
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prenatal diagnostic laboratory procedure23. In accordance with our results, microarray settles 
with the preferences for maximal detection, but also detects more uncertain or clinically 
irrelevant abnormalities, the most negatively valued characteristic of this study. From here we 
envisage two options: either we develop a new test that meets all preferences of women, or 
we offer an individual choice to women, taking into considerations her individual expectations 
and needs. The only currently available realistic option to meet most needs is offering an 
individual choice, so that the decision to either obtain as much cytogenetic information as 
possible versus a rapid but specific result on the most common chromosomal abnormalities 
is most appropriately made by individuals who will bear the responsibility of raising the child.
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ABSTRACT
Objective
To determine expert-consensus on which chromosomal abnormalities should and should not 
be detected in prenatal diagnosis, and for which abnormalities disagreement remains after 
structured discussion.
Methods
An expert panel of 24 prenatal experts (8 clinical cytogeneticists, 8 clinical geneticists and 
8 obstetricians) rated 15 chromosomal abnormalities sampled from a nationwide study 
on rapid aneuploidy detection. In two individual anonymous rating rounds and one group 
meeting, participants rated pro or against detection and stated their main argument. The 
15 chromosomal abnormalities were described in detail by a stylized vignette containing an 
obstetrical history, the indication for prenatal diagnosis and the range of possible outcomes 
of the chromosomal abnormality. Consensus was defined to be present if at least 80% of the 
experts agreed. 
Results
Consensus was reached in 12 of 15 cases. In 10 cases, there was agreement pro detection 
and in two cases experts agreed against detection. At the end of the 3rd round, dissensus 
remained on three abnormalities.
Conclusion
Experts largely agreed on detecting chromosomal abnormalities with severe consequences 
and against detection in case of irrelevant clinical consequences. For chromosomal 
abnormalities with mild or uncertain outcomes, dissensus remained. None of the currently 
available tests corresponds to these demands. 
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INTRODUCTION
In prenatal diagnosis, conventional karyotyping is considered the gold standard to detect 
fetal chromosomal abnormalities. New molecular techniques emerged which challenged 
routine practice based on karyotyping. Many evaluation studies have focused on diagnostic 
accuracy of these new techniques, either at the laboratory or at the clinical level. These 
studies, however, are ineffective if 1) outcomes undisputedly relate to different domains 
(e.g. ethical, emotional and medical aspects), 2) multiple stakeholders are relevant with 
potentially unreconciled interests (e.g. government, patients, doctors, ethical and religious 
representatives, lay people), 3) new techniques develop too rapidly to allow a long term 
comprehensive analysis.
Availability of rapid aneuploidy detection (RAD) tests allows an accurate result on trisomies 
13, 18, 21 and numerical sex chromosome aberrations to be obtained within a few days1,2 
and at considerably lower costs compared to karyotyping2,3. RAD -by design- cannot detect 
other chromosomal abnormalities than trisomies 13, 18, 21 and numerical sex chromosome 
aberrations, leading to an estimated undetected chromosomal abnormality with severe 
consequences for the unborn child in 1: 1000 to 1:1659 invasive tests4-6. A profound 
debate has emerged on which test should be offered: should it be targeted and quick at 
low costs with a small risk of missing rare severe chromosomal abnormalities, or should the 
test detect as much as possible with higher costs and longer waiting time, and accepting 
the detection of chromosomal abnormalities with no or unclear clinical consequences? The 
latter provoke difficult counseling issues and emotional parental dilemmas to continue or 
terminate pregnancy. So far, formal evaluations and decision-support techniques have failed 
to arrive at an agreed set on which chromosomal abnormalities should be detected and 
which not. 
This paper describes an alternative approach (‘nominal group technique’) to arrive at a 
consensus judgment on which chromosomal abnormalities experts want to detect in prenatal 
diagnosis for women with advanced maternal age, increased risk following prenatal 
screening or parental anxiety. A formalized expert meeting was set up, with participation 
of a nationwide sample of prenatal diagnosis experts, representing current policymakers. 
We aimed to reach consensus on which chromosomal abnormalities should be detected, 
and which not, regardless the test. Secondly, we explored the key arguments underlying the 









The nominal group technique, also known as expert panel, is a consensus method and was 
developed in the United States in the 1960s. It is used when unanimity of opinion cannot be 
achieved due to divergent outcomes on multiple domains or conflicts of primary interests and 
a lack of remuneration on consensus. The nominal group technique gathers information from 
relevant experts, using a highly structured face-to-face meeting with or without a preceding 
individual survey. In the former case the individual round serves as anonymous input for 
the face-to-face meeting. The final goal of the nominal technique is to assess the initial 
agreement, to resolve disagreement by structured information exchange, to assess final 
agreement, and to redefine remaining issues of dissensus in terms of principal arguments 
at stake7. In health care the method has been applied to examine the appropriateness of 
clinical interventions, where straightforward application of guidelines was insufficient8. 
Our expert study consisted of three rounds. In the first round we asked for anonymous 
individual judgment regarding the desirability to detect 15 chromosomal abnormalities, 
presented in stylized fashion (‘vignettes’, see below). In the second round, again anonymous 
individual judgment was aimed at, now after feedback of the total group’s responses. In the 
third round, individual judgments were no longer anonymous; group consensus was aimed 
at after extensive group considerations and remaining dissensus was explored.  
Participants
We purposely selected 24 leading experts from three professional stakeholder groups; clinical 
geneticists (8), clinical cytogeneticists (8) and obstetricians (8) from all prenatal clinics in the 
Netherlands, based on their experience and publications in the area. The participants were 
informed on the study aim, the amount and type of work expected, the study deadlines, and 
the lack of monetary compensation. The experts were guaranteed that no individual data on 
their personal opinion or stated arguments would be presented in any public report or would 
be made available otherwise.
Clinical Study
From February 2007 until July 2008, we performed a prospective study comparing the 
diagnostic accuracy of Multiplex Ligation-dependent Probe Amplification (MLPA), a molecular 
technique that detects trisomies 13, 18, 21 and numerical sex chromosome abnormalities, 
with karyotyping on 4585 amniotic fluid samples2,9.  In 4484/4585 samples (97.8%) MLPA 
and karyotyping were concordant, showing normal results in 4387/4585 (95.7%) and 
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aneuploidy in 98/4585 (2.1%). Discordant results were found in 26/4585 (0.6%) samples, 
representing in all cases an abnormal karyotype yet undetected by MLPA (supplemental table 
1). The failure rate was 1.6% for MLPA and 0.02% for karyotyping. The cases in which a 
chromosomal abnormality was detected are used in the current expert study.
Vignettes
A research team of four people (EMB, EB, GB, JvL) described chromosomal abnormalities 
in a stylized fashion (‘vignette’, see table 2) and facilitated the meeting (figure 1). Vignettes 
have been used in a variety of other studies to communicate relevant specific info to a 
panel of voters with a specific task10,11; this technique of data reduction and effective 
communication is common in decision science. We included all chromosomal abnormalities 
which both tests can detect, as well as the abnormalities that RAD cannot disclose. Per 
group of comparable chromosomal abnormalities (e.g. inherited apparently balanced 
chromosomal abnormalities), we randomly drew one case from this group, otherwise we 
described each chromosomal abnormality separately (table 1). In the vignette we used the 
unchanged patient background data from the M.A.K.E. study. The consequences of the 
chromosomal abnormality were described by using the full range of outcomes as described 
in literature. Amendments to the vignettes were allowed during the course of the process, 
as experts sometimes could dispose of information yet to become available in the public 
domain. An independent clinical geneticist helped with describing and, when necessary, 
adjusting the cases.
Consensus rule
Consensus was stated to be reached when at least 80% of the experts agreed on whether 
chromosomal abnormalities should or should not be detected, otherwise dissensus existed. 
For all cases, we used a multiple choice response mode with four options; strongly PRO 
Table 1. Selection of chromosomal abnormalities (vignettes) for the expert study drawn from the 
data of the clinical MLPA and Karyotyping, an Evaluation (M.A.K.E.) study
chromosomal abnormalities in M.A.K.E.study n vignettes
Trisomy 21 69 1
trisomy 18 15 1
trisomy 13 1 1
sex chromosomal abnormalities 12 2
mosaic trisomy 21 and mosaic Turner 1 0
structural inherited balanced chromosome aberration 14 1
structural de novo apparently balanced chromosome aberration 4 1
supernumerary marker chromosome 3 3
mosaicism 3 2
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detection, probably PRO detection, probably AGAINST detection, strongly AGAINST 
detection. The adjectives ‘probably or strongly’ were regarded equal to calculate consensus. 
Study procedures
The questionnaire for round 1 was piloted among four gynecological researchers. For 
round 1 and 2, we used web-based provider of survey software (QuestionPro, Seattle USA). 
Responses were collected through computer generated reports. One reminder was sent three 
weeks after the initial sending of the survey invitation. The study took place from December 
2008 to February 2009.
Round 1: Individual session
Here we collected the answers anonymously and the experts were unaware of the results 
of other participating experts. We gathered participants’ socio-demographical data. We 
presented fifteen 15 vignettes describing the chromosomal abnormalities (table 1, figure 1 and 
supplemental figure 1). For each vignette, respondents answered whether the chromosomal 
abnormality should be detected in prenatal diagnosis for the indication advanced maternal 
age or increased risk following prenatal screening. We used a multiple choice response 
mode with four options; strongly PRO detection, probably PRO detection, probably AGAINST 
detection, strongly AGAINST detection. Next we calculated consensus. Participants also 
had to state the most important reason(s) why they thought the chromosomal abnormality 
should or should not be detected by using a multiple choice set including an open answer. 
Participants were allowed to explain their answers in detail or add further remarks, which 
were used to optimize the vignettes in round 2 with the help of the independent clinical 
geneticist.
Round 2: Individual session
In 2nd round, participants were informed on the consensus cases of round 1 and on the 
adjustments made in the remaining dissensus cases. For each dissensus case, feedback 
was given by displaying the individual expert’s judgment compared to the overall group’s 
judgment using bar graphs as well as the most frequently cited reasons pro and against 
detection. Next, experts were invited to reconsider their answers from round 1, but it was 
emphasized that conformation to the group view was unnecessary11. Again they were asked 
to give their opinion: strongly PRO detection, probably PRO detection, probably AGAINST 
detection, strongly AGAINST detection, of the case presented. The same consensus rule was 
applied.
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Figure 1: Design of the study
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Round 3: Plenary session
Round 3 consisted of a plenary two hour meeting of the experts. We first summarized the 
results of consensus cases in round 1 and 2. Next, for the dissensus cases, we showed the 
expert’s judgment in round 1 and 2 using bar graphs with the most frequently stated reasons. 
Participants had time to read the vignette and evaluate the feedback from the previous 
rounds. An open discussion followed to exchange different views, to share knowledge, and 
to make sure that all experts voted with identical information of the cases. Next, each expert 
voted openly PRO or AGAINST detection. Figure 1 shows a flowchart of the study.
Analysis
Results were reported as absolute numbers and percentages. Agreement was established 
after each round according to the above mentioned consensus rule. In case consensus was 
established in round 1 or 2, the case was excluded from further rounds. We calculated the 
percentage of agreement and multi-rater kappa (adapted from Fleiss, http://justusrandolph.
net/kappa/) between rounds for the complete group and per professional group to investigate 
a potential role for professional background. Although no absolute definitions are available, 
we used the following interpretation of ranges of the multi-rater kappa: within the range 0.21 
to 0.40 agreement was judged as fair, from 0.41 to 0.60 as moderate, from 0.61 to 0.80 
as good and from 0.81 to 1.00 as very good12.
RESULTS
All 24 invited experts agreed to participate (11 male, 13 female). Participants were on 
average 47 years old and were employed for on average 13 years in the field of prenatal 
diagnosis in academic hospitals. Twenty-one of the 24 respondents participated in all three 
rounds (87.5%); one clinical geneticist, one cytogeneticist and one obstetrician were not 
available for round 3. 
In the 1st round consensus was reached for six of the fifteen cases. Experts voted that these 
cases should be detected in prenatal diagnosis (table 2). For the dissensus cases, most 
cited reasons PRO and AGAINST detection are given in table 3. Overall agreement for 
all participants in round one was moderate (overall agreement 70%, free-marginal kappa 
0.40).
In the 2nd round, three amendments were made; 1) we added that mosaic Turner syndrome 
is associated with an increased risk of congenital heart abnormalities, 2) we added for the 
case with an inherited marker chromosome that the mother (who had the same chromosomal 
abnormality) had no clinical consequences 3) we added that learning difficulties (not 
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otherwise specified) in children with mosaic trisomy 20 were observed. Of the nine cases, 
consensus was reached only in one case, indicating that normal variants should not be 
detected in prenatal diagnosis (table 3). Most cited reasons PRO and AGAINST detection did 
not change between round 1 and 2 (table 4), except for the Triple X case, where the most cited 
reasons pro detection was the possible severe consequences for offspring. Experts changed 
their opinion between round 1 and 2 from PRO or AGAINST detection on average 1.5 times 
per 9 cases (min 0 changes, max 4 changes). Overall agreement between participants in 
round two was poor (overall agreement 58%, free-marginal kappa 0.15).
The 3rd round took two hours. We presented the eight remaining dissensus cases. Six 
adjustments were made during this group discussion, mostly on the consequences for the 
unborn child; 1) for the Klinefelter syndrome case, a 15% risk of psychological difficulties 
was added, 2) For the Triple X case, normal fertility was accepted 3) for the Robertsonian 
translocation, a 1% risk for the unborn child of having offspring with trisomy 13 was added 
4) for the mosaic Turner syndrome case, participants agreed that the grade of mosaicism was 
not related to the consequences, 5 and 6) for the inherited and mosaic marker chromosome, 
participants agreed that a 5% risk for the unborn child on uniparental disomy was present 
and -if present- this leads to severe consequences. After ample consideration of the vignettes 
and group discussion, again participants voted by PRO or AGAINST detection. Consensus 
was reached in 5 out of 8 cases (table 3).  Experts changed their opinion between round 2 
and 3 from PRO and AGAINST detection on average 2.4 times per 8 cases (min 0 changes, 
max 4 changes). Overall, agreement was moderate (overall agreement 77%, free-marginal 
kappa 0.53). Obstetricians voted more frequently against detection compared to the other 
Table 2. Example of the representation of a chromosomal abnormality (vignette of case 1)
Case 1
Age and parity 43 year old G3P0
Obstetrical history 2 miscarriages
Indication Prenatal Diagnosis Maternal age and increased risk for Down syndrome 1:50
Procedure Uncomplicated amniocentesis at gestational age 16+1 weeks 
MLPA Male, trisomy 21
Karyotype 47,XY+21
Chromosome abnormality fetus Down syndrome; 47,XY+21
Consequences of the chromosomal 
abnormality for the fetus
Down syndrome leads to a mild or severe mental handicap, and 
specific physical features. There is an increased risk of congenital 
abnormalities and physical disabilities. Physical and mental 
development is delayed. There is considerable interpersonal 
variance.
Consequences of the chromosomal 
abnormality for a future pregnancy
The additional risk of a child with a chromosomal abnormality in 
a future pregnancy is 1%. Prenatal diagnosis is offered in a next 
pregnancy.
Consequences of the chromosomal 
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Table 3: Rating scores and reached consensus on 15 cases per round
Case Round 1 N=24 Round 2 N=24 Round 3 N=21 Consensus
   nr description ++ + - - - ++ + - -- + -
1 Trisomy 21 22 2 0 0 Yes, PRO
2 Trisomy 13 19 4 1 0 Yes, PRO
3 Trisomy 18 20 3 1 0 Yes, PRO
4 Klinefelter syndrome 7 7 9 1 6 9 8 1 15 6 No
5 Triple X 4 3 13 4 2 3 15 4 2 19 Yes, AGAINST
6 Normal variant 2 3 8 11 2 2 7 13 Yes, AGAINST
7 Robertsonian translocation 12 6 5 1 15 3 4 2 14 7 No
8 Mosaic Turner syndrome 7 8 8 1 12 7 3 2 17 4 Yes, PRO
9 Inherited marker chromosome 15 1 5 15 3 6 3 13 2 21 0 Yes, PRO
10 De novo marker chromosome 9 18 4 2 0 Yes, PRO
11 De novo deletion chromosome 7 20 2 2 0 Yes, PRO
12 Mosaic unbalanced rearrangement of 
chromosome 18
18 4 2 0 Yes, PRO
13 Mosaic trisomy 20 4 5 14 1 4 7 11 2 1 20 Yes, AGAINST
14 Mosaic marker chromosome 7 9 9 5 1 7 7 8 2 21 0 Yes, PRO
15 De novo balanced translocation of 
chromosome 11 and 13
9 9 5 1 11 7 5 1 16 5 No
Round 1 and 2: ++ = Strongly pro detection; +  = Probably pro detection; -  = Probably against 
detection; -- = Strongly against detection
Round 3: + = Pro detection; - = Against detection
Table 4: Stated reasons for dissensus cases PRO or AGAINST detection in round 1. 
Most cited reason PRO detection Cases
Provide informed decision-making to parents, so they 
can decide whether to continue or terminate pregnancy
Klinefelter syndrome
Triple X syndrome
Inherited marker chromosome 15
Mosaic trisomy 20 
Mosaic marker chromosome 7
De novo balanced translocation of chromosome 11 
and 13




Early support may lead to improved clinical outcome Mosaic Turner syndrome
Most cited reason AGAINST detection Cases




Mosaic trisomy 20 
Mosaic marker De novo balanced
translocation of chromosome 11 and 13





Inherited marker chromosome 15
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experts. Table 5 shows agreement between the different professional groups per round. 
Agreement varied from poor to moderate between rounds. In the 2nd round agreement was 
lowest; in particular with low agreement among clinical geneticists.  
DISCUSSION
This study systematically elicited the views of prenatal experts on which chromosomal 
abnormalities should be detected bearing in mind the emerging possibilities of targeted and 
broad prenatal tests. Experts agreed on 12 of 15 chromosomal abnormalities; in 10 cases 
they agreed that they should be detected, and in 2 cases that they should not be detected. 
At the end of the 3rd round, a majority favored detection in the remaining three cases, but 
a significant minority disagreed. Overall, experts agreed on the detection of chromosomal 
abnormalities with severe consequences and on not detecting chromosomal abnormalities 
with no or minor consequences. 
Immediate consensus was reached in round one for the chromosomal abnormalities 
with severe, untreatable consequences for the unborn child. Apparently, there is greater 
agreement at the extremes; the professional experts preferred to detect all chromosomal 
abnormalities with severe consequences, and they also agreed not to detect chromosomal 
abnormalities without clinical consequences. However, for the chromosomal abnormalities 
Table 3: Rating scores and reached consensus on 15 cases per round
Case Round 1 N=24 Round 2 N=24 Round 3 N=21 Consensus
   nr description ++ + - - - ++ + - -- + -
1 Trisomy 21 22 2 0 0 Yes, PRO
2 Trisomy 13 19 4 1 0 Yes, PRO
3 Trisomy 18 20 3 1 0 Yes, PRO
4 Klinefelter syndrome 7 7 9 1 6 9 8 1 15 6 No
5 Triple X 4 3 13 4 2 3 15 4 2 19 Yes, AGAINST
6 Normal variant 2 3 8 11 2 2 7 13 Yes, AGAINST
7 Robertsonian translocation 12 6 5 1 15 3 4 2 14 7 No
8 Mosaic Turner syndrome 7 8 8 1 12 7 3 2 17 4 Yes, PRO
9 Inherited marker chromosome 15 1 5 15 3 6 3 13 2 21 0 Yes, PRO
10 De novo marker chromosome 9 18 4 2 0 Yes, PRO
11 De novo deletion chromosome 7 20 2 2 0 Yes, PRO
12 Mosaic unbalanced rearrangement of 
chromosome 18
18 4 2 0 Yes, PRO
13 Mosaic trisomy 20 4 5 14 1 4 7 11 2 1 20 Yes, AGAINST
14 Mosaic marker chromosome 7 9 9 5 1 7 7 8 2 21 0 Yes, PRO
15 De novo balanced translocation of 
chromosome 11 and 13
9 9 5 1 11 7 5 1 16 5 No
Round 1 and 2: ++ = Strongly pro detection; +  = Probably pro detection; -  = Probably against 
detection; -- = Strongly against detection
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Table 5: Differences in multi-rater kappa and agreement per professional group between the 
three rounds
Experts Round 1 Round 2 Round 3
kappa % of overall 
agreement 
kappa % of overall 
agreement 
kappa % of overall 
agreement
Obstetricians 0.43 71% 0.25 62% 0.55 77%
Clinical cytogeneticists 0.39 69% 0.19 60% 0.52 76%
Clinical geneticists 0.41 71% -0.04 48% 0.57 79%
with uncertain or mild consequences, consensus was not reached. Even in round three in 
which all respondents had identical information, opinions still differed markedly. Most likely, 
these differences are based on disagreement in principle. Some experts value being informed 
as the most important asset, while for others clinical consequences are decisive. 
Despite the high consensus rate, change of opinion between rounds was common, with 
poor to moderate agreement across rounds. The judgments also differed by expert group; 
obstetricians rated more frequently AGAINST detection and changed their opinion more 
often than the other expert groups. The caregiver’s role in the counseling process might 
be an explanation for this difference, or the amount of education and experience with the 
conditions. While obstetricians inform patients on possibilities in prenatal diagnosis before a 
definite diagnosis is made, geneticists are mainly involved when a chromosomal abnormality 
has been detected.
We made several observations during the group meeting. Firstly, we noticed that experts judged 
the cases from a doctor-patient perspective rather than from a public health perspective. 
Apparently by using vignettes, experts judge the case as their own patient, which is reassuring 
from a validity point of view. Furthermore, in the 3rd round two experts were responsible for 
most of the adjustments. The group did not judge these two experts to dominate or otherwise 
unduly influence opinion; rather the reverse, there comments were appreciated and their 
additions regarded as correct and justified. We cannot explain why these experts did not 
provide this feedback in the first two anonymous rounds. This would probably have led to 
earlier consensus. However, the adaptation of vignette information at this stage should not 
be regarded a bias, it increased the validity of the judgments and consensus verdicts. Finally, 
in the 3rd round we reached consensus in more cases than we expected based on results in 
previous rounds. While we in retrospect believe this convergence was for the greater part 
explained by the information exchange and group deliberation, we cannot exclude that 
group pressure may have played a role. 
This prospective, multidisciplinary study with high participation rate gives insight into which 
chromosomal abnormalities should and should not be detected according to experts and 
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provides important information on the experts’ motives. The execution of a group meeting 
improved knowledge transfer and it allowed the exchange of opinions and an open 
discussion. During the group meeting it was remarkable that experts spent much time on 
deliberations on knowledge of facts, but little effort was spent to explain their principles and 
to persuade others to vote pro or against detection.
While our multidisciplinary experts were all clinicians practicing prenatal diagnosis in 
academic hospitals, clearly more stakeholders are involved outside of this study design: 
obstetricians working in non-university training and non-training centers, general practitioners 
and midwives. The expected level of expertise and experience will be less, but the effect 
on opinion and consensus is difficult to predict13. Evidently client’s opinion should be 
incorporated14, although the vignettes used in this study are not suitable for this matter. 
Future research should focus on eliciting the views of these stakeholders.   
In view of the consensus verdicts, one may consider the most appropriate test. On the one 
hand, the expert group recommends detecting all chromosomal abnormalities with severe 
consequences for the child. RAD as it is currently designed will not meet the case since 
it detects only the most common chromosomal abnormalities with severe consequences 
(trisomies 13, 18, 21), but karyotyping does to a large degree. On the other hand, experts 
want to avoid the detection of chromosomal abnormalities without clinical consequences. 
While RAD is capable of that to a large degree, karyotyping certainly is not. Hence, a test 
that meets all criteria is currently unavailable. From here we envisage three directions; 1) 
Effort should be put into the development of a test that is more in agreement with the expert’s 
recommendations. However, it is likely that each test has its benefits and disadvantages and 
it is likely that each test has its limitations. 2) A uniform test is offered, meeting most needs 
of the experts, in this case karyotyping. 3) An individual choice is offered allowing a tailor-
made strategy according to a patient’s risk and preferences. Or, within the same scope, 
agreements can be made on which test results are reported to clients and which not. For 
instance, in the currently performed microarray study by Wapner et al abnormalities smaller 
than 1 Mb are not reported to patients15. However, future research should assess whether 
it is feasible in clinical practice to implement this strategy and if parents and caregivers are 
able to make a shared informed decision on the abnormalities that should be detected.
We hypothesize that if the most experienced stakeholders (i.e. experts) disagree on what 
should be detected in prenatal diagnosis, the implementation of a uniform nationwide policy 
is outdated. Tailor-made strategies, incorporating patient’s risk and demands, can overcome 
this problem. Patients, in consultation with their doctor, decide which test meets their risk and 
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order to allow informed decision-making and on the availability of an up-to-date genetic 
database on rare chromosomal abnormalities.
Concluding, experts agree that chromosomal abnormalities with severe consequences 
should be detected and not to disclose abnormalities without clinical consequences. Experts 
disagree on abnormalities with uncertain clinical consequences. These differences are based 
on disagreement in principle; some experts value ‘being informed’ as an extremely valuable 
asset, while for others the clinical consequences are decisive. None of the currently available 
tests corresponds to the experts’ demands. While karyotyping is able to detect chromosomal 
abnormalities without clinical consequences, RAD is unable to disclose all chromosomal 
abnormalities with severe consequences. 
Supplemental table 1: Total of chromosomal abnormalities detected with karyotyping and not 
detected with MLPA out of 4585 amniocentesis; arranged in order of clinical consequences























mos 45,X[6]/46,XX[11] confirmed postpartum 45,X[3]/46,XX[32]
Mos 47,XX,der (17)(p11.1q11.1)[10]/46,XX[12]






Age and parity 43 year old G3P0
Obstetrical history 2 miscarriages
Indication Prenatal Diagnosis Maternal age and increased risk for Down syndrome 
1:50
Procedure Uncomplicated amniocentesis at gestational age 16+1 
weeks 
MLPA Male, trisomy 21
Karyotype 47,XY,+21
Chromosome abnormality fetus Down syndrome; 47,XY,+21
Consequences of the chromosomal abnormality for 
the fetus
Down syndrome leads to a mild or severe mental 
handicap, and specific physical features. There is an 
increased risk of congenital abnormalities and physical 
disabilities. Physical and mental development is delayed. 
There is considerable interpersonal variance.
Consequences of the chromosomal abnormality for 
a future pregnancy
The additional risk of a child with a chromosomal 
abnormality in a future pregnancy is 1%. Prenatal 
diagnosis is offered in a next pregnancy.
Consequences of the chromosomal abnormality for 
relatives of the parents
None
Case 2
Age and parity 39 year old G1P0
Obstetrical history -
Indication Prenatal Diagnosis Maternal age and increased risk for Down syndrome 
1:82
Procedure Uncomplicated amniocentesis at gestational age 16+2 
weeks 
MLPA Male, trisomy 13
Karyotype 47,XY,+13
Chromosome abnormality fetus Patau syndrome; 47,XY,+13
Consequences of the chromosomal abnormality for 
the fetus
Patau syndrome leads to severe intellectual disabilities, 
and specific physical features. Due to the presence of 
several life-threatening medical problems, intrauterine 
death is common. 75% of the infants with trisomy 13 die 
within their first 2 months of life, and 95% of the infants 
die within 1 year.
Consequences of the chromosomal abnormality for 
a future pregnancy
The additional risk of a child with a chromosomal 
abnormality in a future pregnancy is 1%. Prenatal 
diagnosis is offered in a next pregnancy.
Consequences of the chromosomal abnormality for 
relatives of the parents
None








Age and parity 38 year old G4P1
Obstetrical history Normal delivery, 2 miscarriages
Indication Prenatal Diagnosis Maternal age
Procedure Uncomplicated amniocentesis at gestational age 15+5 
weeks 
MLPA Male, trisomy 18
Karyotype 47,XY,+18
Chromosome abnormality fetus Edwards syndrome; 47,XY,+18
Consequences of the chromosomal abnormality for 
the fetus
Edwards syndrome leads to severe intellectual 
disabilities, and specific physical features. Due to the 
presence of several life-threatening medical problems, 
intrauterine death is common. 95% of infants with 
trisomy 18 die within their first 6 months. 
Consequences of the chromosomal abnormality for 
a future pregnancy
The additional risk of a child with a chromosomal 
abnormality in a future pregnancy is 1%. Prenatal 
diagnosis is offered in a next pregnancy.
Consequences of the chromosomal abnormality for 
relatives of the parents
None
Case 4
Age and parity 37 year old G3P1
Obstetrical history 1 miscarriage, 1 normal delivery
Indication Prenatal Diagnosis Maternal age
Procedure Uncomplicated amniocentesis at gestational age 16+6 
weeks 
MLPA Male, two X chromosomes, one Y chromosome
Karyotype 47,XXY
Chromosome abnormality fetus Klinefelter syndrome; 47,XXY
Consequences of the chromosomal abnormality for 
the fetus
In general, men with Klinefelter syndrome have few 
noticeable symptoms and normal IQ scores, however 
verbal IQ scores lower than performance IQ. In some 
men physical features are present; small testes, a tall 
posture and in 30% reversible gynecomastia. The most 
common symptom is infertility. 
Consequences of the chromosomal abnormality for 
a future pregnancy
The additional risk of a child with a chromosomal 
abnormality in a future pregnancy is less than 1%. 
Prenatal diagnosis is offered in a next pregnancy.
Consequences of the chromosomal abnormality for 




Age and parity 36 year old G1P0
Obstetrical history -
Indication Prenatal Diagnosis Maternal age and increased risk for Down syndrome 
1:120
Procedure Uncomplicated amniocentesis at gestational age 16+6 
weeks 
MLPA Female, three X chromosomes
Karyotype 47,XXX
Chromosome abnormality fetus Triple X syndrome; 47,XXX
Consequences of the chromosomal abnormality for 
the fetus
Women with triple X syndrome have normal intelligence, 
without physical complaints and no specific physical 
features although they are often tall. Developmental 
delay in motor and verbal skills is possible. IQ scores 
are within the normal range, but are 10-20 points less 
compared to siblings.
Consequences of the chromosomal abnormality for 
a future pregnancy
The additional risk of a child with a chromosomal 
abnormality in a future pregnancy is less than 1%. 
Prenatal diagnosis is offered in a next pregnancy.
Consequences of the chromosomal abnormality for 
relatives of the parents
None
Case 6
Age and parity 36 year old G1P0
Obstetrical history -
Indication Prenatal Diagnosis Maternal age




Chromosome abnormality fetus Normal variant; 46,XX,der(22)t(Y;22)(q12;p12)pat
Consequences of the chromosomal abnormality for 
the fetus
None
Consequences of the chromosomal abnormality for 
a future pregnancy
None
Consequences of the chromosomal abnormality for 









Age and parity 35 year old G1P0
Obstetrical history -
Indication Prenatal Diagnosis Increased risk for Down syndrome 1:110




Chromosome abnormality fetus Balanced inherited Robertsonian translocation; 
45,XY,der(13;22)(q10;q10)pat
Consequences of the chromosomal abnormality for 
the fetus
The probability on congenital abnormalities is 
considerably low. Offspring of the infant can inherit the 
abnormality in an unbalanced manner, which usually 
leads to miscarriage, but it can also lead to a severely 
handicapped child. 
Consequences of the chromosomal abnormality for 
a future pregnancy
The probability of a child with trisomy 13 in a future 
pregnancy is 1%. There is an increased risk on 
miscarriages. Prenatal diagnosis is offered in a next 
pregnancy.
Consequences of the chromosomal abnormality for 
relatives of the parents
Parents and siblings of the father may also have the 
chromosomal abnormality and are offered karyotyping. 
Case 8
Age and parity 40 year old G4P1
Obstetrical history 1 normal delivery, 2 miscarriages
Indication Prenatal Diagnosis Maternal age
Procedure Uncomplicated amniocentesis at gestational age 16+4 
weeks 
MLPA Normal female
Karyotype mos 45,X[6]/46,XX[11] 
Chromosome abnormality fetus Mosaicism of a normal female karyotype in 11 cell 
clones and monosomy X in 6 cell clones, mosaic Turner 
syndrome; mos 45,X[6]/46,XX[11]
Consequences of the chromosomal abnormality for 
the fetus
84 % of women with this chromosomal abnormality 
have no specific physical features (Hsu). In some cases 
fertility problems exist and specific physical features 
(16%); e.g.  short stature, no or little secondary sex 
characteristics . Of these women 10-34% will get 
pregnant (Birkebaek 2002). In several case reports a 
slightly increased risk on chromosomal abnormalities in 
their offspring is reported.  
Consequences of the chromosomal abnormality for 
a future pregnancy
The additional of a child with a chromosomal 
abnormality in a future pregnancy is less than 1%. 
Prenatal diagnosis is offered in a next pregnancy.
Consequences of the chromosomal abnormality for 




Age and parity 34 year old G2P1
Obstetrical history Normal delivery
Indication Prenatal Diagnosis increased risk for Down syndrome 1:150




Chromosome abnormality fetus Inherited marker chromosome 15; 
47,XY+mar.ish psu idic(15)(q11.2)(289D12+,SNRPN-
,446P9-)mat
Consequences of the chromosomal abnormality for 
the fetus
There is a low risk on congenital abnormalities in 
this pregnancy. For offspring of the infant, there is an 
increased risk on this chromosomal abnormality.  
Consequences of the chromosomal abnormality for 
a future pregnancy
There is an increased probability on another infant with 
an inherited marker chromosome. However, the risk 
figure is unknown. Prenatal diagnosis is offered in a next 
pregnancy.
Consequences of the chromosomal abnormality for 
relatives of the parents
Parents and siblings of mother may also have the 
chromosomal abnormality and are offered karyotyping.
Case 10
Age and parity 43 year old G3P2
Obstetrical history 2 normal deliveries
Indication Prenatal Diagnosis Maternal age 
Procedure Uncomplicated amniocentesis at gestational age 16+2 
weeks 
MLPA Normal female
Karyotype 47,XX,+mar  (9)(p)
Chromosome abnormality fetus De novo marker of chromosome 9; 47,XX,+mar (9)(p)
dn
Consequences of the chromosomal abnormality for 
the fetus
The infant probably has mental disabilities with or 
without congenital abnormalities. Most common 
abnormalities are; heart defects; and abnormalities of 
kidneys, brain, skull, eyes, ears, and extremities. 
Due to the presence of several life-threatening medical 
problems, most infants die in utero.  Only one case 
report showed one infant to be alive at 4 months that 
was severely handicapped. 
Consequences of the chromosomal abnormality for 
a future pregnancy
Likely, there is no recurrence risk. Prenatal diagnosis is 
offered in a next pregnancy.
Consequences of the chromosomal abnormality for 









Age and parity 38 year old G2P0
Obstetrical history 1 miscarriage
Indication Prenatal Diagnosis Maternal age and increased NT 




Chromosome abnormality fetus De novo interstitial deletion of chromosome 7; 
46,XY,del(7)(p?15p2?2)dn
Consequences of the chromosomal abnormality for 
the fetus
Likely, the infant has mental disabilities with or without 
congenital abnormalities. More than 60% of these cases 
have specific physical disabilities. 
Consequences of the chromosomal abnormality for 
a future pregnancy
There is a recurrence risk of 0.3%. Prenatal diagnosis is 
offered in a next pregnancy.
Consequences of the chromosomal abnormality for 
relatives of the parents
None
Case 12
Age and parity 31 year old G2P1
Obstetrical history 1 normal delivery
Indication Prenatal Diagnosis increased risk for Down syndrome 1:61
Procedure Uncomplicated amniocentesis at gestational age 15+6 
weeks 
MLPA Normal female
Karyotype mos 46,XX,del(18)(p11.21)[15]/ 46,XX,dup(18)
(p11.21p11.32)[13]
Chromosome abnormality fetus Mosaicism of an unbalanced structural abnormality of 
chromosome 18. In 15 cell clones a deletion is present 
and in 13 a duplication is present. mos 46,XX,del(18)
(p11.21)[15]/ 46,XX,dup(18)(p11.21p11.32)[13]
Consequences of the chromosomal abnormality for 
the fetus
Likely, the infant has mental disabilities with or without 
congenital abnormalities. The disabilities may vary per 
individual and are not predictable. 
Consequences of the chromosomal abnormality for 
a future pregnancy
There is a recurrence risk of less than 1%. Prenatal 
diagnosis is offered in a next pregnancy.
Consequences of the chromosomal abnormality for 




Age and parity 36 year old G4P2
Obstetrical history 2 normal deliveries, 1 miscarriage
Indication Prenatal Diagnosis Maternal age




Chromosome abnormality fetus Mosaicism of a normal male karyotype in 16 cell clones 
and an additional chromosome 20 in 2 cell clones; mos 
47,XY,+20[2]/46,XY[16]
Consequences of the chromosomal abnormality for 
the fetus
Of individuals with this chromosomal abnormality 
90%-93% have normal intelligence and no physical 
disabilities or specific features. However, scoliosis, 
hypotonia and ‘dropping’ shoulders cannot be 
excluded. Learning problems despite normal IQ have 
been reported. 
Consequences of the chromosomal abnormality for 
a future pregnancy
There is no recurrence risk. Prenatal diagnosis is offered 
in a next pregnancy.
Consequences of the chromosomal abnormality for 
relatives of the parents
None
Case 14
Age and parity 36 year old G2P1
Obstetrical history 2 miscarriages
Indication Prenatal Diagnosis Maternal age




Chromosome abnormality fetus Mosaicism of a normal female karyotype 
in 10 cell clones and an additional marker 
chromosome without coding DNA in 7 cell clones; 
mos47,XX+mar[7]/46,XX[10].ish(acro)(p10)
(wcp14+,wcp15+)15q11.2(PWS/AS-)dn
Consequences of the chromosomal abnormality for 
the fetus
There is a 5% risk on mental retardation or congenital 
abnormalities. 
Consequences of the chromosomal abnormality for 
a future pregnancy
Likely, there is no recurrence risk. Prenatal diagnosis is 
offered in a next pregnancy.
Consequences of the chromosomal abnormality for 









Age and parity 36 year old G3P2
Obstetrical history 2 normal deliveries
Indication Prenatal Diagnosis Maternal age and increased risk for Down syndrome 
1:116




Chromosome abnormality fetus De novo balanced structural abnormality; 
46,XX,t(11;13)(q21;q14)dn
Consequences of the chromosomal abnormality for 
the fetus
There is a 10% probability of mental retardation or 
congenital abnormalities. Normal findings at the 
advanced ultrasound reduce the probability to 5%. 
Consequences of the chromosomal abnormality for 
a future pregnancy
Likely, there is no recurrence risk. Prenatal diagnosis is 
offered in a next pregnancy.
Consequences of the chromosomal abnormality for 
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Prenatal diagnosis is routinely offered to all pregnant women in developed countries who 
have an increased risk of carrying a child with a chromosomal abnormality. Karyotyping 
is considered the standard method in prenatal cytogenetic diagnosis. The test is capable 
of detecting a range of numerical and structural chromosomal abnormalities with high 
accuracy (99.4-99.9%)1-3 within two to three weeks (see introduction). 
Since 1990 new competitive techniques have become available due to rapid technological 
developments in molecular genetics. These techniques, i.e. FISH, QF-PCR and MLPA 
commonly referred to as rapid aneuploidy detection (RAD), are able to detect the most 
common aneuploidies within a few days through highly automated protocols at lower costs. 
The studies evaluating diagnostic accuracy of RAD techniques were seldom performed 
under clinical practice conditions. Information on health-related quality of life and cost-
effectiveness were absent. Moreover, little evidence existed on patient and physicians 
preferences regarding the choice between karyotyping and RAD. Little was known about 
the patient’s and professional’s opinions on which chromosomal abnormalities should be 
detected or never missed.
Despite considerable gaps in knowledge, in our study we chose MLPA as our RAD technique of 
choice (2005), since a preclinical study showed MLPA to be robust in detecting aneuploidies 
of chromosomes 13, 18, 21 and non-mosaic sex chromosome abnormalities using amniotic 
fluid4. For MLPA a commercially available kit (SALSA P095) was available and validated on 
amniotic fluid in the eight genetic centres in the Netherlands.
The aim of the study and this thesis was to resolve most of these knowledge gaps for MLPA 
as RAD test. For that purpose, several empirical studies were conducted between 2006 and 
2009. The final objective was, by combining new and existing information, to arrive at an 
assumed best practice proposal, which might include standard combined testing of MLPA 
and karyotyping, substitution of karyotyping by MLPA, or the addition of MLPA to the current 
test process (serial testing). 
The MLPA And Karyotyping, an Evaluation (M.A.K.E.) study 
We performed the nationwide M.A.K.E. study between March 2007 and October 2008. 
All eight Dutch prenatal diagnostic centres and their affiliated hospitals participated. In the 
M.A.K.E. study we tested 4585 consecutive amniotic fluid samples with both MLPA and 
karyotyping, allowing a pair wise comparison of test results. Diagnostic accuracy of MLPA 
was similar (non-inferior) to that of karyotyping for the detection of trisomies 13, 18, 21 
and sex chromosomal aneuploidies. In 75 cases MLPA failed (1.6%); karyotyping failed 
once (0.02%). Compared with karyotyping, MLPA shortened the waiting time with 14.5 days 






For our first quality of life study, we compared anxiety, personal perceived control, stress and 
health related quality of life of 132 women receiving a karyotype result and 181 women 
receiving MLPA and karyotyping. The combined strategy reduced anxiety and stress two 
weeks earlier compared to karyotyping only, but it did not influence overall anxiety, stress, 
personal perceived control, and generic mental and physical health, when compared to 
a karyotype only strategy. For our second study, we compared anxiety, personal perceived 
control, stress and health related quality of life of 68 women receiving standalone karyotyping 
and 61 women receiving standalone MLPA after they were offered individual choice between 
the two tests. Furthermore, we explored the reasons and perceptions to choose between 
standalone MLPA versus fetal karyotyping. Overall, women had a clear individual preference 
for targeted or broad testing. Despite individual differences in choices and motives, our study 
showed no systematic differences in health-related quality of life and anxiety over time. 
The cost-minimization analysis showed that a standalone MLPA strategy reduced costs 
compared to karyotyping with € 240.13 or 14.9% per sample. This cost reduction is mainly 
related to the lower cost of the MLPA test; part of the MLPA cost reduction is offset by costs 
induced by missed cases. Costs were sensitive to the likelihood of termination of pregnancy, 
sample throughput, whether or not individual choice is offered, and centralised care.
In our preference study, comparing standalone MLPA and karyotyping, we found that 
women’s preferences were highly divergent: 50% opted for karyotyping and 43% for MLPA. 
Our discrete choice experimentation showed that the potential clinical consequences of 
the detected chromosomal abnormality and failure rate had large impact on the preferred 
test, while the effect of anxiety and waiting time on women’s preferences was modest. We 
also found a striking heterogeneity in caregiver’s preferences. A preference study among 
77 caregivers in prenatal diagnosis (i.e. obstetricians, midwives, clinical geneticists, clinical 
cytogeneticists and general practitioners), showed that most caregivers preferred MLPA over 
karyotyping. 
Our expert panel - which judged in detail 15 test cases - consisted of 8 clinical cytogeneticists, 
8 clinical geneticists and 8 obstetricians. They were invited to rate pro or con the detection 
of 15 chromosomal abnormalities using a nominal group technique; these experts largely 
agreed on the detection with severe consequences and against the detection of chromosomal 
abnormalities with irrelevant clinical consequences. For chromosomal abnormalities with 
mild or uncertain outcomes, however, dissensus remained.
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MLPA in international perspective
While we conducted our study, several larger retrospective and prospective monocentre 
cohort studies on MLPA emerged and provided further evidence on the quick, high quality 
and low cost results of RAD. These studies showed a sensitivity of MLPA of 96%-100%, a 
specificity of 99.8%-100% and failure rate of 1.7%-4.5% using amniotic fluid cells and 
chorionic villi5-10. The aggregate results of these monocentre studies and our multicentre 
study showed an overall sensitivity of 99.8% and overall specificity of 100% for the detection 
of trisomies 13, 18, 21, X and Y. 
MLPA compared to other RAD techniques
Sound methodological studies that directly compare the various RAD techniques simultaneously 
have not been performed, and may be difficult to carry out for practical (e.g. available 
amniotic fluid) and financial constraints. In contrast, many studies have been performed 
on diagnostic accuracy of QF-PCR and FISH specifically. These studies show a sensitivity of 
62.5%-100% and specificity of 99.9-100% for QF-PCR11-19 and a sensitivity of 80-100% and 
specificity of 95%-100% for FISH20-29, with the karyotype result as reference. If one excludes 
all studies before the commercial kits became available, sensitivity of QF-PCR improves to 
98.8%-100%. The sensitivity of FISH is 99.3% if we only include studies from 2001. 
Although no direct comparison of RAD techniques is available, these data suggest that 
diagnostic accuracy of the three RAD techniques is similar. We cannot conclude which 
RAD technique is best, since required comparative studies on quality of life and costs are 
still absent. Compared with FISH, MLPA and QF-PCR seem both more suitable for high-
throughput testing at lower costs30 (Chapter 5). FISH, however, is preferred if chromosomal 
mosaicism is suspected, as detection levels of 5% or more can be achieved31; in context of 
this thesis this feature is not relevant as no ready signs exists for mosaicism. Compared with 
QF-PCR, MLPA is relatively sensitive to DNA quality and is unable to detect maternal cell 
contamination in female samples or female triploidies. MLPA can detect 45 genomic targets 
in one reaction and avoids the problem of non-informativeness of the polymorphic markers 
that may occur with QF-PCR4,32. 
All RAD techniques are able to detect sex chromosome aneuploidies using appropriate 
probes or primer sets. Despite increasing knowledge on the consequences of sex 
chromosomal abnormalities in the last decades, the knowledge of the consequences of 
various chromosomal abnormalities are still limited. Currently, each laboratory decides 
whether or not X and Y probes are included. For specific features, e.g. cystic hygroma or 
hydrops, cardiac abnormalities or NT>4mm which are suggestive of Turner syndrome, X 






we are not aware of studies on this topic. Furthermore, non-disclosure following karyotyping 
is also possibility to adjust the detection capacity.    
Apart from test performance, it is important to be informed on the patient’s and physician’s 
preferences regarding the detection capacity of a test. Essentially, this is a normative question, 
where some regard the judgement to be confined to the political process of decision-making. 
We tried to reveal the preference of relevant stakeholders.
Preferences of patients and physicians
In our study, pregnant women least preferred a Down only test compared to a RAD test 
detecting the most common chromosomal abnormalities and karyotyping (Chapter 6). This 
suggests that the additional diagnostic information on the presence of sex chromosome 
abnormalities is regarded important. In our discrete choice experimentation, however, 
women had no overt preference for a RAD test with or without X and Y probes (Chapter 7). 
Results from our expert study suggest that experts did not agree whether Klinefelter syndrome 
(47,XXY) should or should not be detected in prenatal diagnosis, but they agreed that Turner 
syndrome (45,X) should be detected. In summary, there is no clear answer whether the 
probes for sex chromosomes should or should not be included in the test. 
Two studies of alternating quality reported on patient preferences for RAD and karyotyping. 
Both showed a preference for RAD over karyotyping30,33. The design of both studies was 
rather simplified and did not give insight into the motivations why women chose for RAD or 
karyotyping. Our discrete choice experimentation showed that women value the potential 
clinical consequences of detected chromosomal abnormality highest. This is supported by 
previous research which showed that patients in clinical practice prefer clear consequences 
with major impact for their child over uncertain or mild consequences34. These studies suggest 
that clear results are favoured over complete results. The fact that pregnant women in our study 
based their preference mainly on the consequence of the test result is understandable. In our 
expert study, we noticed that the prenatal experts also wanted as much information as possible 
on the clinical outcomes before voting pro or con detection. One study assessed caregivers’ 
preference for RAD and karyotyping, with 57% of the obstetricians and 71% of the midwives 
choosing RAD30. These results are comparable to our preference study which showed that 
78% of the caregivers (mostly midwives and gynaecologists) opted for RAD (Chapter 6). 
Alternative diagnostic strategies
In theory, five prenatal diagnostic strategies can be distinguished; standalone karyotyping 
(strategy 1), standalone RAD (strategy 2), RAD with subsequent karyotyping in case of a 
negative RAD result (strategy 3), RAD with subsequent karyotyping in case of a positive  RAD 
result (strategy 4) and combination of RAD and karyotyping (strategy 5). First, we will discuss 
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the five strategies and their implications and eventually arrive at the optimal test protocol and 
discuss individual choice for patients.
Strategy 1: Standalone karyotyping
This strategy represents the current practice in prenatal diagnosis. As stated before, 
karyotyping detects a range of numerical and structural chromosomal abnormalities with high 
accuracy. There were no differences in quality of life compared to strategy 4, RAD followed 
by karyotyping in case of a positive RAD test result. The associated costs of karyotyping 
are substantially higher compared to other test strategies, but they are accepted as part of 
current practice. 
Strategy 2: Standalone RAD
The accuracy, low cost and quick results of RAD make RAD a suitable routine test for 
prenatal diagnosis. However, if standalone RAD replaces karyotyping, some severe 
chromosomal abnormalities will remain undetected since RAD cannot detect by design 
other chromosomal abnormalities than trisomies 13, 18, 21, X and Y. Published audits of 
chromosome abnormalities found by karyotyping at prenatal diagnosis have consistently 
shown a prevalence of between 0.07% and 0.1% for clinically significant abnormalities that 
would not be detected by RAD (consisting of the above mentioned probes) in samples from 
pregnancies without fetal ultrasound abnormalities35-38. In a more cautiously-interpreted 
audit, approximately 1 in 100 samples referred with a Down syndrome risk to be subjected 
to QF-PCR only would have an undetected autosomal chromosome abnormality. Thirty-
three percent of these would have a substantial risk of serious phenotypic consequences, 
equivalent to a prevalence of 0.33%39. A disadvantage of standalone RAD is that genetic 
inheritance of the common aneuploidies, e.g. trisomy 21 and 18 will not be sorted out. 
The diagnostic accuracy of standalone RAD for the common aneuploidies is comparable to 
karyotyping. The costs of a standalone RAD strategy must be lower than the strategy RAD 
with subsequent karyotyping in case of a positive RAD result (strategy 4), but the difference 
in average costs per sample is minimal. Evidence on quality of life in a RAD only strategy is 
lacking. We feel that the limited cost reduction of strategy 2 compared to strategy 4 does not 
outweigh the additional knowledge of the subsequent karyotype in case of a positive RAD 
result, which can be of great importance for genetic counselling.    
Strategy 3: RAD with subsequent karyotyping in case of a negative RAD result 
Although this strategy exists in theory, it is of little value in clinical practice. The advantage 
of this strategy is that the chromosomal abnormalities missed by RAD are detected with 






karyotyping (strategy 1). The disadvantages of this strategy, however, are considerable. 
Firstly, the additional knowledge of the karyotype in case of a positive RAD test results is still 
lacking. Secondly, the prior likelihood of a chromosomal abnormality is low; therefore this 
strategy almost amounts to strategy 5. The costs are much higher than strategy 1, without 
any additional gain.
Strategy 4: RAD with subsequent karyotyping in case of a positive RAD result 
In this strategy, RAD is, like in strategy 3, used as a diagnostic technique. However, here 
subsequent karyotyping will be carried out if RAD detects a chromosomal abnormality 
to detect genetic inheritance. This strategy is similar to strategy 2. Rare chromosomal 
abnormalities with clinical significance remain undetected with an estimated prevalence of 
0.07-0.33% at time of testing35-39. In contrast to strategy 2, the advantage is that karyotype 
reveals the genetic inheritance pattern.
No studies measured differences in patients’ quality of life after being allocated to either 
RAD or karyotyping alone. One study mimicked a standalone policy by treating the RAD 
result as final diagnosis40. However, as karyotyping was still performed and the result was 
only disclosed in case of an additional chromosomal abnormality, the crucial difference of 
substitution was not reflected in this design.  
When strategy 4 is applied, costs will significantly decrease compared to strategy 130 
(Chapter 5) because the costs of the RAD test are lower than the costs of karyotyping and 
karyotyping is avoided for the majority of pregnant women with a RAD negative test result. A 
fair comparison requires that the long term effects of undetected chromosomal abnormalities 
should be incorporated in the RAD strategy, reflecting the comparable but still imperfect 
diagnostic accuracy. While this effect may be small due to the low probabilities, many studies 
regard the inclusion of the costs associated with a chromosomal abnormality in this type of 
analysis as controversial41. In our study, we nevertheless achieved a crude estimate of these 
long term costs based on extrapolations from scarce literature42, and concluded that overall 
RAD was still significantly less costly compared to karyotyping (Chapter 5). 
Strategy 5: Combining RAD and karyotyping
In this strategy, all women receive RAD first and, regardless of the RAD test result, subsequent 
karyotyping is initiated. Since both tests are always performed, the overall detection capacity 
of this strategy is equal to that of standalone karyotyping. The main advantage is that a 
quick first test result for the common abnormalities covered by RAD becomes available which 
may reduce parent’s anxiety. Several studies have assessed the course of anxiety when the 
combined strategy RAD and karyotyping is compared to a karyotyping only strategy 25, 30, 
40, 43 (Chapter 3). These studies showed that maternal anxiety was sharply reduced during 
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after receiving the RAD result, but anxiety slightly increased after receiving karyotyping results 
in the combined group30, 40, 43. Compared to the karyotyping only strategy, quality of life 
was therefore not influenced by the combined strategy with quick first results. Furthermore, 
the preference study shows that the valuation assigned to shortened waiting time is modest 
compared to other test characteristics (Chapter 7). The main disadvantage of this strategy is 
that the costs are increased considerably30 (Chapter 5) since all RAD tests are repeated also 
for the women with negative RAD test results. We conclude that strategy 5 produces no gain 
over strategy 1.
If all pros and cons of the five strategies are weighed, only strategy 1, strategy 2 and strategy 
4, remain as acceptable alternatives. However, in clinical practice, karyotyping is always 
performed after a positive RAD test to exclude rare cases of genetic inheritance. Therefore, we 
only describe strategy 1 and 4. Table 1 summarizes the differences in detected chromosomal 
abnormalities and costs between these strategies. 
The clinical M.A.K.E. study shows that three clinically significant chromosomal abnormalities 
would remain undetected by MLPA, but the total costs are considerably less. From an 
efficiency point of view, strategy 4 is the optimal test protocol, unless society is prepared 
to spend over € 364,000 incrementally to detect one extra chromosomal abnormality with 
clinically significant consequence. Although society may nevertheless adopt that point of 
Table 1: Comparison of standalone karyotyping (strategy 1) and RAD with subsequent karyotype 
in case of a positive RAD test result (strategy 4).*
Standalone karyotyping
(strategy 1)
RAD with subsequent 
karyotype in case of a 
positive RAD result
(strategy 4)
Detected trisomies 13, 18, 21 85 85
Detected aneuploidies of X and Y 13 13
Undetected abnormalities with clinically 
significant consequences
0 3
Undetected abnormalities with uncertain 
clinical consequences
0 6
Undetected abnormalities with no clinical 
consequences
0 17
Total costs € 7,368,086.52 € 6,275,310.77
Average total costs per detected trisomy € 86,683.37 € 73,827.19
Incremental costs per undetected abnormality 
with clinically significant consequence
€ - € 364,258.84      
Incremental costs per undetected abnormality 
with clinically or uncertain significant 
consequence
€ -    € 121,419.61   
Incremental costs per any undetected 
abnormality
€ -    € 42,029.87    






view, we have to realise that the selection of women before undergoing prenatal diagnosis is 
currently not optimal. The amount of chromosomal abnormalities and their associated costs 
are also subject to the prenatal indications applied and risk selection process and criteria. 
Prenatal screening tests i.e. nuchal translucency measurement and maternal serum screening 
improve the detection rate for Down syndrome and are cost-effective44.  In 2007, the average 
screening uptake in the Netherlands was only 27%. In our country, co-payment is required 
for women below 36 years of age who enter prenatal screening. Abolishment of copayments 
could lead to a higher uptake. Furthermore, in the Netherlands, advanced maternal age 
(at least 36 years of age in the 18th gestational week) still is the most important referral 
indication for prenatal diagnosis (59%)45. Approximately 20% of women older than 36 years 
choose to have prenatal diagnosis. Maternal age, however, is a -less effective- risk selection 
criterium. It should be noted that the prior risk of an abnormality in our study is about 1/50. 
An increase in the uptake of prenatal screening could increase the prior risk as well as the 
relative optimality of strategy 4.
Room for individual choice?
In current practice, women are entitled to accept or decline participation in prenatal 
screening, in prenatal diagnosis, and to decide on the termination of pregnancy. If they 
decide to undergo prenatal diagnosis, they have to choose for amniocentesis or chorionic 
villus biopsy. However, choice is restricted; women cannot choose the test they want, since no 
other accepted test than karyotyping is available yet. However, if one is prepared to accept 
strategy 4 as the optimal test protocol, the question rises how that strategy should be offered. 
If we implement strategy 4 as uniform strategy, all pregnant women who consent to prenatal 
diagnostics undergo MLPA first and receive karyotyping if the MLPA test result is positive. 
Alternatively, one may offer free choice to women who consent to prenatal diagnostics; 
some women prefer definite results over probabilities and therefore may prefer a prenatal 
diagnostic instead of a risk estimate. 
One normative question has to be addressed at this point; Are pregnant women free to 
decide on the testing procedure, i.e. on (a) the screening test that is being used, on (b) 
whether prenatal diagnostic test(s) is (are) offered standalone or serially, and on (c) on the 
contents of the test? If the answer generally is yes, we have to accept inefficiencies associated 
with free choice, e.g. inefficiencies due to logistics and sample throughput at a smaller scale. 
Allowing individualised choice is less efficient than offering women strategy 4 as a uniform 
policy because women are also allowed to choose the least efficient strategy (Chapter 6). 
When the economic perspective dominates, one may stick to the current RAD yield as 
societal acceptable; the gain from karyotyping by detecting relevant abnormalities at a price 
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of 350.000 euro each may not imply a change in the course of pregnancy. Therefore it is 
important to discuss the possibilities of individual choice. 
Two perspectives on individual choice exist. The first perspective is that individualised 
decision making is allowed for reasons of principle or ethics, regardless of efficiency, quality 
of care, quality of life or other considerations. Whether or not to participate in screening 
programmes or women’s prerogative to decide on the continuation or termination of 
pregnancy belongs to this perspective. According to the second perspective, it is the patient 
who is designated to decide which strategy is best when there are fundamental differences 
in outcomes associated with these strategies. Both perspectives lend arguments in favour 
of individual choice. Choices can, however, be validly limited by economic constraints. 
Kassirer has distinguished seven cases of fundamental differences in which patient 
preferences could be decisive46. Several of these cases also apply to the optimal prenatal 
diagnostic strategy. These are the following: 1) there are major differences in the kinds 
of possible outcomes (e.g. Down syndrome versus balanced translocation); 2) one 
of the choices can result in a small risk of a grave outcome (e.g. de novo unbalanced 
abnormality); 3) a patient attaches unusual importance to certain possible outcomes 
(e.g. broad detection capacity); 4) the patient is highly adverse to taking risks (e.g. broad 
detection capacity); and 5) the patient has to trade off long term and short term outcomes 
(long term consequences associated with an undetected chromosomal abnormality). 
In our quality of life study (chapter 4), women were offered a choice between MLPA and 
karyotyping. The majority reported that they were convinced they had made the correct 
choice. There were no systematic differences over time between standalone RAD versus 
karyotyping in terms of anxiety, general physical and mental health, perceived personal 
control and stress. When the outcomes of this study are compared with the same outcome 
parameters of women who were allocated to karyotyping or a combined strategy (chapter 3), 
the decrease in anxiety and stress two days following amniocentesis is sharper in the choice 
group. This suggests that individual choice might have a favourable impact on anxiety. 
Similar studies have not been carried out yet. While our results suggest that HRQOL is not 
compromised when women are offered individual choice, it is conceivable that HRQOL 
might also improve. When women are offered individual choice and women base their 
choice on individual considerations and needs.
Taking into account the specific field of prenatal diagnosis and the results from the quality 
of life and preferences studies, we support individual choice. Our primary argument is that 
such a decision is of lifelong interest to the family, rather than a short term decision for the 






within reasonable economic constraints - is most appropriately made by individuals who will 
bear the responsibility of raising the child.
Policymaking in the Netherlands
Following the results from the M.A.K.E. study, a nationwide debate has emerged on the 
implementation of RAD. Despite several meetings of the Working Party of Prenatal Diagnosis 
and Fetal Therapy, no agreement was reached. Although it seems that experts prefer to 
offer a nationwide uniform policy in the Netherlands, the lack of consensus has contributed 
to regional differences; individual choice is offered in Nijmegen, a combined strategy is 
performed in Maastricht, while the other centres still use the karyotype. In other European 
countries, no uniform policy is formed (personal communication Bui, Voligno, Rieneri); some 
centres offer a choice, while others perform a combined strategy. In the UK, the UK National 
Screening committee recommended the use of standalone RAD. However, a nationwide 
implementation did not follow. Even in the participating hospitals 12.5% of women received 
the combined strategy of RAD and karyotyping47. Overall, looking at our fellow European 
countries, reveals that uniform policymaking in prenatal diagnosis is difficult to reach and in 
practice to achieve. Elaborating on the patient and physician preference studies, it is unlikely 
that all stakeholders on the short term will agree on one strategy. From here we envisage 
four options; 
1  Policymakers decide which test generally meets most needs and this test is offered 
nationwide. A major disadvantage of this strategy is that women’s preferences cannot 
play a role. 
2  Each centre decides which test(s) is (are) offered. A major disadvantage of this strategy 
is that clients may not be informed on the differences between centres or clients have to 
travel for the test they want. Besides, arrangements on financial compensation for the 
laboratories should be made. 
3  Shared decision-making is offered. Clinicians and clients discuss the benefits and 
disadvantages of prenatal testing and find mutual agreement on the test(s) to be 
performed. They can decide to perform karyotyping, MLPA or other molecular tests on 
e.g. cystic fibrosis. 
4  Future studies on new techniques are awaited before a uniform policy is formed. 
Implementation of RAD in clinical practice
The identification of RAD as optimal test strategy as well as the opportunity of individualised 
choice implies that two alternative prenatal diagnostic strategies will co-exist. This has 
profound consequences for clinical practice. Firstly, the failure rate of RAD is a burden 
leading to a longer waiting time and possible repeat amniocentesis. Our study showed that 
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failed RAD tests are mainly associated with contaminated samples. Therefore, obstetricians 
should try to obtain uncontaminated samples by e.g. avoiding a placental approach and 
using continuous ultrasound control48 (Chapter 2). We propose that still 10 to 20 millilitres 
of amniotic fluid should be withdrawn for short-term storage of remaining material to allow 
karyotyping should RAD fail and subsequent storage of DNA to allow follow-up molecular 
diagnostics and avoid repeated amniocentesis should ultrasound examination show an 
abnormality. 
Secondly, clinical cytogeneticists and molecular geneticists are recommended to cooperate 
closely. However, this is not only the case in prenatal diagnosis, since the role of molecular 
applications rise rapidly in all fields of medicine. Substitution of karyotyping will lead to a 
decrease in cytogenetic procedures and increase in molecular tests.
Thirdly, partial substitution of karyotyping will also change the role of clinical geneticists in 
prenatal diagnosis, since they will often be the clinical professional involved when babies are 
born with undetected chromosomal abnormalities. Furthermore, they have to decide which 
test should be applied after RAD has been performed on the stored material, choosing from 
a range of molecular applications when second trimester ultrasound detects abnormalities. 
To achieve successful implementation of individual choice, the following requirements must 
be met; 
1  Both tests should be offered. 
2  Clear, reliable and complete information on test options should be provided, describing 
the consequences, benefits and disadvantages of each test. 
3  Clinicians should be willing to offer both tests and provide nondirective prenatal 
counselling. An open discussion on benefits and disadvantages of tests should follow 
including clients’ risks and preferences. 
 When these three requirements are satisfied, shared decision making is feasible49.
4  Effort should be put into educating the public on the possibilities, the advantages and 
disadvantages of prenatal tests, and the variety of consequences of chromosomal 
abnormalities. In that way, the future users of prenatal diagnosis are informed and 
hopefully public awareness and acceptance is created. 
Future techniques
At this point, microarray genomic analysis (MA) and non-invasive prenatal diagnosis are 
the most promising future techniques. It is remarkable that the current debate focuses on 
targeted testing, while the future techniques are likely to detect more than the current broad 






At this moment studies are carried out on the diagnostic accuracy, appropriate construction 
of prenatal devices, and costs of MA in prenatal diagnosis, which allows the detection of 
multiple microscopic and submicroscopic deletions and duplications in a single simultaneous 
assay, without the detection of balanced rearrangements50. MA is presented as having 
the potential to become the primary prenatal diagnostic laboratory procedure. First of 
all diagnostic accuracy (clinical validity) needs to be established. Currently, four genetic 
laboratories in the USA perform a prospective study funded by the US National Institute of 
Child Health and Development comparing MA and karyotyping on consecutive prenatal 
samples51. The results of this study are expected in 2013. Two aspects of the MA technique 
are challenging. Firstly, by extending the detection capacity to hundreds of discrete genomic 
loci for DNA copy number gains and losses, it is likely to lead to the identification of findings 
without known clinical interpretation. Many of these will be benign variants which have the 
potential to be misinterpreted as clinically significant abnormalities. This will result in the 
need for complex genetic counselling, additional costly testing, and perhaps unwarranted 
pregnancy termination. Besides, it is unclear who should decide which content is suitable 
for a MA in prenatal diagnosis; should it be based on whole-genome analysis, or should it 
be targeted or can parents decide themselves what they want to know? The ethical debate 
about genetic selection is likely to intensify over the next years.  Again, data on costs, quality 
of life, procedural aspects and preferences should be assessed before offering the technique 
in prenatal diagnosis. 
Another promising technique is non-invasive prenatal diagnosis (NIPD). In the near future, 
it is expected that NIPD using fetal cells from maternal blood will be available in the first 
trimester of pregnancy, avoiding the procedure related miscarriage risk of amniocentesis 
and chorionic villus sampling52, 53. Again diagnostic accuracy (clinical validity) needs to be 
established.  Apart from evident major improvements, it is feared that the relative ease of 
the test will lead to an increase in testing, selective abortion, testing for minor abnormalities 
and non-medical traits as well54.  At this point, the technique focuses on the detection 
of Down syndrome, but in the future expansion of its detection capacity is possible. The 
above mentioned debate on genetic selection therefore also applies to NIPD as well. Future 
research should assess if this test complies with women’s demands and if NIPD will replace 
prenatal screening and invasive diagnostic tests. 
Future research
In this thesis, the clinical use of RAD is established for women undergoing amniocentesis 
for advanced maternal age, increased Down syndrome risk following prenatal screening 
or parental anxiety. These results cannot be extrapolated to chorionic villus biopsy. One 
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preclinical study assessed 100% diagnostic accuracy to detect euploidies and non-mosaic 
aneuploidies in 152 samples7. A clinical evaluation study should be performed to evaluate 
its performance in clinical practice. Future research may also be valuable in optimizing the 
RAD technique itself and improving sampling techniques, thereby improving the success rate. 
As stated above, new techniques are within reach. Clinical validity studies are needed to 
establish the performance of these techniques, i.e. microarray and non-invasive prenatal 
diagnosis. Above all ethical dilemmas need to be resolved; should late onset disease be 
detected and how should we ensure the ‘right not to know’ of the future child?  Does the 
high uptake of NIPD lead to an increase in selective abortion because it can be done early 
in pregnancy?  
A very important aspect of offering tailor-made strategies is the quality of prenatal counselling. 
Future research should assess whether patients are informed properly on the pros and cons 
of the tests and if it is feasible in clinical practice to make a shared informed decision. Web 
based decision aids may be helpful to prospective parents to better understand the possibilities 
in prenatal diagnosis, the disadvantages of each test, and to clinicians to see which test or 
process characteristics parents value high and low. A valuable tool for prenatal counsellors 
would be a clearly structured document with training to support uniform counselling since, 
especially in the Netherlands, prenatal counselling is provided by many professionals and it 
should include all aspects of prenatal testing. It is a challenge to develop a tool with multiple 
stakeholders involved (parents, obstetricians, midwives, geneticists, ethicists). Especially with 
rapidly developing techniques with a different scope, informed shared decision-making is an 
incentive for high quality care. 
The changing scope in prenatal diagnosis from cytogenetic karyotyping to a variety 
of molecular tests may lead to major policy changes. It is expected that in the nearby 
future, women in the US will have a microarray analysis instead of karyotyping. Currently, 
microarrays are more often used for ultrasound abnormalities in the Netherlands. The goal 
of prenatal diagnosis is the equal provision of information so the parents can make an 
informed decision. The widespread introduction of molecular tests changes the scope of 
prenatal diagnosis and should encourage the development of strategies that tailor the type 
of diagnostic test offered to the risk identified. 
Concluding recommendations
The field of prenatal diagnosis is rapidly changing. With the introduction of karyotyping in 
1966, development of prenatal screening in the 1980s and introduction of RAD tests in 
1990s, and forthcoming techniques within the next ten years intensify the need for clarity 






karyotyping when the MLPA test result is positive, is a suitable strategy for prenatal diagnosis. 
Women’s quality of life is not considerably affected by applying a combined or karyotyping 
only strategy. If we offer women a choice between the tests, anxiety and stress reduction is 
higher compared to a group not being able to choose. Women’s preferences differ greatly 
based on their own considerations and attitude. Customized prenatal diagnosis incorporating 
patients’ risk and preferences seems feasible. The results presented in this thesis, together 
with studies on other RAD techniques and patient preferences provide convincing evidence to 
support this view. Constructive collaboration among obstetricians, cytogeneticists, molecular 
geneticists and clinical geneticists is essential to achieve successful implement RAD and 
to incorporate shared decision-making. To facilitate this process, guidelines for the Dutch 
Society of Obstetricians and Gynaecologists (NVOG) will be needed, together with patient 
material and education. It is our intention to provide these requirements. 
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OBJECTIVE OF THIS THESIS
Prenatal diagnosis is routinely offered to all pregnant women in developed countries who 
have an increased risk of carrying a child with a chromosomal abnormality. The aim of 
prenatal diagnosis is to provide information on the presence and nature of chromosomal 
abnormalities, in order to allow parents an informed choice on the course of pregnancy. This 
may imply a decision to continue or terminate pregnancy, but it also implies the arrangement 
of treatment planning and psychological preparation. The selection of women with a higher 
than average risk for fetal chromosomal abnormalities is based on several factors: maternal 
age, family history, prenatal screening tests and ultrasound abnormalities. In the Netherlands, 
the main indications for prenatal diagnosis are advanced maternal age and an increased 
Down syndrome risk following first trimester prenatal screening. Prenatal diagnosis for these 
indications is for the most part focussed on detecting Down syndrome. Since almost 50 
years, karyotyping is the diagnostic test used to detect fetal chromosomal abnormalities. 
Karyotyping is highly accurate. It requires cultured cells at metaphase stage, leading to a 
waiting time of two to three weeks. It is labour-intense leading to high costs. Karyotyping can 
detect any structural and numerical microscopic chromosomal abnormality, which may lead 
to chromosomal abnormalities with no, mild, or unclear clinical consequences. The latter 
findings lead to difficult counselling issues and emotional dilemmas for parents who have to 
decide to continue or terminate pregnancy. 
In 2003, MLPA became available, detecting the most common chromosomal abnormalities, 
i.e. trisomies 13, 18, 21, and non-mosaic sex chromosomal abnormalities on uncultured 
amniocytes. Preclinical studies showed high sensitivity and specificity and presented the 
technique as promising and possibly able to replace karyotyping. However, no large clinical 
comparative studies were available to support these claims. Besides, the replacement 
of karyotyping is not only based on test performance. Patient preferences and quality of 
life, physicians’ preferences and costs should be incorporated into this medical decision. 
Therefore, we performed the M.A.K.E. (MLPA And Karyotyping, an Evaluation) study, a 
nationwide study comparing MLPA and karyotyping in routine prenatal diagnosis. 
Patients
Pregnant women were included in the M.A.K.E. study when they chose to undergo 
amniocentesis for advanced maternal age (36 years or older), increased risk of Down 
syndrome following prenatal screening or parental anxiety. We excluded women with other 
indications for amniocentesis since they have an increased risk of chromosomal abnormalities 









mandatory; ultrasound abnormalities including a nuchal translucency measurement of 
3.5 mm, a parental chromosomal abnormality, or a previous child with a chromosomal 
abnormality. 
Interventions
For the MLPA procedure, DNA was isolated from 1 to 8 ml uncultured amniotic fluid samples, 
depending on the total amount of amniotic fluid received. We used a commercially available 
kit, the SALSA MLPA P095 (MRC Holland, the Netherlands). For each genomic target, a 
set of 2 probes is designed to hybridize immediately adjacent to each other on the same 
target strand. Both probes consist of a short target sequence and a universal polymerase 
chain reaction (PCR) primer-binding site. One of the probes contains a stuffer sequence 
with a unique length and sequence. Following hybridization, each pair of adjacent probes 
is joined by a ligation reaction. Next, PCR is performed using a fluorescent-labeled primer 
pair, which ensures that the relative yield of each of the PCR products is proportional to the 
amount of each of the target sequences. The different length products are separated on 
an automated capillary sequencer. The size and peak areas for each probe are quantified 
and analyzed by data analyzing software (GeneMarker, SoftGenetics, LLC, State College, 
PA, USA or Genescan and Genemapper version 3.7/4.0, Applied Biosystems, CA, USA). 
Relative probe signals are calculated and compared with samples of normal male and 
female sex. In chromosomally normal samples, the relative probe signal is expected to be 1 
for all probes. A normal value is defined as a relative probe signal between 0.7 and 1.3. A 
relative probe value of <0.7 indicates a monosomy, whereas a relative probe value of >1.3 
indicates a trisomy. MLPA is not expected to detect low grade chromosomal mosaicism. 
For karyotyping, fetal cells were cultured and spread on slides, which were stained for 
chromosomal banding. Routinely, metaphases for 10 colonies were investigated. All centers 
followed national quality guidelines but minor differences in the amount of cell colonies 
cultured, staining and reporting of the results were allowed. 
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OUTCOMES OF THE M.A.K.E. STUDY
Diagnostic accuracy (Chapter 2)
In a national comparative cohort study, 4585 amniotic fluid samples were included of 
women who had an amniocentesis on behalf of their age (75.6%), increased risk following 
prenatal screening (23.4%)or maternal anxiety (1%). Amniotic fluid samples were tested 
independently with both MLPA and karyotyping. In 4484/4585 samples (97.8%) MLPA and 
karyotyping were concordant, showing normal results in 4386/4585 (95.7%) and aneuploidy 
in 98/4585 (2.1%). Discordant results were found in 26/4585 (0.6%) samples, representing 
an abnormal karyotype not detected by MLPA. Diagnostic accuracy of MLPA was 1.0 (95 
% confidence interval 0.99 to 1.0), sensitivity was 100% (95% confidence interval 0.96-
1.0) and specificity was 100% (95% confidence interval 0.999-1.0). Diagnostic accuracy 
of MLPA was statistically similar (noninferior) to that of karyotyping (P<0.001). In 75 cases 
MLPA failed (1.6%); karyotyping failed once (0.02%). Compared with karyotyping, MLPA 
shortened the waiting time with 14.5 days (P<0.001, 95% confidence interval 14.3-14.6).  
Quality of life (Chapter 3 and 4)
First, we assessed anxiety, personal perceives control, stress and health related quality of life 
by validated questionnaires between women receiving a karyotype result only (n=132) and 
women receiving both the result of MLPA and karyotyping (n=181). There were no systematic 
differences in time of the combined strategy versus karyotyping only in terms of anxiety 
(P=0.91), generic physical health (P=0.76, P=0.46), generic mental health (P=0.52, 
P=0.72), personal perceived control (P=0.91), and stress (P=0.13). The combined strategy 
reduced anxiety and stress two weeks earlier compared to karyotyping only. In general 
MLPA as add-on to karyotyping reduces anxiety and stress in the short term, but it does not 
influence overall anxiety, stress, personal perceived control, and generic mental and physical 
health when compared to a karyotype only strategy
Secondly, we assessed the impact of standalone MLPA and karyotyping on anxiety, personal 
perceives control, stress and health related quality of life by validated questionnaires. 
Furthermore, we explored the reasons and perceptions to choose between standalone MLPA 
versus fetal karyotyping. Women were offered a choice between karyotyping (n=68) and 
standalone MLPA (n=61). The most commonly cited reason for choosing karyotyping was 
obtaining as much information as possible, while for standalone MLPA it was the short 
waiting time. Prenatal screening (OR 7.09), no knowledge of karyotyping (OR 4.2) and an 
intermediate perceived risk for chromosomal abnormalities (OR 3.6) were associated with 









standalone MLPA in terms of anxiety (P= 0.11), generic physical and mental health (P=0.94, 
0.52; P=0.66, P=0.07), personal perceived control (P=0.69), and stress (P=0.66). In 
general, offering a choice between karyotyping and standalone RAD does not influence 
anxiety, stress, personal perceived control, and generic health.
Costs (Chapter 5)
This chapter describes the costs of MLPA compared to karyotyping for women who choose 
to undergo amniocentesis on behalf of their age (≥36 years), an increased risk following 
first trimester prenatal screening or parental anxiety. Clinical data and the use of medical 
resources were based on the clinical M.A.K.E. study. The cost-minimisation analysis showed 
that MLPA reduced costs in the short term (time from amniocentesis until the decision to 
continue or terminate pregnancy) with € 315.68 (95% CI: € 315.63 to € 315.74; -44.4%) 
per sample compared to karyotyping. In the long term (time from the decision to continue or 
terminate pregnancy), MLPA increased cost € 76.42 (95%CI: 71.32 to 81.52; +8.6%) per 
sample. Overall, MLPA reduced costs with € 240.13 (bootstrap 95%CI: 235.02 to 245.23;-
14.9%) per sample. Costs were sensitive to the likelihood of termination of pregnancy, 
sample throughput and centralised care. From a societal economic perspective, MLPA is the 
preferred strategy in women who undergo amniocentesis on behalf of their age, following 
prenatal screening or parental anxiety.  
Patient preferences (Chapter 6 and 7)
We assessed patient preferences in two chapters.
In chapter 5, we assessed patient preferences for three test strategies (a test detecting trisomy 
21, a test detecting trisomies 13, 18, 21, X and Y, and a test with comparable detection 
capacity as karyotyping). Detection capacity, the comprehensibility of the result in case of 
a detected abnormality, and the waiting time for the test result were described. We invited 
150 pregnant women undergoing amniocentesis on behalf of their age (84.1%), increased 
risk following prenatal screening (11.5%) and maternal anxiety (2.7%). Seventy-five percent 
(113/150) responded to the survey. They expressed a preference for the test resembling 
karyotyping (50.4%) or the rapid technique detecting the most common aneuploidies 
(43.4%). A minority of women chose the test detecting Down’s syndrome only. 
Secondly (Chapter 7) we described patient preferences and determined which test attributes 
influence their preference most by using a discrete choice experiment. Pregnant women who 
visited the hospital for prenatal counselling were invited to participate. In total 103/118 
(87%) women participated. Women placed most value on the detection of chromosomal 
abnormalities with severe consequences for their child (P<0.01). The failure rate of the test, 
the waiting time for test results, and the experienced anxiety influenced women’s preferences 
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significantly (P <0.05). For the currently available tests, women prefer karyotyping to RAD (P 
<0.01) in a setting where the detected chromosomal abnormalities have severe consequences 
for their child. However, in a setting where karyotyping detects chromosomal abnormalities 
with uncertain or no clinical consequences for their child, RAD tests are preferred (P <0.01). 
While anxiety and waiting time have some effect on women’s preferences, the potential 
clinical consequences of the detected chromosomal abnormality and failure rate influenced 
test choice most. Since RAD and karyotyping both detect the most common chromosomal 
abnormalities with severe consequences, both tests are appropriate for prenatal diagnosis.
Expert opinion (Chapter 6 and 8)
In two chapters we discuss the professionals’ opinion on karyotyping and MLPA. In chapter 
6, we assessed caregivers’ preferences for three test strategies (a test detecting trisomy 
21, a test detecting trisomies 13, 18, 21, X and Y, and a test with comparable detection 
capacity as karyotyping). Detection capacity, the comprehensibility of the result in case of a 
detected abnormality, and the waiting time for the test result were described. We invited 140 
caregivers involved in prenatal diagnosis, i.e. obstetricians, midwives, clinical geneticists, 
clinical cytogeneticists and general practitioners to participate. Of the caregivers (70% 
female; median age 44 years, 26 to 63 years), 55% (77/140) returned the questionnaire. 
The majority of the caregivers preferred a test detecting the most common chromosomal 
abnormalities (77.9%) while the remaining preferences for the other tests were equally 
divided (10.4%). 
In chapter 8, we determined expert consensus on which chromosomal abnormalities should 
and should not be detected in prenatal diagnosis, and for which abnormalities disagreement 
remains after structured discussion. An expert panel of 24 prenatal experts (8 clinical 
cytogeneticists, 8 clinical geneticists and 8 obstetricians) rated pro or against detection for 
15 chromosomal abnormalities in two individual anonymous rating rounds and one group 
meeting. Consensus was defined to be present if at least 80% of the experts agreed. Consensus 
was reached in 12 of 15 cases. In 10 cases, there was agreement pro detection and in two 
cases experts agreed against detection. At the end of the 3rd round, dissensus remained on 
three abnormalities. Experts largely agreed on detecting chromosomal abnormalities with 
severe consequences and against detection in case of irrelevant clinical consequences. For 
chromosomal abnormalities with mild or uncertain outcomes, dissensus remained. None of 
the currently available tests (MLPA and karyotyping) corresponds to these demands, except 











In chapter 9 the findings of this thesis are discussed, clinical implications are given and 
future research recommendations are made. The results of this thesis show that MLPA is a 
highly accurate test for the detection of trisomies 13, 18, 21, X and Y and is noninferior to 
karyotyping with comparable patient quality of life and significant cost reduction. 
Based on decision analytic considerations and our study results, two strategies can be 
applied: 1) karyotyping only or 2) RAD with subsequent karyotype in case of a positive RAD 
result. The latter leads to substantial cost reduction compared to a karyotyping strategy 
without considerable loss in information. If economics decide, the gain from karyotyping by 
detecting relevant abnormalities at a price for 350.000 euro each, while it is uncertain what 
the knowledge of the chromosomal abnormalities adds, one may stick to the current RAD 
yield as societal acceptable. However, patient preferences are not incorporated in such a 
strategy. It is also possible to offer pregnant women a free choice. Our primary argument 
is that such a decision is of lifelong interest for the family, rather than on short term for the 
pregnant women alone, and also we believe non-health arguments prevail. Such a decision 
- within reasonable economic constraints - is most appropriately made by individuals who 
will bear the responsibility of raising the child.
Caregivers (obstetricians, clinical geneticists, clinical cytogeneticists, midwives, and general 
practitioners) prefer RAD over karyotyping. However, when realistic clinical cases are 
placed, experts in prenatal diagnosis agree that all chromosomal abnormalities with major 
consequences should be detected and chromosomal abnormalities without consequences 
should not be detected. 
We prefer the introduction of individual choice in prenatal diagnosis. So that parents can 
decide, after nondirective prenatal counselling, which test meets their individual risk and 
needs most. 
Future research should focus on promising future techniques, such as microarray genomic 
analysis and non-invasive prenatal diagnosis. In these clinical comparative studies, patient 
preferences and ethical discussion should be incorporated. Future research should assess 
the feasibility of shared informed decision in clinical practice and focus on the development 












DOELSTELLING VAN DIT PROEFSCHRIFT 
Prenatale diagnostiek wordt routinematig aangeboden aan alle zwangere vrouwen, die 
een verhoogd risico hebben op het krijgen van een kind met een chromosomale afwijking. 
Het doel van de prenatale diagnostiek is informatie te verstrekken over de aanwezigheid 
en de aard van chromosomale afwijkingen, zodat ouders een weloverwogen keuze 
kunnen maken over het verloop van de zwangerschap. Ouders kunnen hierna besluiten 
om de zwangerschap te beëindigen, maar zij kunnen ook regelingen treffen voor tijdige 
medische behandeling of psychische ondersteuning. Bovendien kunnen zij zich op de 
situatie voorbereiden. 
De selectie van vrouwen met een hoger dan gemiddeld risico voor foetale chromosomale 
afwijkingen kan gebaseerd zijn op verschillende informatie: de hogere leeftijd van de 
moeder, een belaste familiegeschiedenis, afwijkende prenatale screening testen en 
dan wel afwijkende bevindingen bij echoscopisch onderzoek. In Nederland zijn de 
belangrijkste indicaties voor prenatale diagnostiek leeftijd van de moeder van 36 jaar 
en ouder, en een verhoogd risico op Down syndroom na een eerste trimester prenatale 
screening test. Prenatale diagnostiek voor deze indicaties is voor het grootste deel gericht 
op de detectie van het syndroom van Down. 
Sinds bijna 50 jaar is karyotypering de diagnostische test die gebruikt wordt om foetale 
chromosomale afwijkingen te detecteren. Karyotypering is een zeer nauwkeurige test. 
Er zijn gekweekte cellen nodig om cellen in de metafase te kunnen beoordelen. Deze 
kweektijd leidt tot een wachttijd van twee tot drie weken voordat de cellen beoordeeld 
kunnen worden en een uitslag bekend is. Karyotypering is arbeidsintensief en leidt 
tot hoge kosten. Karyotypering kan zowel numerieke als structurele microscopische 
chromosomale afwijkingen detecteren. Soms worden zo chromosomale afwijkingen 
gedetecteerd die geen, lichte, onzekere of onduidelijke klinische consequenties hebben. 
Deze bevindingen leiden tot lastige counselinggesprekken en emotionele dilemma’s 
voor ouders die moeten beslissen om de zwangerschap voort te zetten of te beëindigen. 
In 2003, kwam MLPA beschikbaar, een nieuwe test die de meest voorkomende 
chromosomale afwijkingen (trisomie 13, 18, 21 en niet-mozaïek geslacht chromosomale 
afwijkingen) kan detecteren op ongekweekte vruchtwatercellen. Preklinische studies 
lieten een hoge sensitiviteit en specificiteit zien. De techniek leek veelbelovend en zou 
eventueel een vervanger kunnen zijn van de karyotypering. Er waren toen echter nog geen 
grote klinische vergelijkende studies beschikbaar om de vervanging te ondersteunen. 









impact op de kwaliteit van leven van patiënten, de kosten en de voorkeur van patiënten 
en artsen. Daarom werd de M.A.K.E. (MLPA En Karyotypering, een evaluatie) studie 
opgezet, een landelijke studie waarin MLPA en karyotypering vergeleken worden in de 
klinische prenatale diagnostiek. 
Patiënten 
Zwangere vrouwen werden in de M.A.K.E. studie geïncludeerd als zij een vruchtwaterpunctie 
ondergingen op basis van hun leeftijd (36 jaar of ouder), of op basis van een verhoogd 
risico op het syndroom van Down na prenatale screening of op basis van ouderlijke angst. 
Vrouwen met andere indicaties (echoscopische afwijkingen, waaronder een nekplooidikte 
vanaf 3.5 mm, een ouder met een chromosomale afwijking, of een eerder kind met een 
chromosoomafwijking) voor een vruchtwaterpunctie werden niet geïncludeerd, omdat 
zij een verhoogd risico op andere chromosomale afwijkingen hebben dan de meest 
voorkomende aneuploidieën. Deze andere chromosomale afwijkingen worden die niet 
gedetecteerd door MLPA, maar wel met karyotypering. 
Interventies
Voor de MLPA procedure werd 1 tot 8 ml, afhankelijk van de totale hoeveelheid 
ontvangen vruchtwater ontvangen, DNA geïsoleerd uit ongekweekte vruchtwatercellen. 
De commercieel verkrijgbare kit, de Salsa MLPA P095 (MRC Holland, Nederland) werd 
gebruikt. Voor elke target genoom, is een set van 2 probes ontworpen, die onmiddellijk 
naast elkaar hybridiseren op dezelfde target streng. Beide probes bestaan uit een korte 
target sequentie en een universele polymerase chain reaction (PCR) primer-bindende 
site. Een van de probes bevat een stuffer sequentie met een unieke lengte en volgorde. 
Na hybridisatie, wordt elk paar aangrenzende probes verbonden door een ligatiereactie. 
Vervolgens wordt de PCR uitgevoerd met behulp van een fluorescent gelabeld primerpaar, 
dat ervoor zorgt dat de relatieve opbrengst van elk van de PCR-producten evenredig 
is met de hoeveelheid van de target sequenties. De verschillende producten worden 
op basis van hun lengte gescheiden op een geautomatiseerde capillaire sequencer. 
De grootte en de maximale oppervlakte voor elke probe worden gekwantificeerd en 
geanalyseerd met behulp van software (GeneMarker, SoftGenetics, LLC, State College, 
PA, USA of Genescan en Genemapper versie 3.7/4.0, Applied Biosystems, CA, USA). 
Relatieve probe signalen worden berekend en vergeleken ten opzichte van monsters van 
normaal mannelijk en vrouwelijk geslacht. Als er een normale hoeveelheid chromosomen 
aanwezig is, zal het relatieve probe signaal naar verwachting 1 zijn. Een normale waarde 
wordt gedefinieerd als een relatief probe-signaal tussen de 0,7 en 1,3. Een relatieve 
waarde van <0,7 duidt op een monosomie, terwijl een relatieve waarde van> 1,3 wijst 
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op een trisomie. MLPA detecteert geen laaggradig mosaïcisme. Voor karyotypering, de 
standaardtest, worden foetale cellen gekweekt en in de metafase onderzocht. Daarna 
worden ze gekleurd voor chromosomale bandering. Routinematig worden 10 kolonies 
onderzocht. Alle deelnemende centra volgden de nationale kwaliteitseisen. Kleine 
verschillen in het aantal gekweekte cellen, de manier van kleuren en de rapportage van 
de resultaten waren toegestaan. 
RESULTATEN VAN DE M.A.K.E. STUDIE
Diagnostische nauwkeurigheid (hoofdstuk 2) 
In een nationaal vergelijkende cohort studie werden 4585 vruchtwater monsters 
onderzocht. Alleen vrouwen die een vruchtwaterpunctie ondergingen op basis van hun 
leeftijd (75,6%), een verhoogd risico na prenatale screening (23,4%) of angst (1%) 
werden geïncludeerd. Vruchtwater monsters werden onafhankelijk getest met zowel 
MLPA als karyotypering. In 4484/4585 monsters (97,8%) kwamen karyotypering en 
MLPA overeen. Bij 4386 van de 4585 samples (95,7%) was er sprake van een normaal 
resultaat en bij 98 van de 4585 (2,1%) was er een aneuploidie. Bij 26 van de 4585 (0.6%) 
werden discordante resultaten gevonden; karyotypering liet een abnormaal karyotype 
zien dat niet gedetecteerd kon worden door MLPA. De diagnostische accuratesse 
van MLPA was 1.0 (95% betrouwbaarheidsinterval 0.99 tot 1.0), de sensitiviteit was 
100% (95% betrouwbaarheidsinterval 0.96 tot 1.0) en de specificiteit 100% (95% 
betrouwbaarheidsinterval van 0.999 tot 1.0). De diagnostische accuratesse van MLPA 
was statistisch vergelijkbaar (noninferieur) met die van karyotypering (P <0.001). In 75 
gevallen gaf MLPA geen uitslag (1,6%); karyotypering gaf een keer geen uitslag (0.02%). 
Vergeleken met karyotypering, verkortte MLPA de wachttijd met 14.5 dagen (p <0.001, 
95% betrouwbaarheidsinterval 14.3-14.6).
Kwaliteit van leven (hoofdstuk 3 en 4)
In de eerste studie werden angst, persoonlijke controle, stress en gezondheidgerelateerde 
kwaliteit van leven gemeten met behulp van gevalideerde vragenlijsten. Resultaten 
werden vergeleken van vrouwen die alleen een karyotype kregen (n = 132) en vrouwen 
die zowel een MLPA en karyotypering kregen (n = 181). Er waren geen systematische 
verschillen in de tijd van de gecombineerde strategie versus karyotypering alleen in angst 
(p = 0.91), algemene fysieke gezondheid (p = 0.76, p = 0.46), algemene geestelijke 
gezondheidszorg (p = 0.52, p = 0.72), persoonlijke controle (p = 0.91), en stress (p 









vergelijking met karyotypering. Concluderend verminderde MLPA met karyotypering angst 
en stress op de korte termijn, maar beïnvloedde het de totale angst, stress, persoonlijke 
controle, en generieke gezondheid niet in vergelijking met alleen karyotypering 
In de tweede studie werd de impact van standalone MLPA en karyotypering beoordeeld, 
nadat vrouwen een keuze was aangeboden tussen MLPA en karyotypering. Opnieuw 
werden angst, persoonlijke controle, stress en gezondheidgerelateerde kwaliteit van 
leven gemeten met behulp van gevalideerde vragenlijsten. Ook werden de redenen 
en overwegingen van vrouwen in kaart gebracht bij de keuze tussen standalone MLPA 
(n=61) en karyotypering (n=68). De meest genoemde reden om voor karyotypering 
te kiezen was het krijgen van zoveel mogelijk informatie, terwijl de korte wachttijd voor 
standalone MLPA werd genoemd. Prenatale screening (OR 7,09), onbekend zijn met 
karyotypering (OR 4,2) en een niet klein en niet groot ervaren risico op chromosomale 
afwijkingen (OR 3,6) was geassocieerd met het kiezen van standalone MLPA. Er waren 
geen systematische verschillen in de tijd tussen karyotypering en standalone MLPA in 
angst (p = 0.11), algemene lichamelijke en geestelijke gezondheid (p = 0.94, p= 
0.52, p = 0.66, p = 0.07), persoonlijke gepercipieerde controle (p = 0.69), en stress 
(p = 0.66). Concluderend, heeft de keuze tussen karyotypering en standalone RAD geen 
invloed op angst, stress, persoonlijke controle, en generieke gezondheid.
Kosten (hoofdstuk 5) 
Dit hoofdstuk beschrijft de vergelijking van de kosten van MLPA en karyotypering. Alleen 
vrouwen die een vruchtwaterpunctie ondergingen op basis van hun leeftijd (≥ 36 jaar), 
een verhoogd risico na prenatale screening of angst werden geïncludeerd. Wij gebruikten 
de klinische gegevens en gerealiseerde zorg op basis van de klinische MAKE studie. 
De kosten-minimisatieanalyse toonde aan dat MLPA op de korte termijn (de tijd vanaf 
de vruchtwaterpunctie tot aan de beslissing de zwangerschap te beëindigen) € 315,68 
(95% CI: € 315,63 tot € 315,74; -44,4%) per sample minder kost vergeleken met 
karyotypering. Op de lange termijn - dit is de tijd vanaf de beslissing om de zwangerschap 
voort te zetten of te beëindiging - is MLPA € 76,42 (95% CI: 71,32 tot 81,52; +8,6%) 
duurder per monster. Als de korte en lange termijn worden samengenomen, is MLPA € 
240,13 (bootstrap 95% CI: 235,02 tot 245,23; -14,9%) per monster goedkoper. De 
kosten werden beïnvloed door het aantal zwangerschapsafbrekingen, de hoeveelheid 
monsters en de hoeveelheid laboratoria. Vanuit een economisch perspectief, heeft de 
MLPA strategie de voorkeur bij vrouwen die een vruchtwaterpunctie te ondergaan wegens 
van hun leeftijd, na prenatale screening of wegens angst. 
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Voorkeuren van patiënten (hoofdstuk 6 en 7) 
De voorkeuren van patiënten werden onderzocht in twee hoofdstukken. In hoofdstuk 
5 hebben we de voorkeuren van patiënten gemeten voor drie strategieën (een test 
op trisomie 21, een test op trisomies 13, 18, 21, X en Y, en een test vergelijkbaar 
met karyotypering). De detectie capaciteit, de gevolgen van het resultaat indien een 
afwijking werd geconstateerd en de wachttijd op het testresultaat werden beschreven. 
We nodigden 150 zwangere vrouwen uit die een vruchtwaterpunctie ondergingen op 
basis van hun leeftijd (84,1%), een verhoogd risico na prenatale screening (11,5%) of 
vanwege angst (2,7%). Vijfenzeventig procent (113/150) vulde de vragenlijst in. Vrouwen 
gaven de voorkeur aan de test die lijkt op karyotypering (50,4%) of aan RAD techniek 
(43,4%). Een minderheid van de vrouwen koos voor de test op syndroom van Down. 
In hoofdstuk 7 evalueerden we patiënten preferenties en werd bepaald welke 
testeigenschappen van invloed zijn op de voorkeur met behulp van een discrete choice 
experiment. Zwangere vrouwen die voor prenatale counseling naar het ziekenhuis gingen 
werden uitgenodigd om deel te nemen. In totaal namen 103/118 (87%) vrouwen deel. 
Vrouwen waardeerden de detectie van chromosomale afwijkingen met ernstige gevolgen 
voor hun kind het meest (P <0.01). Het percentage niet gelukte testen, de wachttijd en 
de ervaren angst beïnvloeden de voorkeuren van vrouwen significant (p <0.05). Voor 
de huidige beschikbare testen, verkozen vrouwen karyotypering boven RAD (p <0.01) 
als de gedetecteerde chromosomale afwijkingen maar ernstige gevolgen hadden voor 
hun kind. Als karyotypering chromosomale afwijkingen detecteert met onzekere of geen 
klinische gevolgen voor hun kind, gaven vrouwen de voorkeur aan RAD (p <0.01). Angst 
en wachttijd hadden een gering effect op de voorkeuren van vrouwen, maar de mogelijke 
klinische gevolgen van de gedetecteerde chromosomale afwijking en het percentage niet 
gelukte testen beïnvloeden de keuze het meest. Omdat RAD en karyotypering allebei de 
meest voorkomende chromosomale afwijkingen detecteren met ernstige gevolgen, zijn 
beide testen geschikt voor prenatale diagnostiek.
De voorkeuren van experts (hoofdstuk 6 en 8)
In twee hoofdstukken bespreken we de mening van zorgverleners over karyotypering 
en MLPA. In hoofdstuk 6 hebben we de zorgverleners voorkeuren onderzocht 
voor drie testen (een test op trisomie 21, een test op trisomies 13, 18, 21, X en Y, 
en een test overeenkomend met karyotypering). De detectie capaciteit, de gevolgen 
van het resultaat als een afwijking werd geconstateerd en de wachttijd voor het 
testresultaat werden beschreven. We nodigden 140 zorgverleners uit die betrokken 









genetici, klinisch cytogeneticists en huisartsen. Van de zorgverleners (70% vrouwen; 
gemiddelde leeftijd 44 jaar, 26 tot 63 jaar), antwoordde 55% (77/140) op de 
vragenlijst. Het merendeel gaf de voorkeur aan voor een RAD test (77.9%), terwijl 
de resterende voorkeuren voor de andere testen gelijk waren verdeeld (10.4%). 
In hoofdstuk 8 werd gestreefd naar consensus tussen prenatale experts over welke 
chromosomale afwijkingen wel en niet gedetecteerd moeten worden in de prenatale 
diagnostiek. Een deskundig panel van 24 prenatale experts (8 klinische cytogenetici, 8 
klinisch genetici en 8 verloskundigen) stemden over 15 chromosomale afwijkingen in 
twee individuele anonieme rondes en een gezamenlijke bijeenkomst. De experts moesten 
voor of tegen detectie stemmen. Consensus werd gedefinieerd als minstens 80% van 
de deskundigen het eens was. Consensus werd bereikt in 12 van 15 gevallen. In 10 
gevallen werd er voor detectie gestemd en in twee gevallen tegen detectie. Aan het 
einde van de 3de ronde bleef er voor drie afwijkingen dissensus bestaan. Experts zijn het 
eens dat chromosomale afwijkingen met ernstige gevolgen gedetecteerd moeten worden 
en chromosomale afwijkingen zonder klinische consequenties niet gedetecteerd moeten 
worden. Voor chromosomale afwijkingen met milde of onzekere uitkomsten werd geen 
consensus bereikt. Geen van de momenteel beschikbare testen (MLPA en karyotypering) 
komen overeen met de eisen van alle experts, tenzij men bij karyotypering non-disclosure 
toepast voor bepaalde onzekere bevindingen. 
CONCLUSIES
In hoofdstuk 9 worden de bevindingen van dit proefschrift besproken, de klinische 
implicaties gegeven en worden aanbevelingen gedaan voor toekomstig onderzoek. 
De resultaten van dit proefschrift laten zien dat MLPA eeen zeer nauwkeurige test is 
voor de detectie van trisomie 13, 18, 21, X en Y. MLPA is vergelijkbaar (noninferieur) 
met karyotypering, geeft een vergelijkbare kwaliteit van leven en een significante 
kostenreductie. Men kan beredeneren op grond van besliskundige overwegingen en de 
uitkomsten uit de M.A.K.E. studie dat er 2 primaire varianten zijn waarin MLPA en of TKT 
kunnen worden toegepast: hetzij karyotypering, hetzij RAD gevolgd door karyotypering 
bij een positieve RAD uitslag. 
MLPA gevolgd door karyotypering in geval van een chromosomale afwijking, leidt ten 
opzichte van karyotypering tot een aanzienlijke kostenverlaging met weinig verlies van 
informatie. Deze optie is te verdedigen indien maatschappelijk één variant de voorkeur 
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heeft: de meerkosten voor de detectie van de zeldzame ernstige afwijking die alleen met 
karyotypering wordt vastgesteld ligt boven de 350.000 euro per afwijking.
Men kan ook van mening zijn dat de keuze aan de ouders moet zijn, ongeacht de kosten. 
In onze preferentiestudie waren de meningen van zwangere vrouwen bijna gelijkwaardig 
verdeeld tussen RAD en karyotypering. Zorgverleners (verloskundigen, klinisch genetici, 
klinisch cytogenetici, verloskundigen en huisartsen) geven de voorkeur aan RAD boven 
karyotypering. Wanneer prenatale experts moeten stemmen over realistische klinische 
gevallen, zijn zij het erover eens dat alle chromosomale afwijkingen met ernstige 
gevolgen gedetecteerd dienen te worden en chromosomale afwijkingen zonder gevolgen 
niet gedetecteerd moeten worden.Wij prefereren de invoering van een vrije individuele 
keuze in de prenatale diagnostiek. Zo kunnen ouders, verantwoordelijk voor de zorg van 
hun kind besluiten na niet-directieve counseling welke test voldoet aan hun individuele 
behoefte en risico.Toekomstig onderzoek moet zich richten op veelbelovende toekomstige 
technieken, zoals microarray analyse en niet-invasieve prenatale diagnostiek.
In klinische vergelijkende studies moeten de voorkeuren van patiënten en de ethische 
discussie worden opgenomen. Toekomstig onderzoek moet de haalbaarheid van gedeelde 
besluitvorming in de klinische praktijk evalueren en zich richten op de ontwikkeling van 
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Aan zeer veel mensen ben ik dank verschuldigd voor hun bijdrage aan mijn proefschrift. 
Na hier vier jaar aan gewerkt te hebben, wil ik een paar mensen in het bijzonder bedanken.
Allereerst wil ik de zwangere vrouwen bedanken die belangeloos deel hebben genomen 
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waardevol gemaakt. 
Dr. E. Birnie, beste Erwin, ik wil je zeer hartelijk bedanken voor de methodologische en 
wetenschappelijke vaardigheden die je mij met zoveel geduld hebt bijgebracht. Het was 
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manuscripten werden er een stuk beter van. Enorm bedankt voor jouw intensieve begeleiding.
Prof. Dr. G.J. Bonsel, beste Gouke, wij hebben elkaar misschien niet zoveel gezien, maar 
ik weet dat jij op de hoogte was van alle studies en veelvuldig hebt geadviseerd over de 
methodologie en analyse. Het was een genoegen om jouw brein aan het werk te zien als we 
resultaten aan het bespreken waren. Zeer veel dank voor jouw bijdrage aan dit proefschrift.
De M.A.K.E. stuurgroep, beste Arie, Attie, Carla, Dick, Heleen, Hajo, Johan, Karin, Katelijne, 
Katia, Lia, Mariëtte, Merryn, Jan, Ron, Robert-Jan en Shama, zeer veel dank voor jullie 
betrokkenheid bij het project. Ik heb het zeer gewaardeerd dat ik door jullie moeiteloos 
ben opgenomen binnen het netwerk van cytogenetici en wegwijs ben gemaakt binnen de 
prenatale diagnostiek. You made it happen!
Alle artsen, poli-medewerkers en secretaresses van de deelnemende klinieken, zeer veel 








gelukt! In het bijzonder wil ik Jennie Verdoes bedanken, waardoor elke studie in Leiden 
vlekkeloos is verlopen.
Veel dank gaat uit naar alle mede-auteurs van de manuscripten. Esther de Bekker-Grob, 
zeer veel dank voor jouw deskundige hulp bij de preferentiestudie. 
De medewerkers van de afdeling Verloskunde en Gynaecologie van het OLVG, wat heb ik 
het enorm naar mijn zin gehad in de kliniek. Het is goed te ervaren dat een open kritische 
discussie met een goede sfeer kan samengaan. In het bijzonder dank ik de staf voor de steun 
en aanmoediging om het onderzoeksproject te starten.
De afdeling Verloskunde en Gynaecologie in het AMC wil ik zowel bedanken voor de 
gastvrijheid om deze OLVG-er op te nemen binnen de onderzoeksgroep, als ook voor de 
ontvangst en eerste leerzame maanden van mijn academische opleidingstijd. De academische 
pathologie en laagdrempelige samenwerking met de gynaecologen, verloskundigen en arts-
assistenten maken dat ik elke dag met enthousiasme naar de Bijlmer fiets. 
De afdeling Verloskunde en Gynaecologie in het Spaarne ziekenhuis. Bedankt voor de 
hartelijke sfeer waarin ik het eerste deel van mijn opleiding heb kunnen volgen. Het was zeer 
waardevol om in een veilige omgeving de vele vaardigheden op de operatiekamers en het 
HTC te leren. 
De medeonderzoekers in het AMC. Zonder jullie was het nooit zo’n mooie tijd geweest. Lieve 
Alexandra, Arianne, Emmy, Esther, Katrien, Laura, Liesbeth, Marsha, Menke, Petra, Sylvia en 
Wouter het was me een waar genoegen om dagelijks met jullie te werken op H4. 
Lieve vrienden en vriendinnen. Waar zou ik zijn zonder jullie? Het was het afgelopen jaar niet 
mijn meest sociale jaar. Misschien zal het bij een gynaecoloog nooit een zoete inval worden, 
maar ik hoop dat we vanaf nu weer geregeld bij elkaar aan tafel komen zitten.
Mijn paranimfen, Anna en Stef. Lieve An, wat was het fijn om met jou een kamer te delen: je 
humor, je attentheid en revisie van de Engelse taal. Ik vind het heerlijk dat jij naast me staat. 
Lieve Stef, maatje uit het OLVG en de veroveraar van mijn bureau in het AMC. Het is goed 
om een nuchtere Noord-Hollandse vriend te hebben, zeker in tijden van stress of tegenslag. 
Ik ben trots dat je ook vandaag naast me staat.
190
Mijn broer Joost. We doen eigenlijk al ons hele leven hetzelfde, maar dan net even anders. 
Het kan geen toeval zijn dat jij over 3 maanden gaat promoveren in de urologie. Het was 
goed om de frustraties en hoogtepunten van een promotietraject met je te kunnen delen. 
Dank voor je adviezen en revisies van sollicitatiebrieven en manuscripten. Mijn lieve ouders, 
die mij altijd en overal in hebben gesteund. Mamma, het is gelukt, ik ben onafhankelijk en 
zelfstandig geworden. Pappa, je hebt me vanaf mijn jeugd enthousiast gemaakt voor de 
geneeskunde en blijft ook nu inhoudelijk betrokken bij mijn klinische werkzaamheden. Het is 
goed te weten dat er altijd drie mensen voor me klaar zullen staan. 
Lieve Willem, mijn ondernemende coachende optimist en liefde van mijn leven. Met jou 
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